var title_f41_57_42896="Bipolar limb leads";
var content_f41_57_42896=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65289&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65289&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 557px\">",
"   <div class=\"ttl\">",
"    Bipolar limb lead system",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 537px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Einthoven described a system of three bipolar leads located at the right arm, left arm, and left leg to form a triangle. Lead I represents the potential difference between the right and left arm; an electrical impulse moving from right to left generates a positive ECG deflection in this lead. Lead II is the potential difference between the right arm and leg; a positive ECG deflection occurs when the impulse direction is toward the leg. Lead III is the potential difference between the left arm and leg; there is a positive ECG deflection when the impulse direction is toward the leg.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_57_42896=[""].join("\n");
var outline_f41_57_42896=null;
var title_f41_57_42897="Patient information: Amniocentesis (The Basics)";
var content_f41_57_42897=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15530\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/31/15859\">",
"         Amniocentesis",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?38/46/39663\">",
"         Patient information: Chorionic villus sampling (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?14/28/14785\">",
"         Patient information: Amniocentesis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?2/7/2161\">",
"         Patient information: Chorionic villus sampling (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Amniocentesis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/amniocentesis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H469314445\">",
"      <span class=\"h1\">",
"       What is amniocentesis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Amniocentesis is a procedure that takes a small amount of amniotic fluid out of a pregnant woman&rsquo;s belly. Amniotic fluid is the liquid that surrounds the fetus inside the mother&rsquo;s uterus (womb).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H469314452\">",
"      <span class=\"h1\">",
"       Why is amniocentesis done?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Amniocentesis is done to get a sample of amniotic fluid. The amniotic fluid is tested to get more information about the health of the fetus.",
"     </p>",
"     <p>",
"      The two most common reasons amniotic fluid is tested are to find out if the fetus:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Has a genetic problem, such as Down syndrome. This might be done if another test, such as an ultrasound or blood test on the mother, has shown that something might be wrong with the fetus.",
"       </li>",
"       <li>",
"        Will be able to breathe on its own if it is born before the due date",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H469314459\">",
"      <span class=\"h1\">",
"       When is amniocentesis done?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The test can be done any time after 15 weeks of pregnancy. The timing depends on why the amniotic fluid is being tested.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H469314466\">",
"      <span class=\"h1\">",
"       How is amniocentesis done?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Here are the main steps:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A doctor will do an ultrasound so he or she can see moving pictures of your uterus, your fetus, and the amniotic fluid on a screen (like a TV).",
"       </li>",
"       <li>",
"        This doctor or another doctor will watch the screen as he or she inserts a needle into your belly and then into the amniotic fluid (",
"        <a class=\"graphic graphic_figure graphicRef53857 \" href=\"mobipreview.htm?15/31/15859\">",
"         figure 1",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        The doctor will use the needle to take out a small amount of fluid. The test usually takes about 1 to 2 tablespoons of fluid.",
"       </li>",
"       <li>",
"        The fluid will be sent to a lab for tests.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H469314473\">",
"      <span class=\"h1\">",
"       Does amniocentesis have any risks?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Problems are rare, but they can happen. Risks include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Leaking of amniotic fluid. Sometimes, this can lead to infection, which can lead to miscarriage early in pregnancy, or preterm labor and preterm birth later in pregnancy. (Preterm birth means the baby is born before 37 weeks of pregnancy.)",
"       </li>",
"       <li>",
"        The needle can touch the baby, which in rare cases causes an injury",
"       </li>",
"       <li>",
"        Blood from the placenta can leak into your own bloodstream. (The placenta is the organ that brings the baby nutrients and oxygen and carries away waste.) This can cause problems for later pregnancies.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H469314480\">",
"      <span class=\"h1\">",
"       Should I be worried about symptoms after the procedure?",
"      </span>",
"      &nbsp;&mdash;&nbsp;That depends on what symptoms you have and how bad they are. After amniocentesis, it is normal to have mild cramps in your belly for a short time.",
"     </p>",
"     <p>",
"      Call your doctor if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        You are bleeding or leaking fluid from your vagina",
"       </li>",
"       <li>",
"        You have cramps that are getting worse",
"       </li>",
"       <li>",
"        You have a fever higher than 100.4&deg;F (38&ordm;C)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H469314487\">",
"      <span class=\"h1\">",
"       What if the test shows that something is wrong with my fetus?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You should talk to a genetic counselor before and after the test. He or she can help you understand your feelings and decide what to do.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H469314592\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/46/39663?source=see_link\">",
"       Patient information: Chorionic villus sampling (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/28/14785?source=see_link\">",
"       Patient information: Amniocentesis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/7/2161?source=see_link\">",
"       Patient information: Chorionic villus sampling (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?41/57/42897?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15530 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-41.78.124.10-CD13024F2B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_57_42897=[""].join("\n");
var outline_f41_57_42897=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H469314445\">",
"      What is amniocentesis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H469314452\">",
"      Why is amniocentesis done?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H469314459\">",
"      When is amniocentesis done?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H469314466\">",
"      How is amniocentesis done?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H469314473\">",
"      Does amniocentesis have any risks?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H469314480\">",
"      Should I be worried about symptoms after the procedure?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H469314487\">",
"      What if the test shows that something is wrong with my fetus?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H469314592\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15530\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/31/15859\">",
"      Amniocentesis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/28/14785?source=related_link\">",
"      Patient information: Amniocentesis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/7/2161?source=related_link\">",
"      Patient information: Chorionic villus sampling (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/46/39663?source=related_link\">",
"      Patient information: Chorionic villus sampling (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_57_42898="Drugs for parasitic infections protozoa";
var content_f41_57_42898=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F86520&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F86520&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drugs for parasitic infections: Protozoa",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"centered\" colspan=\"4\">",
"        With increasing travel, immigration, use of immunosuppressive drugs and the spread of AIDS, physicians anywhere may see infections caused by parasites. The table below lists first-choice and alternative drugs for most parasitic infections.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1\">",
"        Infection",
"       </td>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adult dosage",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pediatric dosage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        <em>",
"         Acanthamoeba",
"        </em>",
"        keratitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug of choice:",
"       </td>",
"       <td>",
"        See footnote 1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Amebiasis",
"        <em>",
"         (Entamoeba histolytica)",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        Asymptomatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Drug of choice:",
"       </td>",
"       <td>",
"        Iodoquinol",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td>",
"        650 mg PO tid x 20 d",
"       </td>",
"       <td>",
"        30 to 40 mg/kg/d (max 2 g) PO in 3 doses x 20 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"        Paromomycin",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"       <td>",
"        25 to 35 mg/kg/d PO in 3 doses x 7 d",
"       </td>",
"       <td>",
"        25 to 35 mg/kg/d PO in 3 doses x 7 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"        Diloxanide furoate",
"        <sup>",
"         [4*]",
"        </sup>",
"       </td>",
"       <td>",
"        500 mg PO tid x 10 d",
"       </td>",
"       <td>",
"        20 mg/kg/d PO in 3 doses x 10 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        Mild to moderate intestinal disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"5\">",
"        Drug of choice:",
"        <sup>",
"         [5]",
"        </sup>",
"       </td>",
"       <td>",
"        Metronidazole",
"       </td>",
"       <td>",
"        500 to 750 mg PO tid x 7 to 10 d",
"       </td>",
"       <td>",
"        35 to 50 mg/kg/d PO in 3 doses x 7 to 10 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"        Tinidazole",
"        <sup>",
"         [6]",
"        </sup>",
"       </td>",
"       <td>",
"        2 g once PO daily x 3 d",
"       </td>",
"       <td>",
"        &ge;3 years: 50 mg/kg/d (max 2 g) PO in 1 dose x 3 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"3\">",
"        <strong>",
"         Either followed by",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iodoquinol",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td>",
"        650 mg PO tid x 20 d",
"       </td>",
"       <td>",
"        30 to 40 mg/kg/d (max 2 g) PO in 3 doses x 20 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"        Paromomycin",
"        <sup>",
"         [3*]",
"        </sup>",
"       </td>",
"       <td>",
"        25-35 mg/kg/d PO in 3 doses x 7 d",
"       </td>",
"       <td>",
"        25 to 35 mg/kg/d PO in 3 doses x 7 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        Severe intestinal and extraintestinal disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"5\">",
"        Drug of choice:",
"       </td>",
"       <td>",
"        Metronidazole",
"       </td>",
"       <td>",
"        750 mg PO tid x 7 to 10 d",
"       </td>",
"       <td>",
"        35 to 50 mg/kg/d PO in 3 doses x 7 to 10 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"        Tinidazole",
"        <sup>",
"         [6]",
"        </sup>",
"       </td>",
"       <td>",
"        2 g once PO daily x 5 d",
"       </td>",
"       <td>",
"        &ge;3 years: 50 mg/kg/d (max 2 g) PO in 1 dose x 5 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"3\">",
"        <strong>",
"         Either followed by",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iodoquinol",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td>",
"        650 mg PO tid x 20 d",
"       </td>",
"       <td>",
"        30 to 40 mg/kg/d (max 2 g) PO in 3 doses x 20 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"        Paromomycin",
"        <sup>",
"         [3*]",
"        </sup>",
"       </td>",
"       <td>",
"        25 to 35 mg/kg/d PO in 3 doses x 7 d",
"       </td>",
"       <td>",
"        25 to 35 mg/kg/d PO in 3 doses x 7 d",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Amebic meningoencephalitis, primary and granulomatous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        <em>",
"         Naegleria fowleri",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug of choice:",
"       </td>",
"       <td>",
"        Amphotericin B",
"        <sup>",
"         [7,8]",
"        </sup>",
"       </td>",
"       <td>",
"        1.5 mg/kg/d IV in 2 doses x 3 d, then 1 mg/kg/d x 6 d plus 1.5 mg/d intrathecally x 2 d, then 1 mg/d every other day x 8 d",
"       </td>",
"       <td>",
"        1.5 mg/kg/d IV in 2 doses x 3 d, then 1 mg/kg/d x 6 d plus 1.5 mg/d intrathecally x 2 d, then 1 mg/d every other day x 8 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        <em>",
"         Acanthamoeba",
"        </em>",
"        spp.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug of choice:",
"       </td>",
"       <td>",
"        See footnote 9",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        <em>",
"         Balamuthia mandrillaris",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug of choice:",
"       </td>",
"       <td>",
"        See footnote 10",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        <em>",
"         Sappinia diploidea",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug of choice:",
"       </td>",
"       <td>",
"        See footnote 11",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"4\">",
"        <strong>",
"         <em>",
"          Balamuthia mandrillaris",
"         </em>",
"         , see Amebic meningoencephalitis, primary",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Balantidiasis",
"        <em>",
"         (Balantidium coli)",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug of choice:",
"       </td>",
"       <td>",
"        Tetracycline",
"        <sup>",
"         [7,12]",
"        </sup>",
"       </td>",
"       <td>",
"        500 mg PO qid x 10 d",
"       </td>",
"       <td>",
"        40 mg/kg/d (max 2 g) PO in 4 doses x 10 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Alternative:",
"       </td>",
"       <td>",
"        Metronidazole",
"        <sup>",
"         [7]",
"        </sup>",
"       </td>",
"       <td>",
"        500 to 750 mg PO tid x 5 d",
"       </td>",
"       <td>",
"        35 to 50 mg/kg/d PO in 3 doses x 5 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"        Iodoquinol",
"        <sup>",
"         [2,7]",
"        </sup>",
"       </td>",
"       <td>",
"        650 mg PO tid x 20 d",
"       </td>",
"       <td>",
"        30 to 40 mg/kg/d (max 2 g) PO in 3 doses x 20 d",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        <em>",
"         Blastocystis",
"        </em>",
"        spp. infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug of choice:",
"       </td>",
"       <td>",
"        See footnote 13",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Cryptosporidiosis",
"        <em>",
"         (Cryptosporidium)",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        Non-HIV infected",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug of choice:",
"       </td>",
"       <td>",
"        Nitazoxanide",
"        <sup>",
"         [5]",
"        </sup>",
"       </td>",
"       <td>",
"        500 mg PO bid x 3 d",
"       </td>",
"       <td>",
"        1 to 3 years: 100 mg PO bid x 3 d",
"        <br/>",
"        4 to 11 years: 200 mg PO bid x 3 d",
"        <br/>",
"        &gt;12 years: 500 mg PO bid x 3 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        HIV infected",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug of choice:",
"       </td>",
"       <td>",
"        See footnote 14",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Cyclosporiasis",
"        <em>",
"         (Cyclospora cayetanensis)",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug of choice:",
"        <sup>",
"         [15]",
"        </sup>",
"       </td>",
"       <td>",
"        Trimethoprim-sulfamethoxazole (TMP/SMX)",
"        <sup>",
"         [7]",
"        </sup>",
"       </td>",
"       <td>",
"        TMP 160 mg/SMX 800 mg (1 DS tab) PO bid x 7 to 10 d",
"       </td>",
"       <td>",
"        TMP 10 mg/kg/SMX 50 mg/kg/d PO in 2 doses x 7 to 10 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alternative:",
"       </td>",
"       <td>",
"        Ciprofloxacin",
"        <sup>",
"         [7]",
"        </sup>",
"       </td>",
"       <td>",
"        500 mg PO bid x 7 d",
"       </td>",
"       <td>",
"        &mdash;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Cystoisosporiasis (",
"        <em>",
"         Cystoisospora belli",
"        </em>",
"        , formerly known as",
"        <em>",
"         Isospora",
"        </em>",
"        )",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug of choice:",
"        <sup>",
"         [16]",
"        </sup>",
"       </td>",
"       <td>",
"        Trimethoprim-sulfamethoxazole (TMP/SMX)",
"        <sup>",
"         [7]",
"        </sup>",
"       </td>",
"       <td>",
"        TMP 160 mg/SMX 800 mg (1 DS tab) PO bid x 10 d",
"       </td>",
"       <td>",
"        TMP 10 mg/kg/d/SMX 50 mg/kg/d PO in 2 doses x 10 d",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        <em>",
"         Dientamoeba fragilis",
"        </em>",
"        infection",
"        <sup>",
"         [17]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Drug of choice:",
"        <sup>",
"         [18]",
"        </sup>",
"       </td>",
"       <td>",
"        Iodoquinol",
"        <sup>",
"         [2,7]",
"        </sup>",
"       </td>",
"       <td>",
"        650 mg PO tid x 20 d",
"       </td>",
"       <td>",
"        30 to 40 mg/kg/d (max 2 g) PO in 3 doses x 20 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"        Paromomycin",
"        <sup>",
"         [3,7*]",
"        </sup>",
"       </td>",
"       <td>",
"        25 to 35 mg/kg/d PO in 3 doses x 7 d",
"       </td>",
"       <td>",
"        25 to 35 mg/kg/d PO in 3 doses x 7 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"        Metronidazole",
"        <sup>",
"         [7]",
"        </sup>",
"       </td>",
"       <td>",
"        500 to 750 mg PO tid x 10 d",
"       </td>",
"       <td>",
"        35 to 50 mg/kg/d PO in 3 doses x 10 d",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"4\">",
"        <strong>",
"         <em>",
"          Entamoeba histolytica",
"         </em>",
"         , see Amebiasis",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Giardiasis",
"        <em>",
"         (Giardia duodenalis)",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Drug of choice:",
"       </td>",
"       <td>",
"        Metronidazole",
"        <sup>",
"         [7]",
"        </sup>",
"       </td>",
"       <td>",
"        250 mg PO tid x 5 to 7 d",
"       </td>",
"       <td>",
"        15 mg/kg/d PO in 3 doses x 5 to 7 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"        Tinidazole",
"        <sup>",
"         [6]",
"        </sup>",
"       </td>",
"       <td>",
"        2 g PO once",
"       </td>",
"       <td>",
"        &ge;3 years: 50 mg/kg PO once (max 2 g)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"        Nitazoxanide",
"        <sup>",
"         [5]",
"        </sup>",
"       </td>",
"       <td>",
"        500 mg PO bid x 3 d",
"       </td>",
"       <td>",
"        1 to 3 years: 100 mg PO bid x 3 d",
"        <br/>",
"        4 to 11 years: 200 mg PO bid x 3 d",
"        <br/>",
"        &gt;12 years: 500 mg PO bid x 3 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Alternative:",
"        <sup>",
"         [19]",
"        </sup>",
"       </td>",
"       <td>",
"        Paromomycin",
"        <sup>",
"         [3,7,20*]",
"        </sup>",
"       </td>",
"       <td>",
"        25 to 35 mg/kg/d PO in 3 doses x 5 to 10 d",
"       </td>",
"       <td>",
"        25 to 35 mg/kg/d PO in 3 doses x 5 to 10 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"        Furazolidone",
"        <sup>",
"         [*]",
"        </sup>",
"       </td>",
"       <td>",
"        100 mg PO qid x 7 to 10 d",
"       </td>",
"       <td>",
"        6 mg/kg/d PO in 4 doses x 7 to 10 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"        Quinacrine",
"        <sup>",
"         [4,21*]",
"        </sup>",
"       </td>",
"       <td>",
"        100 mg PO tid x 5 d",
"       </td>",
"       <td>",
"        6 mg/kg/d PO in 3 doses x 5 d (max 300 mg/d)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"4\">",
"        <strong>",
"         <em>",
"          Isospora belli",
"         </em>",
"         , see",
"         <em>",
"          Cystoisospora",
"         </em>",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Microsporidiosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        Ocular (",
"        <em>",
"         Encephalitozoon hellem",
"        </em>",
"        ,",
"        <em>",
"         E. cuniculi",
"        </em>",
"        ,",
"        <em>",
"         Vittaforma [Nosema] corneae",
"        </em>",
"        )",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Drug of choice:",
"       </td>",
"       <td>",
"        Fumagillin",
"        <sup>",
"         [22*]",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"3\">",
"        <strong>",
"         Plus",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Albendazole",
"        <sup>",
"         [7,23]",
"        </sup>",
"       </td>",
"       <td>",
"        400 mg PO bid",
"       </td>",
"       <td>",
"        15 mg/kg/d in 2 doses (max 400 mg/dose)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        Intestinal (",
"        <em>",
"         E. bieneusi",
"        </em>",
"        ,",
"        <em>",
"         E. [Septata] intestinalis",
"        </em>",
"        )",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"4\">",
"        <em>",
"         E. bieneusi",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug of choice:",
"       </td>",
"       <td>",
"        Fumagillin",
"        <sup>",
"         [24*]",
"        </sup>",
"       </td>",
"       <td>",
"        20 mg PO tid x 14 d",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"4\">",
"        <em>",
"         E. intestinalis",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug of choice:",
"       </td>",
"       <td>",
"        Albendazole",
"        <sup>",
"         [7,23]",
"        </sup>",
"       </td>",
"       <td>",
"        400 mg PO bid x 21 d",
"       </td>",
"       <td>",
"        15 mg/kg/d in 2 doses (max 400 mg/dose)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        Disseminated (",
"        <em>",
"         E. hellem",
"        </em>",
"        ,",
"        <em>",
"         E. cuniculi",
"        </em>",
"        ,",
"        <em>",
"         E. intestinalis",
"        </em>",
"        ,",
"        <em>",
"         Pleistophora sp.",
"        </em>",
"        ,",
"        <em>",
"         Trachipleistophora sp.",
"        </em>",
"        and",
"        <em>",
"         Anncaliia [Brachiola] vesicularum",
"        </em>",
"        )",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug of choice:",
"        <sup>",
"         [25]",
"        </sup>",
"       </td>",
"       <td>",
"        Albendazole",
"        <sup>",
"         [7,23]",
"        </sup>",
"       </td>",
"       <td>",
"        400 mg PO bid",
"       </td>",
"       <td>",
"        15 mg/kg/d in 2 doses (max 400 mg/dose)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"4\">",
"        <strong>",
"         <em>",
"          Naegleria",
"         </em>",
"         species, see Amebic meningoencephalitis, primary",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"4\">",
"        <strong>",
"         <em>",
"          Sappinia diploidea",
"         </em>",
"         , See Amebic meningoencephalitis, primary",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"4\">",
"        <strong>",
"         Sarcocystis spp. (intestinal and muscular), see footnote 26",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     %: percent; bid: twice daily; d: days; DS: double strength;&nbsp;IV: intravenous; tid: three times daily; qid: four times daily; PO: by mouth.",
"     <br>",
"      * Availability problems.",
"      <br>",
"       <ol>",
"        <li>",
"         Keratitis is typically associated with contact lens use (Carvalho FR,&nbsp;et al. Cornea 2009; 28:516). Topical 0.02% chlorhexidine and polyhexamethylene biguanide (PHMB, 0.02%), either alone or in combination, have been used successfully in a large number of patients. Treatment with either chlorhexidine or PHMB is often combined with propamidine isethionate",
"         <em>",
"          (Brolene)",
"         </em>",
"         or hexamidine",
"         <em>",
"          (Desmodine)",
"         </em>",
"         . None of these drugs is commercially available or approved for use in the US, but they can be obtained from compounding pharmacies (see footnote 4). Leiter's Park Avenue Pharmacy, San Jose, CA (800-292-6773; www.leiterrx.com) is a compounding pharmacy that specializes in ophthalmic drugs. Propamidine is available over the counter in the UK and Australia. Hexamidine is available in France. The combination of chlorhexidine, natamycin (pimaricin), and debridement also has been successful (Kitagawa K, et al. Jpn J Ophthalmol 2003; 47:616), as has 0.1% sodium diclofenac (Agahan AL,&nbsp;et al. Ann Acad Med Singapore 2009; 38:175) in a small series of&nbsp;three patients. Debridement is most useful during the stage of corneal epithelial infection; keratoplasty in medically unresponsive keratitis was successful in 31 patients (Kitzmann AS, et al. Ophthalmology 2009; 116:864). Most cysts are resistant to neomycin; its use is no longer recommended. Azole antifungal drugs (ketoconazole, itraconazole) have been used as oral or topical adjuncts. Use of corticosteroids is controversial. Prolonged therapy (&ge;6 months) may be necessary (Dart JK, et al. Am J Ophthalmol 2009; 148:487).",
"        </li>",
"        <li>",
"         Iodoquinol should be taken after meals.",
"        </li>",
"        <li>",
"         Paromomycin should be taken with a meal.",
"        </li>",
"        <li>",
"         Not available commercially. It may be obtained through compounding pharmacies such as Expert Compounding Pharmacy, 6744 Balboa Blvd, Lake Balboa, CA 91406 (800-247-9767), or Medical Center Pharmacy, New Haven, CT (203-688-7064). Other compounding pharmacies may be found through the National Association of Compounding Pharmacies (800-687-7850) or the Professional Compounding Centers of America (800-331-2498, www.pccarx.com).",
"        </li>",
"        <li>",
"         Nitazoxanide may be effective against a variety of protozoan and helminth infections (Bobak DA.&nbsp;Curr Infect Dis Rep 2006; 8:91; Diaz E,&nbsp;et al. Am J Trop Med Hyg 2003; 68:384). It is effective against mild to moderate amebiasis, 500 mg bid x 3 d (Rossignol JF, et al. Trans R Soc Trop Med Hyg 2007; 101:1025; Escobedo AE,&nbsp;et al. Arch Dis Child 2009; 94:478). It is FDA-approved only for treatment of diarrhea caused by",
"         <em>",
"          Giardia",
"         </em>",
"         or",
"         <em>",
"          Cryptosporidium",
"         </em>",
"         (Med Lett Drugs Ther 2003; 45:29). Nitazoxanide is available in 500 mg tablets and an oral suspension; it should be taken with food.",
"        </li>",
"        <li>",
"         A nitroimidazole similar to metronidazole, tinidazole appears to be as effective as metronidazole and better tolerated (Med Lett Drugs Ther 2004; 46:70). It should be taken with food to minimize GI adverse effects. For children and patients unable to take tablets, a pharmacist can crush the tablets and mix them with cherry syrup (",
"         <em>",
"          Humco",
"         </em>",
"         , and others). The syrup suspension is good for&nbsp;seven days at room temperature and must be shaken before use (Fung HB, Doan TL.&nbsp;Clin Ther 2005; 27:1859). Ornidazole, a similar drug, is also used outside the US.",
"        </li>",
"        <li>",
"         Not FDA-approved for this indication.",
"        </li>",
"        <li>",
"         A",
"         <em>",
"          Naegleria fowleri",
"         </em>",
"         infection was treated successfully in a nine-year-old girl with combination of amphotericin B and miconazole (both drugs given intravenously and intrathecally) plus oral rifampin (Seidel JS,&nbsp;et al. NEJM 1982; 306:346). While amphotericin B and miconazole appear to have a synergistic effect, Medical Letter consultants believe the rifampin probably had no additional effect (Visvesvara GS, et al. FEMS Immunol Med Microbiol 2007; 50:1). Parenteral miconazole is no longer available in the US. Azithromycin (changed to clarithromycin during therapy because of toxicity concerns and for better CNS penetration) has been used in multidrug combination regimens to treat",
"         <em>",
"          Balamuthia",
"         </em>",
"         infection.",
"         <em>",
"          In vitro",
"         </em>",
"         , azithromycin is more active than clarithromycin against",
"         <em>",
"          Naegleria",
"         </em>",
"         , so may be a better choice combined with amphotericin B for treatment of",
"         <em>",
"          Naegleria",
"         </em>",
"         (Deetz TR, et al. Clin Infect Dis 2003; 37:1304; Schuster FL, Visvesvara GS.&nbsp;Drug Resistance Updates 2004; 7:41). Combinations of amphotericin B, ornidazole, and rifampin (Jain R, et al. Neurol India 2002; 50:470), amphotericin B, fluconazole (IV and PO) and rifampin (Vargas-Zepeda J, et al. Arch Med Research 2005;36:83) and amphotericin B, chloramphicol, and rifampacin have also been used (Rai R,&nbsp;et al. Indian Pediatr 2008; 45:1004). Case reports of other successful therapy have been published (Schuster FL,&nbsp;Visvesvara, GS. Int J Parasitol 2004; 34:1001).",
"        </li>",
"        <li>",
"         Several patients with granulomatous amebic encephalitis (GAE) have been successfully treated with combinations of pentamidine, sulfadiazine, flucytosine, and either fluconazole or itraconazole (Visvesvara GS,&nbsp;et al. FEMS Immunol Med Microbiol 2007; 50:1). GAE in an AIDs patient was treated successfully with sulfadiazine, pyrimethamine, and fluconazole combined with surgical resection of the CNS lesion (Seijo Martinez M, et al. J Clin Microbiol 2000; 38:3892). Chronic",
"         <em>",
"          Acanthamoeba",
"         </em>",
"         meningitis was successfully treated in&nbsp;two children with a combination of oral trimethoprim/sulfamethoxazole, rifampin, and ketoconazole (Singhal T, et al. Pediatr Infect Dis J 2001; 20:623). Disseminated cutaneous infection in an immunocompromised patient was treated successfully with IV pentamidine, topical chlorhexidine, and 2% ketoconazole cream, followed by PO itraconazole (Slater CA,&nbsp;et al. N Engl J Med 1994; 331:85) and with voriconazole and amphotericin B lipid complex (Walia R, et al. Transplant Infect Dis 2007; 9:51). Other reports of successful therapy have been described (Schuster FL, Visvesvara GS.&nbsp;Drug Resistance Updates 2004; 7:41; Aichelburg AC,&nbsp;et al. Emerg Infect Dis 2008; 14:1743). Susceptibility testing of",
"         <em>",
"          Acanthamoeba",
"         </em>",
"         isolates has shown differences in drug sensitivity between species and even among strains of a single species; antimicrobial susceptibility testing is advisable (Schuster FL, Visvesvara GS.&nbsp;Int J Parasitiol 2004; 34:1001).",
"        </li>",
"        <li>",
"         <em>",
"          B. mandrillaris",
"         </em>",
"         is a free-living ameba that causes subacute to fatal granulomatous amebic encephalitis (GAE) and cutaneous disease (MMWR 2008; 57:768; Schuster FL, et al. Clin Infect Dis 2009; 48:879). Three cases of",
"         <em>",
"          Balamuthia",
"         </em>",
"         encephalitis have been successfully treated with pentamidine, flucytosine, fluconazole, and sulfadiazine plus either azithromycin or clarithromycin combined with surgical resection of the CNS lesion; in two cases, flucytosine was given as well. Clarithromycin may have less toxicity and better penetration into CSF than azithromycin (Deetz TR, et al. Clin Infect Dis 2003; 37:1304; Jung S, et al. Arch Pathol Lab Med 2004; 128:466).",
"        </li>",
"        <li>",
"         A free-living ameba that may rarely be pathogenic to humans (Visvesvara GS, et al. FEMS Immunol Med Microbiol 2007; 50:1; Marciano-Cabral F.&nbsp;J Infect Dis 2009; 199:1104).",
"         <em>",
"          S. diploidea",
"         </em>",
"         has been successfully treated with azithromycin, pentamidine, itraconazole, and flucytosine combined with surgical resection of the CNS lesion (Gelman&nbsp;BB,&nbsp;et al. J Neuropathol Exp Neurol 2003; 62:990).",
"        </li>",
"        <li>",
"         Use of tetracyclines is contraindicated in pregnancy and in children &lt;8 years old. Tetracycline should be taken&nbsp;one hour before or&nbsp;two hours after meals and/or dairy products.",
"        </li>",
"        <li>",
"         Blastocystis has been reclassified as a fungus. Clinical significance of these organisms is controversial; metronidazole 750 mg PO tid x 10 d, iodoquinol 650 mg PO tid x 20 d, or trimethoprim/sulfamethoxazole 1 double strength tab PO bid x 7 d have been reported to be effective (Tan KS.&nbsp;Clin Microbiol Rev 2008; 21:639). Metronidazole resistance may be common in some areas (Yakoob J, et al. Br J Biomed Sci 2004; 61:75). Nitazoxanide has been effective in clearing organisms and improving symptoms (Diaz E, et al. Am J Trop Med Hyg 2003; 68:384; Rossignol JF.&nbsp;Clin Gastroenterol Hepatol 2005; 3:987).",
"        </li>",
"        <li>",
"         No drug has proven efficacy against cryptosporidiosis in advanced AIDS (Abubakar I, et al. Cochrane Database Syst Rev 2007; 1:CD004932). Potent antiretroviral therapy (ART) is the mainstay of treatment. Nitazoxanide, paromomycin, or a combination of paromomycin and azithromycin may be tried to decrease diarrhea and recalcitrant malabsorption of antimicrobial drugs, which can occur with chronic cryptosporidiosis (Pantenburg B, et al. Expert Rev Anti Infect Ther 2009; 7:385).",
"        </li>",
"        <li>",
"         Warren CA.&nbsp;Curr Infect Dis Rep 2009; 11:108. In one study of HIV-infected patients with",
"         <em>",
"          Cyclospora",
"         </em>",
"         infection, ciprofloxacin treatment led to resolution in 87 percent&nbsp;of patients compared to 100 percent&nbsp;with trimethoprim-sulfamethoxazole (Verdier RI,&nbsp;et al. Ann Intern Med 2000; 132:885). HIV-infected patients may need higher dosage and long-term maintenance. Nitazoxanide (see also footnote 5) has also been used in a few patients (Zimmer SM, et al. Clin Infect Dis 2007; 44:466; Diaz E, et al. Am J Trop Med Hyg 2003; 68:384).",
"        </li>",
"        <li>",
"         <em>",
"          Isospora belli",
"         </em>",
"         has been renamed and included the",
"         <em>",
"          Cystoisospora",
"         </em>",
"         genus. Usually a self-limited illness in immunocompetent patients. Immunosuppressed patients may need higher doses and longer duration (trimethoprim-sulfamethoxazole qid for up to&nbsp;three to&nbsp;four weeks) (Morbid Mortal Wkly Rep 2009; 58 RR4:1). They may require secondary prophylaxis (trimethoprim-sulfamethoxazole&nbsp;double strength three times a week). In sulfa-allergic patients, pyrimethamine 50 to 75 mg daily in divided doses (plus leucovorin 10 to 25 mg/d) has been effective.",
"        </li>",
"        <li>",
"         Stark DJ, et al. Trends Parasitol 2006; 22:92; Vandenberg O, et al. Pediatr Infect Dis J 2007; 26:88.",
"        </li>",
"        <li>",
"         In one study, single-dose ornidazole, a nitroimidazole similar to metronidazole that is available in Europe, was effective and better tolerated than&nbsp;five days of metronidazole (Kurt O.&nbsp;Clin Microbiol Infect 2008; 14:601).",
"        </li>",
"        <li>",
"         Additional option: albendazole (400 mg/d PO x 5 d in adults and 10 mg/kg/d PO x 5 d in children) (Yereli Y, et al. Clin Microbiol Infect 2004; 10:527; Karabay O, et al. World J Gastroenterol 2004; 10:1215). Refractory disease: standard doses of metronidazole plus quinacrine x 3 weeks (Nash TE, et al. Clin Infect Dis 2001; 33:22). In one study, nitazoxanide was used successfully in high doses (1.5 g PO bid x 30 d) to treat a case of",
"         <em>",
"          Giardia",
"         </em>",
"         resistant to metronidazole and albendazole (Abboud P, et al. Clin Infect Dis 2001; 32:1792).",
"        </li>",
"        <li>",
"         Poorly absorbed; may be useful for treatment of giardiasis in pregnancy.",
"        </li>",
"        <li>",
"         Quinacrine should be taken with liquids after a meal. It is not available in the US but can be compounded by Gallipot Pharmacy (www.gallipot.com; 800-423-6967).",
"        </li>",
"        <li>",
"         Chan CM, et al. Ophthalmology 2003; 110:1420. Ocular lesions due to",
"         <em>",
"          E. hellem",
"         </em>",
"         in HIV-infected patients have responded to fumagillin eyedrops prepared from",
"         <em>",
"          Fumidil-B",
"         </em>",
"         (bicyclohexyl ammonium fumagillin) used to control a microsporidial disease of honey bees (Garvey MJ, et al. Ann Pharmacother 1995; 29:872), available from Leiter's Park Avenue Pharmacy (see footnote 1). For lesions due to",
"         <em>",
"          V. corneae",
"         </em>",
"         , topical therapy is generally not effective and keratoplasty may be required (Davis RM, et al. Ophthalmology 1990; 97:953).",
"        </li>",
"        <li>",
"         Albendazole must be taken with food; a fatty meal increases oral bioavailability.",
"        </li>",
"        <li>",
"         Oral fumagillin (",
"         <em>",
"          Flisint",
"         </em>",
"         &ndash; Sanofi-Aventis, France) has been effective in treating",
"         <em>",
"          E. bieneusi",
"         </em>",
"         in patients with HIV or solid organ transplants (Molina J-M, et al. N Engl J Med 2002; 346:1963; Lanternier F, et al. Transpl Infect Dis 2009; 11:83), but has been associated with thrombocytopenia and neutropenia. Potent antiretroviral therapy (ART) may lead to microbiologic and clinical response in HIV-infected patients with microsporidial diarrhea. Octreotide",
"         <em>",
"          (Sandostatin)",
"         </em>",
"         has provided symptomatic relief in some patients with large-volume diarrhea.",
"        </li>",
"        <li>",
"         Molina J-M, et al. J Infect Dis 1995; 171:245. There is no established treatment for",
"         <em>",
"          Pleistophora",
"         </em>",
"         . For disseminated disease due to",
"         <em>",
"          Trachipleistophora",
"         </em>",
"         or",
"         <em>",
"          Anncaliia",
"         </em>",
"         , itraconazole 400 mg PO once/d plus albendazole may also be tried (Coyle CM, et al. N Engl J Med 2004; 351:42).",
"        </li>",
"        <li>",
"         Sarcocystis in humans is acquired by ingesting sporocysts in infected meat, infections characterized by nausea, abdominal pain, and diarrhea. Muscular infections are usually mild or subclinical (Fayer R.&nbsp;Clin Microbiol Rev 2004; 17:894). Albendazole was reported to be efficacious (Arness MK,&nbsp;et al. Am J Trop Med Hyg 1999; 61:548).",
"        </li>",
"       </ol>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with special permission from: Treatment Guidelines from The Medical Letter, June 2010; Vol. 8 (suppl):e1-20. www.medicalletter.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_57_42898=[""].join("\n");
var outline_f41_57_42898=null;
var title_f41_57_42899="Emphysematous cholecystitis";
var content_f41_57_42899=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F56763&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F56763&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Emphysematous cholecystitis seen on computed tomographic scan",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 325px; height: 514px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) An axial image of a contrast enhanced computed tomographic (CT) scan demonstrating air within the gallbladder lumen (arrows).",
"    <br>",
"     (B) A coronal reformat of a contrast enhanced CT demonstrating air within the wall of the gallbladder (arrow).",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Courtesy of J Pierre Sasson, MD.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_57_42899=[""].join("\n");
var outline_f41_57_42899=null;
var title_f41_57_42900="Bimatoprost: Patient drug information";
var content_f41_57_42900=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Bimatoprost: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44115?source=see_link\">",
"     see \"Bimatoprost: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F141310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Latisse&reg;;",
"     </li>",
"     <li>",
"      Lumigan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F141311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Latisse&reg;;",
"     </li>",
"     <li>",
"      Lumigan&reg;;",
"     </li>",
"     <li>",
"      Lumigan&reg; RC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691860",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat glaucoma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower high eye pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691374",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help eyelashes grow. It may take 2 months to see the full effect.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701628",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to bimatoprost or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697236",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had an eye infection, eye surgery, or eye injury, start a new bottle of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698504",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your eye pressure checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blurred eyesight. Use care when driving or doing other tasks that call for clear eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye color may change with use. This drug may raise the brown pigment. Dark eyelashes and skin around the eye may also happen. These changes may be long-lasting.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705453",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Lumigan:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Latisse&trade;:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eyelid only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean your face and take off make-up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694525",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on upper eyelid using only the applicator that comes with it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a new applicator for the other eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694743",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use the applicators more than 1 time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694565",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blot extra solution from the eyelid.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694687",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on lower lashes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11326 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.97.94.19-18180375D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_57_42900=[""].join("\n");
var outline_f41_57_42900=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141310\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141311\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022858\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022857\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022862\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022863\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022865\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022860\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022861\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022866\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022867\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44115?source=related_link\">",
"      Bimatoprost: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_57_42901="Physiology and classification of shock in children";
var content_f41_57_42901=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Physiology and classification of shock in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/57/42901/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/57/42901/contributors\">",
"     Wendy J Pomerantz, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/57/42901/contributors\">",
"     Mark G Roback, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/57/42901/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/57/42901/contributors\">",
"     Susan B Torrey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/57/42901/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/57/42901/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/57/42901/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shock is a physiologic state characterized by a significant, systemic reduction in tissue perfusion, resulting in decreased tissue oxygen delivery. Although the effects of inadequate tissue perfusion are initially reversible, prolonged oxygen deprivation leads to generalized cellular hypoxia and derangement of critical biochemical processes, including [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42901/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cell membrane ion pump dysfunction",
"     </li>",
"     <li>",
"      Intracellular edema",
"     </li>",
"     <li>",
"      Leakage of intracellular contents into the extracellular space",
"     </li>",
"     <li>",
"      Inadequate regulation of intracellular pH",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These abnormalities rapidly become irreversible and result sequentially in cell death, end-organ damage, failure of multiple organ systems, and death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42901/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Mortality from shock is less among children than adults. For children with severe sepsis, mortality is about 10 percent, in comparison to 35 to 40 percent within one month of the onset of septic shock for adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42901/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Nevertheless, outcomes for children with shock (in terms of morbidity and cost) are significant. Furthermore, unique physiologic responses to poor perfusion among children make it a challenge for clinicians to recognize shock early (before hypotension develops), when responses to treatment are more favorable.",
"   </p>",
"   <p>",
"    This topic will review the physiologic determinants and classification of shock. The initial evaluation and management of shock in children, in general, and hypovolemic and septic shock, specifically, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/49/14104?source=see_link\">",
"     \"Initial evaluation of shock in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/8/26762?source=see_link\">",
"     \"Initial management of shock in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/59/41912?source=see_link\">",
"     \"Hypovolemic shock in children: Initial evaluation and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/6/10346?source=see_link\">",
"     \"Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHYSIOLOGIC DETERMINANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parameters that determine adequate oxygen delivery to tissues include blood flow to tissues (cardiac output), the regional balance between blood flow and metabolic demand, and the oxygen content of blood (hemoglobin concentration and percentage of hemoglobin saturated with oxygen) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42901/abstract/3\">",
"     3",
"    </a>",
"    ]. Physiologic variables that the body can manipulate to compensate for compromised perfusion include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac output (volume of blood flow per unit of time) is the product of stroke volume times heart rate. Hence, tachycardia is a common sign of decreased perfusion and early shock. Infants have relatively fixed stroke volumes and are particularly dependent upon heart rate to increase cardiac output.",
"     </li>",
"     <li>",
"      Stroke volume is determined by preload, cardiac contractility, and afterload. Compensatory mechanisms that improve stroke volume include increased venous smooth muscle tone (improves preload by shunting blood to the heart) and increased cardiac contractility (resulting in more complete emptying of the ventricles).",
"     </li>",
"     <li>",
"      Increased systemic vascular resistance (vasoconstriction) maintains perfusion pressure (measured as blood pressure) despite decreased cardiac output. In addition, blood is shunted away from peripheral structures (including skin, muscle, kidneys, and splanchnic organs) to the heart and central nervous system. As a result, children with compensated shock typically have normal blood pressures, despite signs of poor perfusion (such as decreased peripheral pulses and tachycardia). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/49/14104?source=see_link&amp;anchor=H8#H8\">",
"       \"Initial evaluation of shock in children\", section on 'Evaluation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While decreased perfusion directly reflects decreased cardiac output, the increased cardiac output observed in hyperdynamic shock states also is associated with decreased effective tissue perfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42901/abstract/8\">",
"     8",
"    </a>",
"    ]. This decreased effective perfusion derives from a complex interaction of numerous humoral and microcirculatory processes resulting in patchy, uneven local regional blood flow and a derangement of cellular metabolic processes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42901/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     STAGES OF SHOCK",
"    </span>",
"    &nbsp;&mdash;&nbsp;The shock syndrome is characterized by a continuum of physiologic stages beginning with an initial inciting event that causes a systemic disturbance in tissue perfusion. Subsequently, shock may progress through three stages if not successfully treated, culminating in end-organ damage, irreversible shock, and death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42901/abstract/2,10\">",
"     2,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Compensated shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;During compensated shock, the body's homeostatic mechanisms rapidly compensate for diminished perfusion and systolic blood pressure is maintained within the normal range [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42901/abstract/3\">",
"     3",
"    </a>",
"    ]. Heart rate is initially increased. Signs of peripheral vasoconstriction (such as cool skin, decreased peripheral pulses, and oliguria) can be noted as perfusion becomes further compromised.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Decompensated shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;During this stage, compensatory mechanisms are overwhelmed. Signs and symptoms of organ dysfunction (such as altered mental status as the result of poor brain perfusion) appear. Systolic blood pressure falls, although children who have lost as much as 30 to 35 percent of circulating blood volume can typically maintain normal systolic blood pressures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42901/abstract/3,11\">",
"     3,11",
"    </a>",
"    ]. Once hypotension develops, the child's condition usually deteriorates rapidly to cardiovascular collapse and cardiac arrest.",
"   </p>",
"   <p>",
"    Although hypotension is generally a late finding among children with shock, those with early distributive shock (as with sepsis) may have hypotension because of decreased systemic vascular resistance (SVR). Vital organ perfusion is initially maintained by increased cardiac output.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Irreversible shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;During this stage, progressive end-organ dysfunction leads to irreversible organ damage and death. The process is often irreversible, despite resuscitative efforts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three broad mechanisms of shock are recognized: hypovolemic, distributive, and cardiogenic. Each type is characterized by one primary physiologic derangement (",
"    <a class=\"graphic graphic_table graphicRef73000 \" href=\"mobipreview.htm?17/34/17963\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    For any given condition that can cause shock, the classification may be mixed. Patients with distributive shock, in particular, often have multiple physiologic abnormalities. As an example, children with distributive shock from sepsis may also have volume loss (from vomiting, diarrhea, poor intake, or increased insensible fluid loss from tachypnea and fever) and myocardial depression from the effect of inflammatory mediators released in response to infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42901/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hypovolemic shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypovolemic shock is the most common type of shock encountered in children. It results from decreased preload from extravascular fluid loss (such as with diarrhea or osmotic diuresis) or intravascular fluid loss (as with capillary leak or hemorrhage). Because preload is one of the determinants of stroke volume, cardiac output falls when preload drops. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/59/41912?source=see_link\">",
"     \"Hypovolemic shock in children: Initial evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Distributive shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distributive or vasodilatory shock results from a decrease in SVR, with abnormal distribution of blood flow within the microcirculation and inadequate tissue perfusion. It can lead to functional hypovolemia with decreased preload [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42901/abstract/3,5,8\">",
"     3,5,8",
"    </a>",
"    ]. Distributive shock generally is associated with a normal or increased cardiac output.",
"   </p>",
"   <p>",
"    Causes of distributive shock include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sepsis is the most common etiology of distributive shock among children. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/6/10346?source=see_link\">",
"       \"Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anaphylaxis is an immediate, potentially life-threatening systemic reaction to an exogenous stimulus, typically an allergic, IgE-mediated immediate hypersensitivity reaction. Anaphylactoid responses are clinically indistinguishable reactions that occur by",
"      <span class=\"nowrap\">",
"       nonantigen/antibody-mediated",
"      </span>",
"      mechanisms. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link\">",
"       \"Anaphylaxis: Rapid recognition and treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neurogenic shock is a rare, usually transient disorder that follows acute injury to the spinal cord or central nervous system, resulting in loss of sympathetic venous tone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cardiogenic shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiogenic shock results from pump failure, manifested physiologically as decreased systolic function and depressed cardiac output [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42901/abstract/12\">",
"     12",
"    </a>",
"    ]. Cardiogenic shock is uncommon among children (",
"    <a class=\"graphic graphic_table graphicRef67841 \" href=\"mobipreview.htm?37/34/38445\">",
"     table 2",
"    </a>",
"    ), as compared with adults, among whom ischemic heart disease is the major cause. The mechanisms of cardiogenic shock are diverse and can be divided into three general categories: cardiomyopathies, arrhythmias, and obstructive disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42901/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiomyopathies - Primary myocardial injury is an uncommon cause of shock in children. Causes of myopathic pump failure include familial, infectious, infiltrative, and idiopathic cardiomyopathies. Prolonged ischemia, cardiopulmonary bypass, and the myocardial depression of late sepsis all can contribute to secondary myocardial dysfunction.",
"     </li>",
"     <li>",
"      Arrhythmias - Structural heart disease, drug intoxications, and hypothermia are leading causes of arrhythmia in children. Both atrial and ventricular arrhythmias can cause cardiogenic shock.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Ventricular fibrillation and pulseless ventricular tachycardia abolish cardiac output, while diminished ventricular filling time during ventricular tachycardia decreases preload and stroke volume substantially. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/40/22152?source=see_link\">",
"       \"Management and evaluation of wide QRS complex tachycardia in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prolonged unrecognized supraventricular tachycardia (as can occur with the initial presentation for infants) can decrease cardiac output. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/54/31593?source=see_link\">",
"       \"Supraventricular tachycardia in children: AV reentrant tachycardia (including WPW) and AV nodal reentrant tachycardia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bradyarrhythmias and complete heart block can result in shock caused by chronotropic (heart rate) insufficiency, independent of stroke volume. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/24/33161?source=see_link\">",
"       \"Bradycardia in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obstructive disorders - Obstruction to heart function can result from congenital heart disorders or acquired conditions such as tension pneumothorax, cardiac tamponade, and massive pulmonary embolism. An infant with ductal-dependent congenital heart abnormalities (such as coarctation of the aorta or hypoplastic left ventricle syndrome) may present in cardiogenic shock when the ductus closes during the first few weeks of life. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/39/17018?source=see_link&amp;anchor=H19#H19\">",
"       \"Approach to the septic-appearing infant\", section on 'Prostaglandin E1 (alprostadil)'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     COMMON FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of shock is variable, but several features are common. These include tachycardia and signs of compromised organ perfusion (skin, brain, and kidneys). Children often present before hypotension develops. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/49/14104?source=see_link\">",
"     \"Initial evaluation of shock in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tachycardia &ndash; Tachycardia is typical. Although tachycardia is an important early indicator of shock, it is a nonspecific finding. Many common conditions in children such as fever, pain, and anxiety can cause tachycardia without circulatory compromise. A normal heart rate with signs of compensated shock can occur with spinal cord injury and bradycardia can occur as the result of hypoxia, some ingestions (such as beta blockers and calcium channel blockers), or as an agonal event for patients with shock from any cause (",
"      <a class=\"graphic graphic_table graphicRef77057 \" href=\"mobipreview.htm?17/33/17947\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Skin changes &ndash; In many shock states, regulatory processes compensate for decreased effective tissue perfusion. Potent vasoconstrictive mechanisms redirect blood from the peripheral, splanchnic, and renal vessels to maintain coronary and cerebral perfusion. As a result, the skin is typically cool, clammy, pale, or mottled.",
"      <br/>",
"      <br/>",
"      Notable exceptions are the flushed, hyperemic skin of early distributive shock and the peripheral vasodilation of terminal shock states associated with failure of mechanisms that maintain increased peripheral vascular resistance (irreversible shock).",
"     </li>",
"     <li>",
"      Impaired mental status &ndash; Children with impaired cerebral perfusion may be initially listless or agitated and not interacting with caregivers. Mental status typically deteriorates to obtundation and coma as the shock state worsens.",
"     </li>",
"     <li>",
"      Oliguria &ndash; Oliguria with decreased glomerular filtration rate results from the shunting of renal blood flow to other vital organs and the fall in intraglomerular pressure, which normally drives glomerular filtration.",
"     </li>",
"     <li>",
"      Lactic acidosis &ndash; Progressive tissue hypoperfusion is associated with the development of lactic acidosis. Two factors contribute to this abnormality: increased lactic acid production caused by inadequate delivery of oxygen and decreased clearance of lactate by the liver, kidneys, and skeletal muscle [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/57/42901/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/44/3781?source=see_link\">",
"       \"Causes of lactic acidosis\"",
"      </a>",
"      .) The early stages of sepsis often are associated with a respiratory alkalosis caused by primary hyperventilation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/57/42901/abstract/16\">",
"       16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27288?source=see_link\">",
"       \"Simple and mixed acid-base disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypotension &ndash; Hypotension is typically a",
"      <strong>",
"       late",
"      </strong>",
"      finding among children in shock. Compensatory vasoconstriction is often so pronounced that systemic blood pressure can be maintained within the normal range, despite significant circulatory compromise. In this situation, the main clinical manifestations of shock are tachycardia and signs of organ hypoperfusion.",
"      <br/>",
"      <br/>",
"      For children, hypotension is defined as a systolic blood pressure that is less than the fifth percentile of normal for age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/57/42901/abstract/3\">",
"       3",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Less than 60 mmHg in term neonates (0 to 28 days)",
"     </li>",
"     <li>",
"      Less than 70 mmHg in infants (1 month to 12 months)",
"     </li>",
"     <li>",
"      Less than 70 mmHg + (2 x age in years) in children 1 to 10 years",
"     </li>",
"     <li>",
"      Less than 90 mmHg in children 10 years of age or older",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shock is a physiologic state characterized by a significant, systemic reduction in tissue perfusion, resulting in decreased tissue oxygen delivery. Unique physiologic responses to poor perfusion among children make it a challenge for clinicians to recognize shock early (before hypotension develops), when responses to treatment are more favorable.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physiologic variables that the body can manipulate to compensate for compromised perfusion include cardiac output (stroke volume times heart rate), stroke volume (determined by preload, cardiac contractility, and afterload), and systemic vascular resistance (SVR). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Physiologic determinants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During compensated shock, the body's homeostatic mechanisms rapidly compensate for diminished perfusion and systolic blood pressure is maintained within the normal range. Once hypotension develops, the child's condition usually deteriorates rapidly to cardiovascular collapse and cardiac arrest. Progressive end-organ dysfunction leads to irreversible organ damage and death. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Stages of shock'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Types of shock include hypovolemic shock (characterized primarily by reduction in preload, as the result of fluid loss), distributive shock (decreased SVR with abnormal distribution of blood flow from sepsis, anaphylaxis, or nervous system injury), and cardiogenic shock (pump failure as the result of cardiomyopathies, arrhythmias, or obstruction). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Common features of shock include tachycardia and signs of compromised organ perfusion (skin, brain, and kidneys). Children often present before hypotension develops. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Common features'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42901/abstract/1\">",
"      Barber AE, Shires GT. Cell damage after shock. New Horiz 1996; 4:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42901/abstract/2\">",
"      Kristensen SR. Mechanisms of cell damage and enzyme release. Dan Med Bull 1994; 41:423.",
"     </a>",
"    </li>",
"    <li>",
"     Pediatric Advanced Life Support Provider Manual. Ralston M, et al (Eds), American Heart Association, Subcommittee on Pediatric Resuscitation, Dallas, 2006, p.61.",
"    </li>",
"    <li>",
"     Bell LM. Shock. In: Textbook of Pediatric Emergency Medicine, 6th, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. p.46.",
"    </li>",
"    <li>",
"     Tobin RT, Wetzel RC. Shock and multiple system organ failure. In: Textbook of Pediatric Intensive Care, Rogers MC (Ed), Williams &amp; Wilkins, Baltimore 1996. p.555.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42901/abstract/6\">",
"      Watson RS, Carcillo JA, Linde-Zwirble WT, et al. The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med 2003; 167:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42901/abstract/7\">",
"      Bone RC. Toward an epidemiology and natural history of SIRS (systemic inflammatory response syndrome). JAMA 1992; 268:3452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42901/abstract/8\">",
"      Chittock DR, Russell JA. Oxygen delivery and consumption during sepsis. Clin Chest Med 1996; 17:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42901/abstract/9\">",
"      Hinshaw LB. Sepsis/septic shock: participation of the microcirculation: an abbreviated review. Crit Care Med 1996; 24:1072.",
"     </a>",
"    </li>",
"    <li>",
"     Abboud FM. Pathophysiology of hypotension and shock. In: The Heart, Hurst JW (Ed), McGraw-Hill, New York 1982. p.452.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42901/abstract/11\">",
"      Schwaitzberg SD, Bergman KS, Harris BH. A pediatric trauma model of continuous hemorrhage. J Pediatr Surg 1988; 23:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42901/abstract/12\">",
"      Rodgers KG. Cardiovascular shock. Emerg Med Clin North Am 1995; 13:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42901/abstract/13\">",
"      Witte MK, Hill JH, Blumer JL. Shock in the pediatric patient. Adv Pediatr 1987; 34:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42901/abstract/14\">",
"      Bengur AR, Meliones JN. Cardiogenic shock. New Horiz 1998; 6:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42901/abstract/15\">",
"      Levraut J, Ciebiera JP, Chave S, et al. Mild hyperlactatemia in stable septic patients is due to impaired lactate clearance rather than overproduction. Am J Respir Crit Care Med 1998; 157:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42901/abstract/16\">",
"      Simmons, DH, Nicoloff, J, Guze, LB. Hyperventilation and respiratory alkalosis as signs of gram negative bacteremia. JAMA 1960; 174:219.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6388 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-201.211.0.116-CC27B9A4A4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_57_42901=[""].join("\n");
var outline_f41_57_42901=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHYSIOLOGIC DETERMINANTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      STAGES OF SHOCK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Compensated shock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Decompensated shock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Irreversible shock",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hypovolemic shock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Distributive shock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cardiogenic shock",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      COMMON FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6388\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6388|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/34/17963\" title=\"table 1\">",
"      Types of shock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/34/38445\" title=\"table 2\">",
"      Causes of cardiogenic shock in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/33/17947\" title=\"table 3\">",
"      Heart rates in normal children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/39/17018?source=related_link\">",
"      Approach to the septic-appearing infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/24/33161?source=related_link\">",
"      Bradycardia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/44/3781?source=related_link\">",
"      Causes of lactic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/59/41912?source=related_link\">",
"      Hypovolemic shock in children: Initial evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/49/14104?source=related_link\">",
"      Initial evaluation of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/8/26762?source=related_link\">",
"      Initial management of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/40/22152?source=related_link\">",
"      Management and evaluation of wide QRS complex tachycardia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27288?source=related_link\">",
"      Simple and mixed acid-base disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/54/31593?source=related_link\">",
"      Supraventricular tachycardia in children: AV reentrant tachycardia (including WPW) and AV nodal reentrant tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/6/10346?source=related_link\">",
"      Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_57_42902="Serologic markers of autoimmune hepatitis";
var content_f41_57_42902=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Serologic markers of autoimmune hepatitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/57/42902/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/57/42902/contributors\">",
"     Edward L Krawitt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/57/42902/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/57/42902/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/57/42902/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/57/42902/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/57/42902/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmune hepatitis is a chronic hepatitis characterized by immunologic and autoimmunologic features, generally including the presence of circulating autoantibodies and a high total serum",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    gamma globulin, usually confined to the IgG fraction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42902/abstract/1\">",
"     1",
"    </a>",
"    ]. Most cases respond to antiinflammatory or immunosuppressive therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/7/40058?source=see_link\">",
"     \"Treatment of autoimmune hepatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The main circulating autoantibodies, although not specific for the disease, are antinuclear antibodies (ANA) and anti-smooth muscle antibodies (ASMA) in type 1 disease and, in type 2 autoimmune hepatitis, anti-liver-kidney microsome-1 antibodies (ALKM-1) and anti-liver cytosol antibody-1 (ALC-1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42902/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The autoantibodies are not believed to be involved in the pathogenesis of autoimmune hepatitis and are not predictive of histologic severity or treatment-response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42902/abstract/3\">",
"     3",
"    </a>",
"    ]. Their main role is to identify patients with autoimmune hepatitis and thereby point the way toward appropriate therapy and form the basis for a classification (",
"    <a class=\"graphic graphic_table graphicRef65135 \" href=\"mobipreview.htm?8/0/8203\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/32/27140?source=see_link\">",
"     \"Classification of autoimmune hepatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other circulating autoantibodies in autoimmune hepatitis can also provide help in diagnosing patients without classical autoantibodies, who previously may have been diagnosed as \"autoantibody-negative autoimmune hepatitis\" or cryptogenic chronic hepatitis. As an example, the presence of autoimmune hepatitis is suggested in a patient with chronic hepatitis who, in the absence of serologic markers of viral hepatitis, has anti-soluble liver",
"    <span class=\"nowrap\">",
"     /",
"    </span>",
"    liver pancreas antigen",
"    <span class=\"nowrap\">",
"     (anti-SLA/LP)",
"    </span>",
"    or atypical perinuclear antineutrophil cytoplasmic antibodies (atypical pANCA), also referred to as \"anti-neutrophil nuclear antibody\" (pANNA).",
"   </p>",
"   <p>",
"    Patients may present with autoimmune hepatitis without circulating autoantibodies, referred to as \"autoantibody-negative autoimmune hepatitis\". Although infrequent, their course and response to treatment appear to be identical to autoantibody-positive patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42902/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most of the data on autoantibodies are based upon results obtained by immunofluorescence. By contrast, commercial laboratories tend to measure autoantibodies by ELISA, and thus it is possible that results may differ from those reported in the literature.",
"   </p>",
"   <p>",
"    This topic review will discuss the characteristics of the major autoantibodies that can occur in the two forms of autoimmune hepatitis and, when relevant, compare the findings in autoimmune hepatitis to the autoantibodies that can occur with chronic hepatitis C virus infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANTINUCLEAR ANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antinuclear antibodies are serologic hallmarks for systemic or organ-specific autoimmune disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28520?source=see_link\">",
"     \"Measurement and clinical significance of antinuclear antibodies\"",
"    </a>",
"    .) ANA are the most common circulating autoantibodies in autoimmune hepatitis. They are seen in adults and children with type 1 disease and rarely in type 2 disease. Titers considered positive are dependent in part upon the methodology used and the age of the patient. In most laboratories, titers in the range of 1:80 to 1:100 or greater are considered positive in adults. In children, titers of 1:20 or greater are considered positive. ANA may be the only autoantibody present or may occur in conjunction with ASMA. While ANA are commonly present in patients with autoimmune hepatitis, there are occasional patients whose only marker for autoimmune hepatitis is an elevated serum globulin level, so-called autoantibody negative autoimmune hepatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Immunofluorescence patterns",
"    </span>",
"    &nbsp;&mdash;&nbsp;Correlation of the patterns of ANA immunofluorescence with clinical characteristics, as has been done in rheumatic conditions, has been attempted in a group of patients with autoimmune hepatitis and ANA titers of 1:40 or higher [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42902/abstract/5\">",
"     5",
"    </a>",
"    ]. Using Hep-2 cell lines as a substrate, homogeneous patterns were found in 22 of 65 patients (34 percent) and a speckled pattern in 25 patients (38 percent). Centromeric, diffuse granular, nucleolar, mixed, and unclassified patterns accounted for the remainder. The immunofluorescence patterns were not helpful in determining distinguishing clinical features.",
"   </p>",
"   <p>",
"    When sera were used to search for the presence of antibodies to specific recombinant antigens, multiple reactivities were found. The most prevalent finding was that of antibodies to Cenp-B which was observed primarily, but not exclusively, in patients with a speckled pattern. No clinical correlations were apparent in patients with specific antigens, nor in the 30 percent of patients without reactivity to the nuclear antigens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Comparison with chronic hepatitis C",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the features seen in autoimmune hepatitis occur in chronic viral hepatitis, including hypergammaglobulinemia and circulating autoantibodies. Approximately 5 percent of patients with chronic hepatitis C virus (HCV) infection have ANA at titers of 1:100 or greater [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42902/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. One study compared ANA immunofluorescence patterns in patients with autoimmune hepatitis and chronic hepatitis C with a minimum titer of 1:40 using rat liver and kidney sections as a substrate; a homogeneous pattern was more common in ANA-positive autoimmune hepatitis cases than ANA-positive chronic hepatitis C (71 versus 38 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42902/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are other ways to distinguish autoimmune hepatitis from hepatitis C. Patients with classical hepatitis C infection do not have prominent plasma cell infiltration on liver biopsy, a feature that is often prominent in autoimmune hepatitis. Autoimmune hepatitis has been called \"plasma cell\" hepatitis in the past. In addition, patients with autoimmune hepatitis may have marked elevations in serum IgG, a feature that is unusual in patients with chronic hepatitis C, particularly in Caucasians. Rarely, patients have both hepatitis C and autoimmune hepatitis. In such cases, it is prudent to first treat the autoimmune hepatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ANTI-SMOOTH MUSCLE ANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-smooth muscle antibodies are the second major class of autoantibodies which have proved useful in the diagnosis of type 1 autoimmune hepatitis. Although less prevalent than ANA, they are more specific, particularly when present in titers of 1:80 or more. In children, titers of 1:20 or greater are considered positive. In a study of autoimmune hepatitis in childhood, 26 of 32 children (81 percent) with type 1 autoimmune hepatitis had ASMA titers ranging from 1:10 to 1:2560 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42902/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Antiactin antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiactin antibodies (AAA) are more specific for type 1 autoimmune hepatitis than other autoantibodies but until recently have not generally been measured in clinical laboratories in North America. ASMA titers of 1:320 or greater generally reflect the presence of AAA and can serve as a surrogate marker for these antibodies. In one study, for example, antiactin antibodies were present much more frequently (86 versus 7 percent) in patients with ASMA than in patients without ASMA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42902/abstract/9\">",
"     9",
"    </a>",
"    ]. Antiactin antibodies are closely associated with the HLA phenotypes B8 and DR3, which are associated with a poor prognosis in autoimmune hepatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42902/abstract/9\">",
"     9",
"    </a>",
"    ]. In another report, in patients with ASMA, those who also had AAA were more frequently HLA-B8-positive than those without these antibodies (49 versus 0 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42902/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antiactin antibodies (IgG anti F actin) measured by ELISA have become more readily available, and in some laboratories, have replaced ASMA in autoantibody profiles. They appear to be more sensitive and specific than ASMA measured by immunofluorescence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42902/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Comparison with chronic hepatitis C",
"    </span>",
"    &nbsp;&mdash;&nbsp;Circulating ASMA are also found in patients with chronic hepatitis C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42902/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The mean ASMA titer was higher in patients with autoimmune hepatitis (1:320 versus 1:40 in HCV) in one series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42902/abstract/7\">",
"     7",
"    </a>",
"    ]. There was, however, some overlap. The difference was much greater for AAA, which were present in 28 of 32 (87 percent) patients with autoimmune hepatitis patients compared to only 5 of 59 (8 percent) with chronic hepatitis",
"    <span class=\"nowrap\">",
"     C.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ANTI-SOLUBLE LIVER ANTIGEN/LIVER PANCREAS ANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-SLA/LP",
"    antibodies, also known as SEPSECS (Sep0-phosphpserine) tRNA synthase, have been found in approximately 10 to 30 percent of adult patients with type 1 autoimmune hepatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42902/abstract/12,13\">",
"     12,13",
"    </a>",
"    ], but are more common in children with both type 1 and type 2 disease. The antibodies were initially thought to be directed against several liver antigens, including cytokeratins 8 and 18 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42902/abstract/13\">",
"     13",
"    </a>",
"    ] and subunits of glutathione S-transferases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42902/abstract/14\">",
"     14",
"    </a>",
"    ]. However, subsequent cloning and characterization of the antigen revealed that it is a unique enzyme (possibly a UGA-suppressor or tRNA-associated protein) and is a member of the superfamily of pyridoxal phosphate-dependent transferases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42902/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Furthermore, the antigen was identical to the liver-pancreas antigen, which has also been described in a subset of patients with autoimmune hepatitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/8/19590?source=see_link\">",
"     \"Pathogenesis of autoimmune hepatitis\"",
"    </a>",
"    .) The antibodies themselves are of the IgG1 subtypes, suggesting that they may arise from a specific immune stimulus such as a viral protein. However, no homologous virus-derived peptides could be identified in one report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42902/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     Anti-SLA/LP",
"    </span>",
"    antibodies are the only circulating antibody in some patients, which originally led to their consideration as a distinct type (type 3). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/32/27140?source=see_link\">",
"     \"Classification of autoimmune hepatitis\"",
"    </a>",
"    .) Although these patients are no longer thought to represent a separate type, the isolated appearance of anti-SLA antibodies may help to identify patients who might otherwise have been classified as having \"cryptogenic chronic hepatitis\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42902/abstract/18\">",
"     18",
"    </a>",
"    ]. A study of 144 North American patients (15 percent of whom had",
"    <span class=\"nowrap\">",
"     anti-SLA/LP)",
"    </span>",
"    found a positive association with the serotype DR3 and a negative association with DR4 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42902/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;ANCA are a group of autoantibodies that recognize neutrophil proteins. The antibodies associated with granulomatosis with polyangiitis (Wegener's) and microscopic polyarteritis are directed against serine protease 3 (with a cytoplasmic or c-ANCA pattern on immunofluorescence) and myeloperoxidase (with a perinuclear or p-ANCA pattern on immunofluorescence). Atypical p-ANCA is also seen in inflammatory bowel disease and primary sclerosing cholangitis. These antibodies have a perinuclear or atypical staining pattern on immunofluorescence and appear to be directed against a myeloid 50-kd nuclear envelope protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42902/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/28/9674?source=see_link\">",
"     \"Clinical spectrum of antineutrophil cytoplasmic antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Atypical p-ANCA (pANNA) have been identified in type 1 but not type 2 autoimmune hepatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42902/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. In one series from Italy, for example, atypical p-ANCA was identified in 30 of 46 (65 percent) patients with type 1 autoimmune hepatitis patients as defined by the presence of ANA",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ASMA at titers of 1:40 or greater [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42902/abstract/21\">",
"     21",
"    </a>",
"    ]. Primary sclerosing cholangitis, which is often associated with underlying inflammatory bowel disease (usually ulcerative colitis) may be confused with autoimmune hepatitis because the latter may also be associated with ulcerative colitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ANTIMITOCHONDRIAL ANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimitochondrial antibodies (AMA), although more specific and sensitive for primary biliary cirrhosis, also can occur in type 1 autoimmune hepatitis. The frequency of these autoantibodies in autoimmune hepatitis varied significantly across different reports but is generally in the 5 to 20 percent range. One report from Italy found no AMA in 125 type 1 patients, which was due at least in part to a stricter definition of the autoimmune",
"    <span class=\"nowrap\">",
"     hepatitis/primary",
"    </span>",
"    biliary cirrhosis overlap (variant) syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42902/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/4/35911?source=see_link\">",
"     \"Definition and treatment of variants of autoimmune hepatitis\"",
"    </a>",
"    .) A long-term follow-up study of AMA-positive autoimmune hepatitis reported that no patients progressed to primary biliary cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42902/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Anti-DNA antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not frequently sought, antibodies to double-stranded DNA, which are most commonly associated with systemic lupus erythematosus, and single-stranded DNA can occur in autoimmune hepatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42902/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/10/1192?source=see_link\">",
"     \"Antibodies to double-stranded (ds)DNA, Sm, and U1 RNP\"",
"    </a>",
"    .) Anti-dsDNA positivity is associated with the presence of HLA-DR4, and may identify a subset of patients less likely to respond to glucocorticoid therapy. Antibodies to ssDNA are common, but do not appear to distinguish among clinical patterns.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ANTI-LIVER-KIDNEY MICROSOMAL-1 ANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;ALKM-1 and ALC-1 antibodies are the major autoantibodies in type 2 autoimmune hepatitis, a disease which occurs predominantly in girls and young women (",
"    <a class=\"graphic graphic_table graphicRef65135 \" href=\"mobipreview.htm?8/0/8203\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42902/abstract/8,26,27\">",
"     8,26,27",
"    </a>",
"    ]. ALKM-1 antibodies, which are directed at the cytochrome P450 enzyme CYP2D6, are also found in approximately 5 percent of patients with chronic HCV and 25 percent of those with halothane-induced hepatitis and graft-versus-host disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42902/abstract/26\">",
"     26",
"    </a>",
"    ]. They differ from ALKM-2 and ALKM-3 antibodies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ALKM-2 are detected in ticrynafen-induced hepatitis and are directed at CYP2C9.",
"     </li>",
"     <li>",
"      ALKM-3 are directed against uridine diphosphate-glucuronosyl transferases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/57/42902/abstract/28\">",
"       28",
"      </a>",
"      ]; they are found in some patients with delta hepatitis and occasionally in patients with type 2 autoimmune hepatitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/57/42902/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    ALKM-1 antibodies may be accompanied by anti-liver cytosol-1 (ALC-1) antibodies (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Anti-liver cytosol antibody-1'",
"    </a>",
"    below) and occasionally by ANA",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ASMA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42902/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Comparison with chronic hepatitis C",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some European countries, but apparently not the United States, ALKM-1 occurs with a similar or greater frequency in patients with chronic hepatitis C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42902/abstract/6\">",
"     6",
"    </a>",
"    ]. However, the ALKM-1 antibodies in the two disorders appear to be directed against different epitopes on CYP2D6 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42902/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. The antibodies in autoimmune hepatitis are more homogeneous, titers are higher, and major autoepitopes on CYP2D6 are small and linear; in comparison, ALKM-1 antibodies in HCV are more heterogeneous and have multiple epitopes, many of which are conformational [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42902/abstract/29\">",
"     29",
"    </a>",
"    ]. Cross-reactivity due to molecular mimicry between the CYP2D6 and HCV NS3 and Ns5a proteins might explain the presence of anti-LKM1 in some HCV patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42902/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ANTI-LIVER CYTOSOL ANTIBODY-1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-liver cytosol antibody-1 (ALC-1 or LC1) is also a marker of type 2 autoimmune hepatitis. In one report LC1 antibodies were found in 48 percent of such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42902/abstract/27\">",
"     27",
"    </a>",
"    ]. They generally occur in conjunction with ALKM-1, but may be the sole autoantibody [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42902/abstract/33\">",
"     33",
"    </a>",
"    ]. The antigen recognized by LC1 is formiminotransferase cyclodeaminase (FTCD), a liver-specific 58-kd metabolic enzyme [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42902/abstract/34\">",
"     34",
"    </a>",
"    ]. Measurement of LC1 antibodies is not generally available in commercial laboratories. Whether or not the titers of LC1",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ALKM-1 reflect disease activity in autoimmune hepatitis is not clear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/56/25474?source=see_link\">",
"       \"Patient information: Autoimmune hepatitis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The main serologic markers of autoimmune hepatitis are circulating autoantibodies, which have served to identify patients with autoimmune hepatitis, pointed the way toward appropriate therapy, and formed the basis for a classification (",
"      <a class=\"graphic graphic_table graphicRef65135 \" href=\"mobipreview.htm?8/0/8203\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      ANA are the most common circulating autoantibodies found in type 1 autoimmune hepatitis. They are less specific than SMA, AAA or",
"      <span class=\"nowrap\">",
"       anti-SLA/LP.",
"      </span>",
"      Titers considered positive are dependent in part upon the methodology used and the age of the patient. In most laboratories, a titer of 1:80 or greater is considered positive in adults.",
"     </li>",
"     <li>",
"      ASMA are the second major class of autoantibodies which have proved useful in the diagnosis of type 1 autoimmune hepatitis. Although less prevalent than ANA, they are more specific, particularly when present in titers of 1:80 or more in adults.",
"     </li>",
"     <li>",
"      AAA performed by ELISA appear to be more sensitive and specific than ASMA.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Anti-SLA/LP",
"      </span>",
"      antibodies are found in only 10 to 30 percent of adults with autoimmune hepatitis, but are the most specific of the autoantibodies.",
"     </li>",
"     <li>",
"      ALKM-1 and ALC-1 antibodies are the major autoantibodies in type 2 autoimmune hepatitis, a disease which occurs predominantly in girls and young women (",
"      <a class=\"graphic graphic_table graphicRef65135 \" href=\"mobipreview.htm?8/0/8203\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42902/abstract/1\">",
"      Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006; 354:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42902/abstract/2\">",
"      Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51:2193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42902/abstract/3\">",
"      Mehendiratta V, Mitroo P, Bombonati A, et al. Serologic markers do not predict histologic severity or response to treatment in patients with autoimmune hepatitis. Clin Gastroenterol Hepatol 2009; 7:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42902/abstract/4\">",
"      Czaja AJ. Autoantibody-negative autoimmune hepatitis. Dig Dis Sci 2012; 57:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42902/abstract/5\">",
"      Czaja AJ, Nishioka M, Morshed SA, Hachiya T. Patterns of nuclear immunofluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis. Gastroenterology 1994; 107:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42902/abstract/6\">",
"      Reddy KR, Krawitt EL, Homberg JC, et al. Absence of anti-LKM-1 antibody in hepatitis C viral infection in the United States of America. J Viral Hepat 1995; 2:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42902/abstract/7\">",
"      Cassani F, Cataleta M, Valentini P, et al. Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile. Hepatology 1997; 26:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42902/abstract/8\">",
"      Gregorio GV, Portmann B, Reid F, et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997; 25:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42902/abstract/9\">",
"      Czaja AJ, Cassani F, Cataleta M, et al. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology 1996; 24:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42902/abstract/10\">",
"      Frenzel C, Herkel J, L&uuml;th S, et al. Evaluation of F-actin ELISA for the diagnosis of autoimmune hepatitis. Am J Gastroenterol 2006; 101:2731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42902/abstract/11\">",
"      Granito A, Muratori L, Muratori P, et al. Antibodies to filamentous actin (F-actin) in type 1 autoimmune hepatitis. J Clin Pathol 2006; 59:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42902/abstract/12\">",
"      Manns M, Gerken G, Kyriatsoulis A, et al. Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet 1987; 1:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42902/abstract/13\">",
"      W&auml;chter B, Kyriatsoulis A, Lohse AW, et al. Characterization of liver cytokeratin as a major target antigen of anti-SLA antibodies. J Hepatol 1990; 11:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42902/abstract/14\">",
"      Wesierska-Gadek J, Grimm R, Hitchman E, Penner E. Members of the glutathione S-transferase gene family are antigens in autoimmune hepatitis. Gastroenterology 1998; 114:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42902/abstract/15\">",
"      Wies I, Brunner S, Henninger J, et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 2000; 355:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42902/abstract/16\">",
"      Kernebeck T, Lohse AW, Gr&ouml;tzinger J. A bioinformatical approach suggests the function of the autoimmune hepatitis target antigen soluble liver antigen/liver pancreas. Hepatology 2001; 34:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42902/abstract/17\">",
"      Herkel J, Heidrich B, Nieraad N, et al. Fine specificity of autoantibodies to soluble liver antigen and liver/pancreas. Hepatology 2002; 35:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42902/abstract/18\">",
"      Ballot E, Homberg JC, Johanet C. Antibodies to soluble liver antigen: an additional marker in type 1 auto-immune hepatitis. J Hepatol 2000; 33:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42902/abstract/19\">",
"      Czaja AJ, Donaldson PT, Lohse AW. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. Am J Gastroenterol 2002; 97:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42902/abstract/20\">",
"      Terjung B, Spengler U, Sauerbruch T, Worman HJ. \"Atypical p-ANCA\" in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology 2000; 119:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42902/abstract/21\">",
"      Zauli D, Ghetti S, Grassi A, et al. Anti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitis. Hepatology 1997; 25:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42902/abstract/22\">",
"      Targan SR, Landers C, Vidrich A, Czaja AJ. High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis. Gastroenterology 1995; 108:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42902/abstract/23\">",
"      Muratori P, Granito A, Quarneti C, et al. Autoimmune hepatitis in Italy: the Bologna experience. J Hepatol 2009; 50:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42902/abstract/24\">",
"      O'Brien C, Joshi S, Feld JJ, et al. Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis. Hepatology 2008; 48:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42902/abstract/25\">",
"      Czaja AJ, Morshed SA, Parveen S, Nishioka M. Antibodies to single-stranded and double-stranded DNA in antinuclear antibody-positive type 1-autoimmune hepatitis. Hepatology 1997; 26:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42902/abstract/26\">",
"      Homberg JC, Abuaf N, Bernard O, et al. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of \"autoimmune\" hepatitis. Hepatology 1987; 7:1333.",
"     </a>",
"    </li>",
"    <li>",
"     Homberg JC, Johanet C, Dubel L. Antibodies to cytoplasmic antigens in autoimmune hepatitis. In: Autoimmune Liver Diseases, 2nd ed, Krawitt EL, Wiesner RH, Nishioka M (Eds), Elsevier, Amsterdam 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42902/abstract/28\">",
"      Philipp T, Durazzo M, Trautwein C, et al. Recognition of uridine diphosphate glucuronosyl transferases by LKM-3 antibodies in chronic hepatitis D. Lancet 1994; 344:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42902/abstract/29\">",
"      Manns MP, Obermayer-Straub P. Cytochromes P450 and uridine triphosphate-glucuronosyltransferases: model autoantigens to study drug-induced, virus-induced, and autoimmune liver disease. Hepatology 1997; 26:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42902/abstract/30\">",
"      Yamamoto AM, Cresteil D, Homberg JC, Alvarez F. Characterization of anti-liver-kidney microsome antibody (anti-LKM1) from hepatitis C virus-positive and -negative sera. Gastroenterology 1993; 104:1762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42902/abstract/31\">",
"      Muratori L, Lenzi M, Ma Y, et al. Heterogeneity of liver/kidney microsomal antibody type 1 in autoimmune hepatitis and hepatitis C virus related liver disease. Gut 1995; 37:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42902/abstract/32\">",
"      Marceau G, Lapierre P, B&eacute;land K, et al. LKM1 autoantibodies in chronic hepatitis C infection: a case of molecular mimicry? Hepatology 2005; 42:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42902/abstract/33\">",
"      Bridoux-Henno L, Maggiore G, Johanet C, et al. Features and outcome of autoimmune hepatitis type 2 presenting with isolated positivity for anti-liver cytosol antibody. Clin Gastroenterol Hepatol 2004; 2:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42902/abstract/34\">",
"      Muratori L, Sztul E, Muratori P, et al. Distinct epitopes on formiminotransferase cyclodeaminase induce autoimmune liver cytosol antibody type 1. Hepatology 2001; 34:494.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3628 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-AB43D6AFE1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_57_42902=[""].join("\n");
var outline_f41_57_42902=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANTINUCLEAR ANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Immunofluorescence patterns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Comparison with chronic hepatitis C",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ANTI-SMOOTH MUSCLE ANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Antiactin antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Comparison with chronic hepatitis C",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ANTI-SOLUBLE LIVER ANTIGEN/LIVER PANCREAS ANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ANTIMITOCHONDRIAL ANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Anti-DNA antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ANTI-LIVER-KIDNEY MICROSOMAL-1 ANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Comparison with chronic hepatitis C",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ANTI-LIVER CYTOSOL ANTIBODY-1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3628\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3628|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/0/8203\" title=\"table 1\">",
"      Classif autoimmune hepatitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/10/1192?source=related_link\">",
"      Antibodies to double-stranded (ds)DNA, Sm, and U1 RNP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/32/27140?source=related_link\">",
"      Classification of autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/28/9674?source=related_link\">",
"      Clinical spectrum of antineutrophil cytoplasmic antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/4/35911?source=related_link\">",
"      Definition and treatment of variants of autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28520?source=related_link\">",
"      Measurement and clinical significance of antinuclear antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/8/19590?source=related_link\">",
"      Pathogenesis of autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/56/25474?source=related_link\">",
"      Patient information: Autoimmune hepatitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/7/40058?source=related_link\">",
"      Treatment of autoimmune hepatitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_57_42903="Procedure for vacuum assisted operative vaginal delivery";
var content_f41_57_42903=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Procedure for vacuum assisted operative vaginal delivery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/57/42903/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/57/42903/contributors\">",
"     James Greenberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/57/42903/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/57/42903/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/57/42903/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/57/42903/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/57/42903/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1953, the Swedish obstetrician, Tage Malmstr&ouml;m, introduced a hollow disc-shaped stainless steel metal cup for vacuum assisted delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42903/abstract/1\">",
"     1",
"    </a>",
"    ]. Suction tubing attached to the dome of the cup and a traction chain passed through the tubing. The Malmstr&ouml;m cup quickly became the template for all subsequent vacuum extractor systems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42903/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By the 1970s, the vacuum extractor virtually replaced forceps for assisted deliveries in northern European countries. However, in many English-speaking countries, including the United States and the United Kingdom, adoption of the vacuum device was slower [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42903/abstract/2\">",
"     2",
"    </a>",
"    ]. Nonetheless, by 1992, the number of vacuum assisted deliveries surpassed the number of forceps deliveries in the United States, and by 2000, approximately two-thirds of operative vaginal deliveries were by vacuum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42903/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The technique for vacuum assisted operative delivery will be reviewed here. An overview of methods for operative vaginal delivery, including risks and outcomes, can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/39/15994?source=see_link\">",
"     \"Operative vaginal delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS AND CONTRAINDICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;A vacuum assisted delivery should only be attempted when a specific obstetric indication is present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42903/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The three major categories of indication are prolonged second stage of labor, nonreassuring fetal status, and maternal cardiac or neurological disease, but there is no absolute indication.",
"   </p>",
"   <p>",
"    The indications and prerequisites for operative vaginal delivery are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/39/15994?source=see_link&amp;anchor=H3#H3\">",
"     \"Operative vaginal delivery\", section on 'Indications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/39/15994?source=see_link&amp;anchor=H4#H4\">",
"     \"Operative vaginal delivery\", section on 'Prerequisites'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vacuum devices should not be used to assist delivery prior to 34 weeks of gestation because of the risk of fetal intraventricular hemorrhage. Prior scalp sampling or multiple attempts at fetal scalp electrode placement are also relative contraindications to vacuum extraction since these procedures may increase the risk of cephalohematoma or external bleeding from the scalp wound.",
"   </p>",
"   <p>",
"    In addition, known fetal demineralization diseases (eg, osteogenesis imperfecta), connective tissue disorders (eg, Ehlers-Danlos and Marfan's syndromes), fetal bleeding diatheses (eg, hemophilia, alloimmune thrombocytopenia), and suspected fetal-pelvic disproportion are contraindications to any instrumental vaginal delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Alternatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;A discussion of the choice, benefits, and risks of vacuum versus forceps delivery can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/39/15994?source=see_link&amp;anchor=H10#H10\">",
"     \"Operative vaginal delivery\", section on 'Choice of instrument'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     INSTRUMENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Instrumentation consists of a vacuum pump, a cup to attach to the fetal head, and some type of handle attached to the cup which is pulled to generate traction (",
"    <a class=\"graphic graphic_picture graphicRef55535 \" href=\"mobipreview.htm?21/58/22435\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Vacuum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suction can be generated manually or with an electrical suction device.",
"   </p>",
"   <p>",
"    The Kiwi&reg; vacuum (",
"    <a class=\"graphic graphic_picture graphicRef59015 \" href=\"mobipreview.htm?32/52/33608\">",
"     picture 2",
"    </a>",
"    ) and the Mystic&reg; vacuum both come with a pump integrated into the handle of the device so the operator controls the vacuum without need for an assistant. The Kiwi&reg; disposable device also comes with a traction force indicator, allowing the operator to compare tactile impression with an objective measure of force.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Extractor cup",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vacuum cups may be soft (pliable) or rigid and the shape may be bell or \"M\" shaped (",
"    <a class=\"graphic graphic_picture graphicRef79829 \" href=\"mobipreview.htm?18/28/18882\">",
"     picture 3",
"    </a>",
"    ). Rigid cups were initially made of metal, but these have been almost completely replaced by rigid plastic, polyurethane, or polyethylene cups. Soft cups are made of plastic, silicone, rubber, or polyethylene. Sizes vary somewhat by manufacturer; any standard cup size may be used for any fetus meeting criteria for vacuum assisted delivery (eg, &ge;34 weeks of gestation).",
"   </p>",
"   <p>",
"    The optimum type of cup has not been determined. Two randomized trials comparing a \"standard vacuum cup\" to the newer rigid plastic Kiwi&reg; Omnicup found that the latter was less effective because of more frequent detachments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42903/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The failure rates for the Kiwi&reg; Omnicup versus conventional cups were 30 to 34 percent and 19 to 21 percent, respectively. Of note, in both trials, the \"standard vacuum cup\" was actually any one of a variety of vacuum devices that were already in use at the trial hospitals, and participating obstetricians were allowed to choose their favorite device when not randomized to the newer Kiwi&reg; Omnicup. In a subsequent trial that randomized 164 women to either a Kiwi&reg; Omnicup or Malmstr&ouml;m metal cup, no differences were seen in delivery success rates and the Kiwi&reg; group had a statistically significant reduction in subaponeurotic hemorrhage (1.2 versus 10.1 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42903/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Soft versus rigid",
"    </span>",
"    &nbsp;&mdash;&nbsp;The performance characteristics of soft versus rigid cups have been examined in numerous trials. A Cochrane analysis of data from nine trials including 1375 women concluded that soft cups were more likely to fail to achieve vaginal delivery (failure rate 14.8 versus 9.5 percent, OR 1.65, 95% CI 1.19- 2.29), but were associated with less scalp injury than rigid cups (13 versus 24 percent, OR 0.45, 95% CI 0.15-0.60) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42903/abstract/10\">",
"     10",
"    </a>",
"    ]. There was no difference between the two groups in terms of maternal injury.",
"   </p>",
"   <p>",
"    Rigid cups tended to be more suitable for occiput posterior, occiput transverse, and difficult occiput anterior position deliveries given their increased traction, while soft cups appeared to be more appropriate for uncomplicated occiput anterior extractions where less traction is needed and thus the excess risk of scalp injury could be avoided. Most failures were due to cup detachment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Bell versus mushroom shape",
"    </span>",
"    &nbsp;&mdash;&nbsp;Soft cups are usually bell shaped, while rigid cups tend to be mushroom shaped (",
"    <a class=\"graphic graphic_picture graphicRef79829 \" href=\"mobipreview.htm?18/28/18882\">",
"     picture 3",
"    </a>",
"    ). Conclusive studies comparing the performance characteristics of bell-shaped cups versus the Malmstr&ouml;m mushroom or \"M\" style cups have not been performed. In terms of pure traction force, laboratory studies have demonstrated that bell shaped cups generate significantly less traction force than M-style cups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42903/abstract/11\">",
"     11",
"    </a>",
"    ]. This difference may be the result of the interaction between the cup's edges and the scalp chignon that is formed. Bell-shaped cups tend to draw the chignon into the cup, thereby reducing the available vacuum area and leading to a decrease in cup adhesiveness at the edges. This allows leakage of air and eventual detachments. M-style cups, on the other hand, have a mushroom-shaped design which tends to draw the chignon into the cup while the edges interlock with the base of the chignon, thereby creating a mechanical attachment that seems to compensate for the loss of available vacuum space. These theories have been supported by small clinical trials, although none have definitively answered the question of which cup is superior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42903/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Occiput posterior position",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the flexion point on occiput posterior presentations is positioned more posterior and higher in the vagina than with occiput anterior presentations, certain adjustments must be employed. Specifically, the cup needs to be placed much deeper in the posterior vagina. This accommodation usually necessitates a vacuum device with a discoid, rather than a bell-shaped, cup and a nonfixed traction cord rather than a firm stem. To meet these needs, special cups have been designed for occiput posterior presentation (",
"    <a class=\"graphic graphic_table graphicRef52265 \" href=\"mobipreview.htm?29/25/30108\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Handle",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most plastic bell shaped cups have a relatively rigid rod connecting the handle and cup. This impedes accurate placement of the instrument on deflexed or posterior heads. Higher success rates in these malpresentations may be achieved with rigid, plastic \"M\" cups (",
"    <a class=\"graphic graphic_table graphicRef52265 \" href=\"mobipreview.htm?29/25/30108\">",
"     table 1",
"    </a>",
"    ), one of which (discussed above) consists of a rigid plastic Malmstr&ouml;m-type cup attached by a wire to a unique combined",
"    <span class=\"nowrap\">",
"     handle/vacuum",
"    </span>",
"    pump (Kiwi Omnicup (",
"    <a class=\"graphic graphic_picture graphicRef59015 \" href=\"mobipreview.htm?32/52/33608\">",
"     picture 2",
"    </a>",
"    )).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician must know the indications and contraindications to vacuum assisted delivery and have expertise in proven techniques. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/39/15994?source=see_link&amp;anchor=H3#H3\">",
"     \"Operative vaginal delivery\", section on 'Indications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/39/15994?source=see_link&amp;anchor=H4#H4\">",
"     \"Operative vaginal delivery\", section on 'Prerequisites'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with forceps, good placement of a vacuum cup requires proper assessment of the fetal position and station, with care taken to identify molding, caput, and asynclitism. In addition, the flexion point is a critical landmark for the safe and effective use of a vacuum. Practitioners need to keep in mind that the location of cup placement becomes the leading point of the fetal head. Unlike forceps, which will usually correct asynclitism after application, failure to place the cup over the flexion point impedes delivery, rather than assisting it.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Patient preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The woman's bladder should be empty (via voiding or catheterization). The patient is placed in the dorsal lithotomy position and the fetal presentation, position, and station are confirmed and documented. Adequate anesthesia can be obtained with neuraxial anesthesia or a local block. In contrast to forceps, vacuum extraction can be performed without anesthesia if necessary, but the gravida will likely experience significant discomfort.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Determine the flexion point",
"    </span>",
"    &nbsp;&mdash;&nbsp;To effect most vaginal deliveries (whether spontaneous or assisted), the fetal head must rotate and flex at the neck to allow the passage of the widest diameter of the head through the pelvis. This pathway is optimized when the mentovertical diameter points in the direction of the delivering pathway.",
"   </p>",
"   <p>",
"    The flexion point is the location on the fetal head where outward traction pulls the head so as to allow flexion at the neck while keeping the mentovertical diameter in the direction of the birth canal. In the normally molded fetal head, the flexion point is in the midline, over the sagittal suture, approximately 6 cm from the anterior fontanelle and 3 cm from the posterior fontanelle (",
"    <a class=\"graphic graphic_figure graphicRef69870 \" href=\"mobipreview.htm?5/21/5456\">",
"     figure 1",
"    </a>",
"    ). The center of the vacuum cup should be directly over the flexion point. Since most of the commonly used vacuum cups have a diameter between 50 and 70 mm, when the center of the cup is placed over the flexion point, the edges of the cup should be approximately 3 cm from the anterior fontanelle and just at the edge of the posterior fontanelle. The anterior fontanelle is the reference point for checking the application because access to the posterior fontanelle is partially blocked once the extractor cup is in place.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Place the cup",
"    </span>",
"    &nbsp;&mdash;&nbsp;The practitioner spreads the labia and introduces the bell shaped cup by compressing and inserting it into the vagina while angling the device posteriorly. If an M-shaped or rigid cup is used, the device is flexed at the base of the shaft and inserted sideways into the vagina while angling posteriorly.",
"   </p>",
"   <p>",
"    When contact is made with the fetal head, the center of the cup is placed over the flexion point and symmetrically across the sagittal suture (",
"    <a class=\"graphic graphic_figure graphicRef69870 \" href=\"mobipreview.htm?5/21/5456\">",
"     figure 1",
"    </a>",
"    ). The entire 360&ordm; circumference of the cup must then be digitally inspected to insure that no vaginal, cervical, or vulvar tissues are trapped between the cup and the fetal surface, nor should the cup cover either fontanelle.",
"   </p>",
"   <p>",
"    After correct placement of the cup is confirmed, vacuum pressure should be raised to 100 to 150 mmHg to maintain the cup's position. The edges of the cup should again be swept with a finger to insure that no maternal tissues are entrapped. The vacuum cup is now properly in place and the higher suction pressures required for traction can be administered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Apply suction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suction pressure is measured in various units: 0.8",
"    <span class=\"nowrap\">",
"     kg/cm2",
"    </span>",
"    of atmospheric pressure = 600 mmHg = 23.6 inches of Hg = 11.6",
"    <span class=\"nowrap\">",
"     lb/in(2).",
"    </span>",
"   </p>",
"   <p>",
"    Vacuum",
"    suction pressures of 500 to 600 mmHg have been recommended during traction, although pressures in excess of 450 mmHg are rarely necessary (green zone) (",
"    <a class=\"graphic graphic_picture graphicRef57936 \" href=\"mobipreview.htm?3/24/3457\">",
"     picture 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42903/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. While lower suction pressures increase the risk of cup \"pop-offs,\" pressures beyond 600 mmHg increase the risks of fetal scalp trauma and cerebral, cranial and scalp hemorrhage.",
"   </p>",
"   <p>",
"    Rapid application of negative pressure is recommended. Although a slow, stepwise increase in vacuum pressure over 8 to 10 minutes was initially practiced, randomized trials have demonstrated that rapid application of negative pressure over 1 to 2 minutes reduced the duration of the procedure without compromising effectiveness or safety [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42903/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinician also needs to keep in mind that cup sizes vary among different manufacturers' devices and that cup size affects the overall traction force applied since force = (area under the cup)(suction). Therefore, as the size of the cup increases, the total force applied will rise even with the same amount of applied suction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42903/abstract/17\">",
"     17",
"    </a>",
"    ]. As an example, with 600 mmHg of suction, a 50 mm cup will generate 15.7 kg of traction force while a 60 mm cup will generate 22.6 kg of traction force. Whether the greater traction forces associated with larger cup sizes are associated with higher vaginal delivery rates or more fetal morbidity is unclear.",
"   </p>",
"   <p>",
"    Finally, the notion that the vacuum is \"designed to pop-off before damage occurs\" is erroneous and should not be considered a safety mechanism. The maximum suction pressure should not exceed 600 mmHg.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Exert traction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The absolute \"safe\" traction force for vacuum extraction is unknown. In 1962, one group determined a total traction force of 17.6 kg was typically necessary to affect delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42903/abstract/18\">",
"     18",
"    </a>",
"    ]. Other authors subsequently determined the traction force to be lower, approximately 12 kg in multiparas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42903/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. An observational study of 560 vacuum assisted deliveries using an omnicup vacuum device with a traction force indicator found that 86 percent of extractions occurred with 11.5 kg (25 lbs) or less traction and 14 percent with greater than 11.5 kg traction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42903/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, since traction force needs to be individually calculated and will vary with cup size, suction pressure, and altitude, it is reasonable and practical to rely solely on the suction pressure, which is displayed on all commercially available devices.",
"   </p>",
"   <p>",
"    During an instrumental delivery, practitioners assist by adding to the momentum of the maternal expulsive efforts rather than pulling the baby out independently. As soon as a contraction starts and the mother begins pushing, the vacuum suction pressure is rapidly raised to 500 to 600 mmHg (green zone on the vacuum indicator gauge).",
"   </p>",
"   <p>",
"    Traction is applied gradually as the contraction builds and is maintained for the duration of the contraction, but only in coordination with the mother's pushing (the number of pulls depends on the number of pushes; there is one \"set of pulls\" per contraction). Both hands are employed, and work in tandem. The fingertips of the dominant hand pull the device's crossbar, while the nondominant hand monitors the progress of descent and prevents cup detachment by placing counter pressure with the thumb [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42903/abstract/23\">",
"     23",
"    </a>",
"    ]. During the extraction, the stem of the device is kept perpendicular to the plane of the cup to maintain the seal with the fetal head. The device is more likely to detach if angular traction is applied or with pendulum or rocking motions. Jerking the device will lead to unnecessary pop-offs. Detachment may injure the cranium and should be avoided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42903/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Traction is applied along the axis of the pelvic curve to guide the fetal vertex, led by the flexion point, through the birth canal. Initially, the angle of traction is downward (toward the floor); the higher the beginning station, the steeper the angle of downward traction required. The axis of traction is then extended upwards to a 45 degree angle to the floor as the head emerges from the pelvis and crowns. In addition, the handle of the device is allowed to passively turn as the head auto-rotates through its descent. The handle should never be actively twisted to rotate the head. This dangerous maneuver can cause \"cookie cutter\" injuries to the fetal scalp [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42903/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Traction is gradually discontinued as the contraction ends or the mother stops pushing. Between contractions, suction pressure can be fully maintained or reduced to &lt;200 mmHg; it is well established that fetal morbidity is similar for both regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42903/abstract/24\">",
"     24",
"    </a>",
"    ]. Descent should occur with each application of traction, beginning with the first. When the head is delivered, the suction is released, the cup is removed, and the remainder of the delivery proceeds as usual. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/21/33114?source=see_link\">",
"     \"Management of normal labor and delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Routine episiotomy is not necessary for an assisted vaginal birth and may increase the risk of significant perineal trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42903/abstract/25\">",
"     25",
"    </a>",
"    ]. In a series of 1000 consecutive omnicup-assisted deliveries, the incidence of third and fourth degree tears with versus without an episiotomy was 15.8 and 5.8 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42903/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Rotations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of the fetus in posterior or transverse position may involve expectant management, manual rotation, instrumental delivery, or cesarean. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/21/5462?source=see_link&amp;anchor=H5#H5\">",
"     \"Management of the fetus in occiput posterior position\", section on 'Management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/52/13124?source=see_link&amp;anchor=H5#H5\">",
"     \"Occiput transverse position\", section on 'Management of persistent occiput transverse position'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For a vacuum assisted delivery, the fetus in occiput posterior position is extracted using a vacuum cup designed for the posteriorly position occiput and without attempts at rotation. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Occiput posterior position'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If the fetus is in occiput transverse position, the handle of the device is allowed to passively turn as the head auto-rotates from transverse or other off-midline positions to a direct anterior or posterior position as it descends. The handle should never be actively twisted to rotate the head. This dangerous maneuver can cause \"cookie cutter\" injuries to the fetal scalp [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42903/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/52/13124?source=see_link&amp;anchor=H8#H8\">",
"     \"Occiput transverse position\", section on 'Instrumental rotation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DURATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The maximum time to safely complete a vacuum assisted delivery and the number of acceptable \"pop-offs\" are unknown. A maximum of two to three cup detachments, three sets of pulls for the descent phase, three sets of pulls for the outlet extraction phase,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a maximum total vacuum application time of 15 to 30 minutes are commonly recommended, with most authors advising lesser time limits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42903/abstract/2,21,26\">",
"     2,21,26",
"    </a>",
"    ]. These recommendations are based more upon common sense and experience than scientific data, as observational series have shown no long-term differences in neonatal outcome related to these variables [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42903/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Nevertheless, the majority of successful vacuum assisted deliveries will be achieved within the parameters described above, and thus justify their use. As an example, a series including 1000 consecutive attempted omnicup-assisted deliveries reported &le;3 pop-offs in 99.9 percent of cases, use of &le;5 pulls in 98.7 percent of cases, and duration of cup application &le;10 minutes in 97.4 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42903/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although several studies have demonstrated a relationship between duration of cup application and development of cephalohematoma, the major morbidity of these lesions was largely cosmetic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     DOCUMENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Documentation should include the indication for the procedure, fetal status (station, position, estimated fetal weight, interpretation of the fetal heart rate tracing), a record of the discussion with the patient, and a detailed description of the procedure itself (type of anesthesia, type of vacuum cup, total time of vacuum application and whether vacuum was reduced between contractions, maximum vacuum achieved, number of pulls and contractions, number of detachments, description of progress with each pull, whether or not an episiotomy was performed or lacerations occurred). It is also worth documenting that the prerequisites for vacuum delivery were met: cervix fully dilated, maternal bladder empty, and no known fetal contraindications were present (eg, the gestational age was &ge;34 weeks, no known fetal bleeding diathesis, etc) and the method used for determining station (+2 of 3 or +2 of 5).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     FAILED PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reasons for failure with vacuum assisted deliveries are multifactorial. The key with an unsuccessful operative procedure is to review the events step-by-step to identify areas for future technique alternations or decision changes.",
"   </p>",
"   <p>",
"    Some reasons for failure include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fetopelvic disproportion",
"     </li>",
"     <li>",
"      Incorrect technique &mdash; Pulling the stem too quickly or when maternal expulsive efforts are weak will lead to cup detachments. Moreover, upwards traction before the head is crowning will tend to disrupt the vacuum seal and lead to pop-offs. Incorrect cup size also increases the risk of failure.",
"     </li>",
"     <li>",
"      Paramedian or deflexing applications &mdash; It is essential to identify the flexion point and focus the vacuum traction to leading the mentovertical diameter through the pelvis. Off-midline applications or deflexing applications will pull less favorable diameters of the fetal head through the pelvis and inhibit, rather than assist, delivery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/57/42903/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Large caput succedaneum &mdash; An increase in fetal scalp edema lets more of the scalp to be drawn into the cup, which reduces the available vacuum area, and, in turn, lessens total traction. The effect is more pronounced with bell-shaped cups than in M-style cups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/57/42903/abstract/11\">",
"       11",
"      </a>",
"      ], and with soft cups compared with rigid cups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/57/42903/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Failure of an attempted vacuum assisted delivery increases the likelihood of neonatal morbidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42903/abstract/30\">",
"     30",
"    </a>",
"    ]; the subsequent use of sequential forceps in this setting has been associated with an increased risk of neonatal intracranial hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42903/abstract/31\">",
"     31",
"    </a>",
"    ] and is rarely indicated. Prompt cesarean delivery is advised after an unsuccessful vacuum assisted procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     AVOIDING PROBLEMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most basic technique for avoiding problems is to assiduously adhere to the Food and Drug Administration's recommendation that the vacuum device only be used \"when a specific obstetric indication is present\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42903/abstract/5\">",
"     5",
"    </a>",
"    ]. In addition, the following tips are useful:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Confirm correct cup placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;A successful vacuum assisted delivery requires placement of the cup over the flexion point. Misalignment of the cup relative to the flexion point leads to cranial deflexion or asymmetry as traction is applied, which impedes, rather than assists, the delivery process because a larger cranial diameter is presented to the birth canal. Paramedian application is also associated with a higher rate of neonatal scalp trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42903/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the cup is dislodged, the scalp is examined to make sure there is no injury before reapplying the cup.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Avoid entrapping vaginal soft tissues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Entrapment of maternal tissues between the cup and the fetal head will cause vaginal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vulvar lacerations, which can be difficult to repair and cause unnecessary maternal blood loss and discomfort.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Know when to abandon the procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with any obstetric intervention, practitioners must be willing and able to abandon the procedure and proceed to cesarean delivery promptly when the vaginal delivery is not progressing normally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42903/abstract/32\">",
"     32",
"    </a>",
"    ]. Although there is often a tendency to try to complete the delivery vaginally despite failed progress",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    multiple \"pop-offs,\" prudence dictates abdominal delivery when the fetus is not readily delivered with vacuum assistance. An indicated vaginal delivery that could not be completed with vacuum assistance is unlikely to progress to a spontaneous vaginal delivery with a little more time, and delay may increase the risk of neonatal or maternal morbidity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1753442051\">",
"    <span class=\"h1\">",
"     COMPLICATIONS AND OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complications and outcomes of vacuum delivery are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/39/15994?source=see_link&amp;anchor=H20#H20\">",
"     \"Operative vaginal delivery\", section on 'Risks'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is insufficient evidence upon which to base a recommendation for use of a particular type of vacuum for all circumstances when a vacuum assisted delivery is attempted. A successful vacuum extraction is most likely to be achieved by accurate cup application, appropriate traction technique, a favorable flexed fetal cranial position and low station at the time of application, use of the most appropriate cup design, and absence of fetopelvic disproportion. In general:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The three major categories of indication are prolonged second stage of labor, nonreassuring fetal status, and maternal cardiac or neurological disease, but there is no absolute indication. In addition to the general contraindications to operative vaginal delivery, contraindications specific to vacuum extraction include gestational age less than 34 weeks and previous scalp sampling. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications and contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For occiput anterior deliveries requiring only mild traction, we suggest a soft bell-shaped vacuum cup rather than a rigid cup (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Soft cups result in less scalp injury, but also produce less traction. We use the rigid mushroom-style cup for deliveries likely to require greater traction forces (",
"      <a class=\"graphic graphic_table graphicRef52265 \" href=\"mobipreview.htm?29/25/30108\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Extractor cup'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For occiput posterior deliveries, we use a rigid discoid cup without a rigid stem that was designed for this purpose. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Occiput posterior position'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cup should be applied at the flexion point and the edges swept with a finger to insure that no maternal tissues are entrapped. In the normally molded fetal head, the flexion point is in the midline, over the sagittal suture, approximately 6 cm from the anterior fontanelle and 3 cm from the posterior fontanelle (",
"      <a class=\"graphic graphic_figure graphicRef69870 \" href=\"mobipreview.htm?5/21/5456\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Determine the flexion point'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rapid application to the maximum suction pressure of 600 mmHg is acceptable, although pressures in excess of 450 mmHg are rarely necessary. Slow, stepwise application of suction does not improve safety or efficacy. Between contractions, suction pressure can be fully maintained or reduced to &lt;200 mmHg. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Apply suction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Exert traction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Apply gentle traction along the axis of the pelvic curve (ie, down then up) in concert with maternal pushing. The scalp can be damaged if the handle is actively twisted to rotate the head. A mnemonic is provided in the table (",
"      <a class=\"graphic graphic_table graphicRef53086 \" href=\"mobipreview.htm?0/4/69\">",
"       table 2",
"      </a>",
"      ) to assist in remembering the steps in vacuum extraction. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Exert traction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest limiting vacuum assisted procedures to three contractions for the descent phase, three contractions for the outlet extraction phase, 2 to 3 \"pop-offs,\" and a total time of 15 to 30 minutes (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Duration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Failure of an attempted vacuum assisted delivery increases the likelihood of neonatal morbidity; the subsequent use of sequential forceps in this setting is rarely indicated. Prompt cesarean delivery is advised after an unsuccessful vacuum assisted procedure. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Failed procedures'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42903/abstract/1\">",
"      Malmstr&ouml;m, T. The vacuum extractor: An obstetrical instrument. Acta Obstet Gyncol Scand 1957; 36:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42903/abstract/2\">",
"      Miksovsky P, Watson WJ. Obstetric vacuum extraction: state of the art in the new millennium. Obstet Gynecol Surv 2001; 56:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42903/abstract/3\">",
"      Vacca, A. Vacuum-assisted delivery. OBG Manag 2004; Suppl:S1-7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42903/abstract/4\">",
"      Demissie K, Rhoads GG, Smulian JC, et al. Operative vaginal delivery and neonatal and infant adverse outcomes: population based retrospective analysis. BMJ 2004; 329:24.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Public Health Advisory. Need for caution when using vacuum assisted delivery devices. U.S. Food and Drug Administration: Center for Devices and Radiological Health: www.fda.gov/cdrh/fetal598.html.",
"    </li>",
"    <li>",
"     Johanson, RB. Instrumental vaginal delivery. Guidelines and Audit Committee of the Royal College of Obstetricians and Gynaecologists, 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42903/abstract/7\">",
"      Attilakos G, Sibanda T, Winter C, et al. A randomised controlled trial of a new handheld vacuum extraction device. BJOG 2005; 112:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42903/abstract/8\">",
"      Groom KM, Jones BA, Miller N, Paterson-Brown S. A prospective randomised controlled trial of the Kiwi Omnicup versus conventional ventouse cups for vacuum-assisted vaginal delivery. BJOG 2006; 113:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42903/abstract/9\">",
"      Ismail NA, Saharan WS, Zaleha MA, et al. Kiwi Omnicup versus Malmstrom metal cup in vacuum assisted delivery: a randomized comparative trial. J Obstet Gynaecol Res 2008; 34:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42903/abstract/10\">",
"      Johanson R, Menon V. Soft versus rigid vacuum extractor cups for assisted vaginal delivery. Cochrane Database Syst Rev 2000; :CD000446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42903/abstract/11\">",
"      Muise KL, Duchon MA, Brown RH. The effect of artificial caput on performance of vacuum extractors. Obstet Gynecol 1993; 81:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42903/abstract/12\">",
"      Hofmeyr GJ, Gobetz L, Sonnendecker EW, Turner MJ. New design rigid and soft vacuum extractor cups: a preliminary comparison of traction forces. Br J Obstet Gynaecol 1990; 97:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42903/abstract/13\">",
"      Hammarstr&ouml;m M, Csemiczky G, Belfrage P. Comparison between the conventional Malmstr&ouml;m extractor and a new extractor with Silastic cup. Acta Obstet Gynecol Scand 1986; 65:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42903/abstract/14\">",
"      Ross MG, Fresquez M, El-Haddad MA. Impact of FDA advisory on reported vacuum-assisted delivery and morbidity. J Matern Fetal Med 2000; 9:321.",
"     </a>",
"    </li>",
"    <li>",
"     Billings, RG. The physics of vacuum extraction. OBG Manag 2004; Suppl S7.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42903/abstract/16\">",
"      Suwannachat B, Lumbiganon P, Laopaiboon M. Rapid versus stepwise negative pressure application for vacuum extraction assisted vaginal delivery. Cochrane Database Syst Rev 2012; 8:CD006636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42903/abstract/17\">",
"      Duchon MA, DeMund MA, Brown RH. Laboratory comparison of modern vacuum extractors. Obstet Gynecol 1988; 71:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42903/abstract/18\">",
"      MISHELL D Jr, KELLY JV. The obstetrical forceps and the vacuum extractor: an assessment of their compressive force. Obstet Gynecol 1962; 19:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42903/abstract/19\">",
"      Moolgaoker AS, Ahamed SO, Payne PR. A comparison of different methods of instrumental delivery based on electronic measurements of compression and traction. Obstet Gynecol 1979; 54:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42903/abstract/20\">",
"      Laufe LE. Divergent and crossed obstetric forceps. Comparative study of compression and traction forces. Obstet Gynecol 1971; 38:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42903/abstract/21\">",
"      Vacca A. Vacuum-assisted delivery: an analysis of traction force and maternal and neonatal outcomes. Aust N Z J Obstet Gynaecol 2006; 46:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42903/abstract/22\">",
"      Baskett TF, Fanning CA, Young DC. A prospective observational study of 1000 vacuum assisted deliveries with the OmniCup device. J Obstet Gynaecol Can 2008; 30:573.",
"     </a>",
"    </li>",
"    <li>",
"     Vacca, A. Handbook of vacuum assisted delivery in obstetric practice, 2nd ed, Vacca Research, Brisbane, Australia 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42903/abstract/24\">",
"      Bofill JA, Rust OA, Schorr SJ, et al. A randomized trial of two vacuum extraction techniques. Obstet Gynecol 1997; 89:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42903/abstract/25\">",
"      Kudish B, Blackwell S, Mcneeley SG, et al. Operative vaginal delivery and midline episiotomy: a bad combination for the perineum. Am J Obstet Gynecol 2006; 195:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42903/abstract/26\">",
"      Johanson RB, Rice C, Doyle M, et al. A randomised prospective study comparing the new vacuum extractor policy with forceps delivery. Br J Obstet Gynaecol 1993; 100:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42903/abstract/27\">",
"      Bofill JA, Rust OA, Devidas M, et al. Neonatal cephalohematoma from vacuum extraction. J Reprod Med 1997; 42:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42903/abstract/28\">",
"      Teng FY, Sayre JW. Vacuum extraction: does duration predict scalp injury? Obstet Gynecol 1997; 89:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42903/abstract/29\">",
"      Bird GC. The importance of flexion in vacuum extractor delivery. Br J Obstet Gynaecol 1976; 83:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42903/abstract/30\">",
"      Sadan O, Ginath S, Gomel A, et al. What to do after a failed attempt of vacuum delivery? Eur J Obstet Gynecol Reprod Biol 2003; 107:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42903/abstract/31\">",
"      Towner D, Castro MA, Eby-Wilkens E, Gilbert WM. Effect of mode of delivery in nulliparous women on neonatal intracranial injury. N Engl J Med 1999; 341:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42903/abstract/32\">",
"      Revah A, Ezra Y, Farine D, Ritchie K. Failed trial of vacuum or forceps--maternal and fetal outcome. Am J Obstet Gynecol 1997; 176:200.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5396 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.150.3.100-7D04F74F15-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_57_42903=[""].join("\n");
var outline_f41_57_42903=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS AND CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Alternatives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      INSTRUMENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Vacuum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Extractor cup",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Soft versus rigid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Bell versus mushroom shape",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Occiput posterior position",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Handle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Patient preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Determine the flexion point",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Place the cup",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Apply suction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Exert traction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Rotations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DURATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      DOCUMENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      FAILED PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      AVOIDING PROBLEMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Confirm correct cup placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Avoid entrapping vaginal soft tissues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Know when to abandon the procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1753442051\">",
"      COMPLICATIONS AND OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5396\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5396|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/21/5456\" title=\"figure 1\">",
"      Flexion point fetal skull",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5396|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/58/22435\" title=\"picture 1\">",
"      Equipment for vacuum delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/52/33608\" title=\"picture 2\">",
"      Kiwi vacuum device",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/28/18882\" title=\"picture 3\">",
"      Vacuum suction cups",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?3/24/3457\" title=\"picture 4\">",
"      Vacuum suction pressure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5396|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/25/30108\" title=\"table 1\">",
"      Types of vacuum delivery cups",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/4/69\" title=\"table 2\">",
"      Mnemonic vacuum extraction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/21/33114?source=related_link\">",
"      Management of normal labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/21/5462?source=related_link\">",
"      Management of the fetus in occiput posterior position",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/52/13124?source=related_link\">",
"      Occiput transverse position",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/39/15994?source=related_link\">",
"      Operative vaginal delivery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_57_42904="The sexual history and approach to the patient with sexual dysfunction";
var content_f41_57_42904=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The sexual history and approach to the patient with sexual dysfunction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/57/42904/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/57/42904/contributors\">",
"     Dennis W Cope, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/57/42904/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/57/42904/contributors\">",
"     Robert H Fletcher, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/57/42904/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/57/42904/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/57/42904/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexual dysfunction in both men and women is common. This emphasizes the importance of taking a good sexual history to promote both psychological and physical well-being.",
"   </p>",
"   <p>",
"    This topic will review normal sexual function, the sexual history, and discuss appropriate areas for primary care physicians to intervene in the management of patients with sexual dysfunction. The evaluation and treatment of both female and male sexual dysfunction are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/44/42696?source=see_link\">",
"     \"Overview of male sexual dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32533?source=see_link\">",
"     \"Evaluation of male sexual dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/36/30282?source=see_link\">",
"     \"Treatment of male sexual dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/42/25258?source=see_link\">",
"     \"Sexual dysfunction in women: Epidemiology, risk factors, and evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/10/34985?source=see_link\">",
"     \"Sexual dysfunction in women: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact prevalence of sexual dysfunction varies depending upon the population studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42904/abstract/1-11\">",
"     1-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prevalence in new patients seen by general internists is approximately 50 percent and has remained relatively constant over many years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/57/42904/abstract/1,2\">",
"       1,2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One survey of healthy married couples emphasized the prevalence of this problem by noting sexual dysfunction complaints in 40 percent of men and 63 percent of women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/57/42904/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another report emphasized the increasing prevalence of sexual difficulties in men with aging [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/57/42904/abstract/5\">",
"       5",
"      </a>",
"      ]. At age 40, for example, 40 percent acknowledged some level of impaired sexual function and another 10 percent recognized a waning sexual prowess or interest with each succeeding decade (",
"      <a class=\"graphic graphic_figure graphicRef81051 \" href=\"mobipreview.htm?32/46/33517\">",
"       figure 1",
"      </a>",
"      ). The prevalence of erectile dysfunction in middle-aged and older men ranges between 16 and 52 percent, based on the definition of erectile dysfunction and the patient population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/57/42904/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Consistent inability to attain or maintain an erection satisfactory for intercourse was reported in 67 percent of males over 69 years of age in another review [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/57/42904/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sexual dysfunction diminishes the quality of life and also can be an indication of serious medical problems, including diabetes mellitus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42904/abstract/12-20\">",
"     12-20",
"    </a>",
"    ], atherosclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42904/abstract/17\">",
"     17",
"    </a>",
"    ], pituitary tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42904/abstract/18\">",
"     18",
"    </a>",
"    ], depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42904/abstract/20\">",
"     20",
"    </a>",
"    ], and chronic renal or cardiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42904/abstract/21-27\">",
"     21-27",
"    </a>",
"    ]. It also may be a sign of marital discord [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42904/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. In addition, risk factors for cardiac disease predict subsequent erectile dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42904/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NORMAL SEXUAL FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Masters and Johnson pioneered research efforts that expanded our scientific knowledge of the sexual response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42904/abstract/30\">",
"     30",
"    </a>",
"    ]. They identified four stages of the sexual response: excitement; plateau; orgasm; and resolution. They also confirmed physiologic similarities between males and females.",
"   </p>",
"   <p>",
"    Excitement in both sexes may be initiated by sensory input as well as fantasy. Sight, touch, odor, taste, and a recall of prior experience or fantasy may combine to produce an aroused state. The threshold for each or all to have an effect is influenced by physical, psychological, and social factors. The individual's state of rest and relaxation and sense of well-being may influence how readily a response is elicited. Prior learning and belief systems influence erotic attention to physical or psychological features as well as a sense of appropriateness of sexual behavior. Emotional states such as anxiety, fear, or depression may dampen the receptivity to sensory input, as can neurologic deficits. Androgenic hormones usually augment the response to sensory signals; progesterone and many drugs raise the threshold for response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42904/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Men",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexual excitement in men is most evident by tumescence or penile erection. Full erection may develop within ten seconds after stimulation begins; this varies depending upon age, erotic interest, and the amount of stimulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42904/abstract/30\">",
"     30",
"    </a>",
"    ]. Vasocongestion also causes the testes to increase in size by 50 to 100 percent and the scrotum thickens and tightens. Muscles in the spermatic cords and scrotum draw the testes close to the body. A sexual flush across the chest, breasts, back, and neck occurs in approximately 25 percent of men.",
"   </p>",
"   <p>",
"    As the body prepares for orgasm, respiration increases in rate and depth of breaths. Heart rate and blood pressure also increase as erotic feelings intensify. In the plateau phase prior to orgasm, the penis is engorged to its capacity and further engorgement of the penile corona and glans makes these areas more prominent and deeply colored. A small amount (two or three drops) of clear mucoid fluid is secreted from the cowper's gland and emits from the meatus.",
"   </p>",
"   <p>",
"    Men experience contractions of the vas deferens, seminal vesicles, and prostate as a sign of ejaculatory inevitability, followed by contractions of the urethra and perineal and penile base muscles with ejaculation of spurts of semen. After resolution there is a refractory phase during which there is no response to sexual stimulation. The length of this period varies with age, usually increasing in duration as men get older.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erotic feelings and vascular changes also characterize excitement in the female [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42904/abstract/30\">",
"     30",
"    </a>",
"    ]. Vasocongestion of tissues deep in the vagina cause a transudation of clear fluid that is slightly slippery and has a distinctive odor and taste; this process occurs within 10 to 30 seconds after sexual arousal is initiated. The fluid serves a lubricating function for penile movement, neutralizes normal vagina acidity, and aids in sperm survival. It may be lacking in estrogen deficient states (menopause), vaginal infections, and with use of certain drugs (antihistamines).",
"   </p>",
"   <p>",
"    Vasocongestion also creates a sexual flush across the upper chest, neck, and back in 70 to 75 percent of women. The breasts and areola enlarge because of vasocongestion; nipple erection is an early sign of arousal in females [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42904/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clitoris enlarges and becomes more sensitive to touch and pressure but is covered by the engorged prepuce. The clitoris appears and disappears under its covering as excitement continues.",
"   </p>",
"   <p>",
"    The labia majora vary in response based upon prior parity. In nulliparous women they are made flatter and thinner by muscle contraction during arousal and orgasm. Multiparous women have developed an extensive vascular network in the labia majora, which swells two to three times in size with vasocongestion. The labia minora double to triple in size in all women with vasocongestion during excitation. The labia become a deep red or purple during the plateau phase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42904/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The inner portion of the vagina balloons as excitement continues in the female to form a receptacle for semen, while the uterus becomes engorged and lifts upward. Just prior to orgasm the clitoris turns up 180 degrees and retracts behind the symphysis pubis in a flattened position.",
"   </p>",
"   <p>",
"    During orgasm the inner one-third of the vagina continues to tent while the vasocongested orgasmic platform involving the perineal, bulbocavernosus, and pubococcygeus muscles rhythmically contract (first strongly, then more weakly and at longer intervals). Women frequently experience more orgasmic contractions than men. After orgasm the resolution phase results in mental and physical relaxation. Most women experience a feeling of well-being unless there are conflictual or guilty feelings. Some women report psychological satisfaction and relaxation without apparent orgasm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42904/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Effects of age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many aspects of the sexual response are affected by aging.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Men may reach and attain orgasm more slowly in middle and later life. Erection takes two to three times longer to occur in the 50s than in the 40s; after age 60 a lost erection is more difficult to regain. More direct genital stimulation may be required to achieve full erection as men age. This can be an especially difficult problem if the female partner has assumed a completely passive role [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/57/42904/abstract/32,33\">",
"       32,33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Most women experience a diminution in vaginal transudation after menopause; it may take several minutes to occur after age 60. The vagina becomes narrower and shorter and the vaginal walls become atrophic. These changes can cause coitus to be painful. Women who continue regular sexual activity after menopause experience fewer of these changes; estrogen replacement also minimizes their occurrence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/57/42904/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The normal changes associated with aging may be misunderstood and require changes in foreplay or the use of water soluble lubricants.",
"   </p>",
"   <p>",
"    The frequency of sexual activity decreases in both men and women with aging. There is a strong suggestion that regular sexual activity is protective against male erectile dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42904/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CAUSES OF SEXUAL DYSFUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexual dysfunction in men and women may be the consequence of psychological or emotional factors, hormonal abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42904/abstract/35-39\">",
"     35-39",
"    </a>",
"    ], autonomic neuropathy, vascular insufficiency, or drug side effects (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32533?source=see_link\">",
"     \"Evaluation of male sexual dysfunction\"",
"    </a>",
"    ). While the data are somewhat discordant, hysterectomy probably does not adversely effect sexual function and may even improve function in women with identifiable gynecologic pathology prior to the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42904/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/42/25258?source=see_link\">",
"     \"Sexual dysfunction in women: Epidemiology, risk factors, and evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Psychological and emotional factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of nocturnal erections in males suggests that the neurogenic reflexes and corpora cavernosae blood flow are intact and should alert the physician to possible psychological or social issues. In addition, the abrupt onset of impotence without trauma or a new medication is invariably psychogenic in origin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32533?source=see_link\">",
"     \"Evaluation of male sexual dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Depression, performance anxiety, and lack of sensate focus are readily identifiable psychologic causes of impotence.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Loss of libido and lack of interest in any sexual activity are common components of depressive illness in men. Standard scales of depression, including the Beck Depression Index (BDI) and Hamilton Depression Scale (HAM-D), prominently explore questions on sexual interest and function. Scores indicating high indices of sexual apathy and erectile failure are considered to be diagnostic of depression. However, impotence is itself a depressing illness, and many men, regardless of the etiology of their impotence, will score high on these scales. Corroborating evidence from other queries on the BDI or HAM-D are required to distinguish men who are impotent because they are depressed from men who are depressed because they are impotent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/57/42904/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Performance anxiety commonly surfaces in men who suddenly experience one or more erectile failures during attempted intercourse. Then the focus of the sexual act shifts from a sensual experience to one fraught with anxiety. During subsequent attempts at lovemaking, the ability to acquire and maintain an erection dominates the sexual experience.",
"     </li>",
"     <li>",
"      Lack of sensate focus refers to the waning sexual function of men in their middle age. Sexual intercourse, an exhilarating and thrilling preoccupation of youth, has by then lost some of its novelty. As a man matures, his arena of interests and concerns expand. Other issues vie for his attention, even during sexual intercourse. If, in the midst of sexual intimacy, he finds himself preoccupied with financial pressures or travails of the business world, his mind will drift and he will lose his sexual focus and erectile stamina [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/57/42904/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fatigue is a common disincentive to sexual activity. This can be a particular problem for couples who watch television in bed until they are exhausted and sleepy; the best solution to this problem may be removing the television from the bedroom. Finding a time when both partners are rested to enjoy sexual relations is something each couple should consider to facilitate the best relationship.",
"   </p>",
"   <p>",
"    A lack of privacy also may impede sexual activity. A couple with small children may need to consider a lock on their bedroom door to prevent unwanted visits by the children. If an in-law occupies the adjoining bedroom, creating a fear of being heard during sexual activity, the solution may be architectural (such as improved sound insulation or a different home or apartment).",
"   </p>",
"   <p>",
"    Most couples who have unresolved anger toward each other find amorous feelings difficult to generate. Resolution of conflict may be necessary for successful sexual functioning to occur; marital counseling may be the best prescription.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hormonal abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The testicular hormone testosterone plays an integral role in normal male sexual function. Testosterone deficiency causes impotence in experimental animals and humans and is corrected with testosterone treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42904/abstract/43\">",
"     43",
"    </a>",
"    ]. Testosterone is important for normal libido and is necessary to maintain intrapenile nitric oxide synthase levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42904/abstract/44\">",
"     44",
"    </a>",
"    ]. Hypogonadal men experience nocturnal erections but usually lack sufficiently rigid erections to allow coitus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/44/42696?source=see_link\">",
"     \"Overview of male sexual dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/44/42696?source=see_link&amp;anchor=H2095523#H2095523\">",
"     \"Overview of male sexual dysfunction\", section on 'Hormonal influences'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other disruptions in hormone secretion, including hyperprolactinemia, hyperthyroidism, and hypothyroidism are commonly associated with impotence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42904/abstract/45\">",
"     45",
"    </a>",
"    ]. Restoration of a normal state of endocrine function usually results in the return of erectile potency.",
"   </p>",
"   <p>",
"    Lack of normal serum estrogen levels in women can result in too little lubrication, vaginal epithelial atrophy, and dyspareunia (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/1/43032?source=see_link\">",
"     \"Approach to the woman with sexual pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/42/25258?source=see_link\">",
"     \"Sexual dysfunction in women: Epidemiology, risk factors, and evaluation\"",
"    </a>",
"    ). Androgens are important in facilitating libido in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42904/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/45/20184?source=see_link&amp;anchor=H5#H5\">",
"     \"Androgen production and therapy in women\", section on 'Physiologic role of androgens'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Autonomic neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autonomic neuropathy, especially as a complication of diabetes mellitus, is an important cause of sexual dysfunction (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/28/38341?source=see_link\">",
"     \"Erectile dysfunction in diabetes mellitus\"",
"    </a>",
"    ). An early sign of this problem in male diabetics is retrograde ejaculation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42904/abstract/48\">",
"     48",
"    </a>",
"    ]. Normal parasympathetic nerve fibers release nitric oxide in response to sexual stimulation. This locally produced nitric oxide diffuses into and causes relaxation of smooth muscle cells, thereby allowing arterial blood to enter the corpus cavernosae and cause an erection. Nitric oxide physiology is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/44/42696?source=see_link\">",
"     \"Overview of male sexual dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Vascular insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not surprising that vascular insufficiency can inhibit or prevent complete arousal since genital vasocongestion is important in both sexes for normal sexual intercourse. Vascular insufficiency may arise due to atherosclerosis with obstruction of major arteries such as the iliac or pudendal vessels, or to small vessel (arterioles) disease found in diabetic patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of drugs or other chemical substances can impede normal sexual functioning. Excessive alcohol consumption is the most common offender. Other recreational substances including marijuana, cocaine, and heroin also can lead to sexual dysfunction. Antihypertensive drugs, including thiazide diuretics, calcium channel blockers, and angiotensin converting enzyme (ACE) inhibitors all have been reported to interfere with normal genital vasocongestion; thiazides are most commonly implicated, while the alpha-adrenergic blockers are least likely to cause erectile dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42904/abstract/49\">",
"     49",
"    </a>",
"    ]. It has been thought that beta blockers are an important cause of erectile dysfunction, but a systematic review of randomized, controlled trials found only a small increased risk of sexual dysfunction with beta blocker therapy (5 per 1000 patients treated) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42904/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/39/3704?source=see_link\">",
"     \"Major side effects of beta blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anticholinergic drugs inhibit normal vaginal transudation (lubrication). Antidepressants, including tricyclics and selective serotonin uptake inhibitors (SSRIs) have been implicated in erectile, ejaculatory, and orgasmic dysfunction, as well as diminished desire [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42904/abstract/51\">",
"     51",
"    </a>",
"    ]. Antiandrogens such as GnRH agonists and 5-alpha-reductase inhibitors also can contribute to erectile dysfunction.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"     Ketoconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    are androgen antagonists that diminish the effect of testosterone peripherally, while H2 blockers (particularly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/54/2921?source=see_link\">",
"     cimetidine",
"    </a>",
"    ) may stimulate prolactin release and secondarily reduce serum testosterone levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SEXUAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many challenges to taking a good sexual history. The patient must be made to feel comfortable and safe in self-disclosure. A nonjudgmental, accepting attitude coupled with empathetic statements fosters alignment with the patient. Straightforward inquiries about sexual function that are delivered with a sense of comfort elicit candid responses.",
"   </p>",
"   <p>",
"    Stating the context or rationale for the sexual inquiries is facilitatory if the patient expresses verbal or nonverbal reluctance or embarrassment. The physician may acknowledge that such discussions are difficult and can be embarrassing, but are nevertheless important. Questioning should proceed from open-ended questions (\"How is your sexual functioning?\") to specific, sufficiently detailed questions (\"Does your partner touch your genitals?\").",
"   </p>",
"   <p>",
"    Sexual history taking not only legitimizes a discussion of sexual concerns but also increases the patients' comfort and freedom in sharing other highly personal concerns or problems of a nonsexual nature. This open communication strengthens the physician-patient relationship and solidifies rapport.",
"   </p>",
"   <p>",
"    Examples of some general routine questions that can be asked during the patient interview include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Are you having sexual relations currently?",
"     </li>",
"     <li>",
"      If so, with men or women or both?",
"     </li>",
"     <li>",
"      If not, when did you last have sexual intercourse?",
"     </li>",
"     <li>",
"      Are you satisfied with the frequency and quality of your sexual experience?",
"     </li>",
"     <li>",
"      Do you have more than one sexual partner?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Vague answers should prompt more detailed questioning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Barriers to history taking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexual dysfunction may go undetected in the medical interview because of both patient and physician barriers.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There may be embarrassment by both parties in discussing sexual issues, and differences in culture, socioeconomic level, age, gender, and race.",
"     </li>",
"     <li>",
"      The terminology used by the physician to phrase inquiries must be understood by the patient and be acceptable. Similarly, information supplied by the patient must be specific rather than ambiguous.",
"     </li>",
"     <li>",
"      The physician's comfort in discussing sexual issues and his or her interviewing skills are critical for creating a conducive environment in which the physician is perceived as understanding, accepting, and nonjudgmental.",
"     </li>",
"     <li>",
"      A discussion of sexual issues may be avoided if the physician feels time pressure to accomplish other tasks in the medical interview, sees no connection between the sexual history and the patients health status, or lacks knowledge in treating sexual dysfunction.",
"     </li>",
"     <li>",
"      Lack of privacy or fear of lack of confidentiality may prevent the patient from freely sharing sexual concerns. In addition, the patient is unlikely to discuss sexual problems with physicians if sexuality is not viewed as a medical issue.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ASSESSMENT AND INTERVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the physician learns through the history that the patient is suffering from sexual dysfunction, a thorough assessment of the etiology of the dysfunction should follow, with subsequent intervention as indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Organic causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should elicit an explicit, thorough sexual history, including a complete history of drug and substance use. Any drugs affecting sexual function should be discontinued if possible. A careful physical examination for evidence of neuropathy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vascular insufficiency should be performed. Hormonal and nocturnal penile tumescence testing can be considered in men. (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32533?source=see_link\">",
"     \"Evaluation of male sexual dysfunction\"",
"    </a>",
"    ). A detailed pelvic exam should be done in women and hormonal evaluation may be considered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/42/25258?source=see_link\">",
"     \"Sexual dysfunction in women: Epidemiology, risk factors, and evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Psychological causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A psychological assessment for possible depression or anxiety should be sought, including areas such as appetite or sleep disturbance and change in bowel habits or weight. Treatment of depression and anxiety disorders can dramatically improve sexual function. Many of the newest and most effective antidepressants of the serotonin reuptake inhibitor class (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    ) are burdened by sexual side effects, which stifle both libido and erectile function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42904/abstract/37\">",
"     37",
"    </a>",
"    ]. On the other hand, some antidepressants such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/0/24584?source=see_link\">",
"     trazodone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/41/41624?source=see_link\">",
"     imipramine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/14/39144?source=see_link\">",
"     desipramine",
"    </a>",
"    can cause delayed or retarded ejaculation, a \"side effect\" that may actually be beneficial for men suffering from premature ejaculation.",
"   </p>",
"   <p>",
"    Exploration of the patient's concerns and beliefs about sexual function may uncover issues that can be addressed educationally or through reassurance. This is especially true for couples in which one or both partners have a serious medical condition. Anxiety over the safety of sexual activity may be present in both the medically ill patient and his or her partner; discussing safe levels of sexual activity and dispelling myths is helpful.",
"   </p>",
"   <p>",
"    Psychological counseling, including the use of sensate focus exercises by both partners, can be helpful when the man is suffering from performance anxiety. This is usually best accomplished by referral to a certified sexual therapy counselor. Interpersonal conflicts that result in anger or resentment toward the sexual partner may require couples therapy to address conflict.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Sexual therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;One author suggested a mnemonic model for approaching sexual therapy that is helpful in deciding which problems may be addressed by the primary care provider and which should be referred for specialized care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42904/abstract/52\">",
"     52",
"    </a>",
"    ]. The PLISSIT model has four stages of treatment; the first three can be performed by the primary care physician.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Permission giving (P) - This first stage can be accomplished by indicating that certain sexual practices (such as oral sex) are normal and practiced by many couples. Individuals may be inhibited by fear that certain desires or practices are abnormal. If the physician is comfortable in normalizing such actions, sexual functioning may be enhanced or restored for couples.",
"     </li>",
"     <li>",
"      Limited information (LI) - This involves helping patients who have limited information about certain aspects of sexual function by explaining normal changes that occur with aging. Some couples and individuals may benefit from an understanding of the importance of foreplay or normal aspects of male and female arousal. The effect of antihistamines in reducing vaginal lubrication is an example of information that may not be widely appreciated.",
"     </li>",
"     <li>",
"      Specific suggestions (SS) - Specific suggestions include advice on subjects such as the use of estrogen, KY jelly, or Astroglide, removing a TV from the bedroom, and installing a lock on the bedroom door.",
"     </li>",
"     <li>",
"      Intensive therapy (IT) - Intensive therapy should probably be accomplished by referral to a specialist because of both time and expertise considerations. However, a motivated primary care provider can become knowledgeable in most aspects of intensive therapy if he or she desires.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of medications and devices are now available to treat male sexual dysfunction (",
"    <a class=\"graphic graphic_table graphicRef80719 graphicRef53269 \" href=\"mobipreview.htm?4/44/4815\">",
"     table 1A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef76992 \" href=\"mobipreview.htm?9/45/9950\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42904/abstract/53-61\">",
"     53-61",
"    </a>",
"    ]. These are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/36/30282?source=see_link\">",
"     \"Treatment of male sexual dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Counseling regarding sexual activity and treatment of sexual dysfunction in patients with heart disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/15/8442?source=see_link\">",
"     \"Sexual activity in patients with heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Exercise and weight loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies in obese men with erectile dysfunction have shown improvement in sexual dysfunction with lifestyle change in approximately one-third of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42904/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/24/386?source=see_link\">",
"       \"Patient information: Sex problems in men (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/17/11538?source=see_link\">",
"       \"Patient information: Sex problems in women (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/33/29205?source=see_link\">",
"       \"Patient information: Sexual problems in men (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/4/12357?source=see_link\">",
"       \"Patient information: Sexual problems in women (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prevalence of sexual dysfunction in patients seen by general internists is estimated to be 50 percent. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Normal sexual function involves four stages in both men and women: excitement, plateau, orgasm, and resolution. With age, erection and orgasm occur more slowly in men and vaginal transudation decreases in women. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Normal sexual function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sexual dysfunction may be the consequence of psychological or emotional factors, hormonal abnormalities, autonomic neuropathy, vascular insufficiency, or drug side effects. Depression, performance anxiety, and distraction are common psychologic causes of impotence. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Causes of sexual dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Testosterone is important for normal libido and is necessary to maintain intrapenile nitric oxide synthase levels. Hypogonadal men experience nocturnal erections but usually lack sufficiently rigid erections to allow coitus. Low estrogen in women can cause vaginal atrophy and dyspareunia, hyperprolactinemia, and thyroid abnormalities are associated with impotence. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Hormonal abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Retrograde ejaculation may be an early sign of autonomic neuropathy associated with diabetes. Vascular insufficiency due to atherosclerosis can inhibit sexual activity. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Autonomic neuropathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multiple drugs, both illicit and medicinal, impede sexual functioning. Commonly-implicated drugs are alcohol, marijuana, antihypertensive agents (eg, thiazides), antidepressants, and H2 blockers. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Taking a sexual history should involve straightforward nonjudgmental inquiry, starting with open-ended questions. Lack of privacy or fear of lack of confidentiality may prevent the patient from freely sharing sexual concerns. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Sexual history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The PLISSIT model can guide treatment for sexual dysfunction. This involves permission-giving for sexual practices, filling information gaps, offering suggestions such as use of lubricants, and referral for intensive therapy by a specialist when these measures are not helpful. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Assessment and intervention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of medications and devices are now available to treat male sexual dysfunction (",
"      <a class=\"graphic graphic_table graphicRef80719 graphicRef53269 \" href=\"mobipreview.htm?4/44/4815\">",
"       table 1A-B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/36/30282?source=see_link\">",
"       \"Treatment of male sexual dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/1\">",
"      Ende J, Rockwell S, Glasgow M. The sexual history in general medicine practice. Arch Intern Med 1984; 144:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/2\">",
"      Pauly I, Goldstein S. Prevalence of significant sexual problems in medical practice. Med Aspects Hum Sex 1979; 48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/3\">",
"      Frank E, Anderson C, Rubinstein D. Frequency of sexual dysfunction in \"normal\" couples. N Engl J Med 1978; 299:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/4\">",
"      Slag MF, Morley JE, Elson MK, et al. Impotence in medical clinic outpatients. JAMA 1983; 249:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/5\">",
"      Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/6\">",
"      Araujo AB, Mohr BA, McKinlay JB. Changes in sexual function in middle-aged and older men: longitudinal data from the Massachusetts Male Aging Study. J Am Geriatr Soc 2004; 52:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/7\">",
"      Godschalk MF, Sison A, Mulligan T. Management of erectile dysfunction by the geriatrician. J Am Geriatr Soc 1997; 45:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/8\">",
"      Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999; 281:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/9\">",
"      Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the US. Am J Med 2007; 120:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/10\">",
"      McVary KT. Clinical practice. Erectile dysfunction. N Engl J Med 2007; 357:2472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/11\">",
"      Fung MM, Bettencourt R, Barrett-Connor E. Heart disease risk factors predict erectile dysfunction 25 years later: the Rancho Bernardo Study. J Am Coll Cardiol 2004; 43:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/12\">",
"      Ellenberg M. Impotence in diabetes: the neurologic factor. Ann Intern Med 1971; 75:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/13\">",
"      Kolodny RC. Sexual dysfunction in diabetic females. Diabetes 1971; 20:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/14\">",
"      McCulloch DK, Campbell IW, Wu FC, et al. The prevalence of diabetic impotence. Diabetologia 1980; 18:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/15\">",
"      McCulloch DK, Young RJ, Prescott RJ, et al. The natural history of impotence in diabetic men. Diabetologia 1984; 26:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/16\">",
"      Kedia KR. Vascular disorders and male erectile dysfunction. Current status in diagnosis and male erectile dysfunction. Current status in diagnosis and management by revascularization of the corpora cavernosa. Urol Clin North Am 1981; 8:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/17\">",
"      Gazzaruso C, Giordanetti S, De Amici E, et al. Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated type 2 diabetic patients. Circulation 2004; 110:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/18\">",
"      Carter JN, Tyson JE, Tolis G, et al. Prolactin-screening tumors and hypogonadism in 22 men. N Engl J Med 1978; 299:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/19\">",
"      Osborne D. Psychological aspects of male sexual dysfunction. Diagnosis and management. Urol Clin North Am 1981; 8:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/20\">",
"      De Berardis G, Pellegrini F, Franciosi M, et al. Identifying patients with type 2 diabetes with a higher likelihood of erectile dysfunction: the role of the interaction between clinical and psychological factors. J Urol 2003; 169:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/21\">",
"      Mehta, J, Krop, HO. The effect of myocardial infarction on sexual functioning. Sex Disabil 1979; 2:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/22\">",
"      Hellerstein, HK, Freidman, EH. Sexual activity and the post-coronary patient. Med Aspects Hum Sex 1969; 3:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/23\">",
"      Bruce RA, Fisher LD, Cooper MN, Gey GO. Separation of effects of cardiovascular disease and age on ventricular function with maximal exercise. Am J Cardiol 1974; 34:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/24\">",
"      Pinderhughes, CA, Grace, ED, Reyna, LJ, Anderson, RT. Interrelationships between sexual functioning and medical conditions. Med Aspects Hum Sex 1972; 6:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/25\">",
"      Renshaw, DC. Profile of 2376 patients treated at Loyola Sex Clinic. J Sex Marital Ther 1988; 3:111.",
"     </a>",
"    </li>",
"    <li>",
"     Master W, Johnson B, Kolodny R. Sex and Human Loving, Brown and Company, Boston 1986.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/27\">",
"      Sadoughi W, Leshner M, Fine HL. Sexual adjustment in a chronically ill and physically disabled population: a pilot study. Arch Phys Med Rehabil 1971; 52:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/28\">",
"      Levine SB, Rosenthal M. Marital sexual dysfunction: female dysfunctions. Ann Intern Med 1977; 86:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/29\">",
"      Levine SB. Marital sexual dysfunction: erectile dysfunction. Ann Intern Med 1976; 85:340.",
"     </a>",
"    </li>",
"    <li>",
"     Masters WH, Johnson VE. Human Sexual Response, Little, Brown and Company, Boston 1966.",
"    </li>",
"    <li>",
"     Diamond M, Karlen A. The sexual response cycle. In: Sexual Problems in Medical Practice, American Medical Association, 1981. p.37.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/32\">",
"      Pfeiffer E, Verwoerdt A, Wang HS. Sexual behavior in aged men and women. I. Observations on 254 community volunteers. Arch Gen Psychiatry 1968; 19:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/33\">",
"      Verwoerdt A, Pfeiffer E, Wang HS. Sexual behavior in senescence. II. Patterns of sexual activity and interest. Geriatrics 1969; 24:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/34\">",
"      North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause 2007; 14:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/35\">",
"      Hutchinson KA. Androgens and sexuality. Am J Med 1995; 98:111S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/36\">",
"      Laughlin GA, Barrett-Connor E, Kritz-Silverstein D, von M&uuml;hlen D. Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: the Rancho Bernardo Study. J Clin Endocrinol Metab 2000; 85:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/37\">",
"      Morley JE, Haren MT, Kim MJ, et al. Testosterone, aging and quality of life. J Endocrinol Invest 2005; 28:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/38\">",
"      Morales A. Andropause (or symptomatic late-onset hypogonadism): facts, fiction and controversies. Aging Male 2004; 7:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/39\">",
"      Jockenh&ouml;vel F. Testosterone therapy--what, when and to whom? Aging Male 2004; 7:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/40\">",
"      Rhodes JC, Kjerulff KH, Langenberg PW, Guzinski GM. Hysterectomy and sexual functioning. JAMA 1999; 282:1934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/41\">",
"      Reynolds, CF, Frank, E, Thase, ME, et al. Assessment of sexual function in depressed, impotent and healthy men. Psychiatry Res 1988; 24:231.",
"     </a>",
"    </li>",
"    <li>",
"     Kaplan HS. Psychiatric evaluation and therapy: What's new?. In: World Book of Impotence, Lue TF (Ed), Smith Gordon, London 1992. p.59.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/43\">",
"      Bancroft J, Wu FC. Changes in erectile responsiveness during androgen replacement therapy. Arch Sex Behav 1983; 12:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/44\">",
"      Mills TM, Wiedmeier VT, Stopper VS. Androgen maintenance of erectile function in the rat penis. Biol Reprod 1992; 46:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/45\">",
"      Spark RF, White RA, Connolly PB. Impotence is not always psychogenic. Newer insights into hypothalamic-pituitary-gonadal dysfunction. JAMA 1980; 243:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/46\">",
"      Buster JE, Kingsberg SA, Aguirre O, et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol 2005; 105:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/47\">",
"      Braunstein GD, Sundwall DA, Katz M, et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch Intern Med 2005; 165:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/48\">",
"      Ellenberg M, Weber H. Retrograde ejaculation in diabetic neuropathy. Ann Intern Med 1966; 65:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/49\">",
"      Grimm RH Jr, Grandits GA, Prineas RJ, et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension 1997; 29:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/50\">",
"      Ko DT, Hebert PR, Coffey CS, et al. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002; 288:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/51\">",
"      Herman JB, Brotman AW, Pollack MH, et al. Fluoxetine-induced sexual dysfunction. J Clin Psychiatry 1990; 51:25.",
"     </a>",
"    </li>",
"    <li>",
"     Annon TX. The Behavioral Treatment of Sexual Problems, Bret Therapy, Enabling Systems, Honolulu 1974. Vol 1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/53\">",
"      Padma-Nathan H, Hellstrom WJ, Kaiser FE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med 1997; 336:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/54\">",
"      Willke RJ, Glick HA, McCarron TJ, et al. Quality of life effects of alprostadil therapy for erectile dysfunction. J Urol 1997; 157:2124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/55\">",
"      Sundaram CP, Thomas W, Pryor LE, et al. Long-term follow-up of patients receiving injection therapy for erectile dysfunction. Urology 1997; 49:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/56\">",
"      Doggrell S. Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction? Int J Impot Res 2007; 19:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/57\">",
"      Mehrotra N, Gupta M, Kovar A, Meibohm B. The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy. Int J Impot Res 2007; 19:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/58\">",
"      Greco EA, Spera G, Aversa A. Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences. Eur Urol 2006; 50:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/59\">",
"      Lindau ST, Schumm LP, Laumann EO, et al. A study of sexuality and health among older adults in the United States. N Engl J Med 2007; 357:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/60\">",
"      Tadalafil (Cialis) once a day for erectile dysfunction. Med Lett Drugs Ther 2008; 50:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/61\">",
"      Porst H, Giuliano F, Glina S, et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol 2006; 50:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42904/abstract/62\">",
"      Esposito K, Giugliano F, Di Palo C, et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA 2004; 291:2978.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6839 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-218.189.88.190-EF2F3CD7BB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_57_42904=[""].join("\n");
var outline_f41_57_42904=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NORMAL SEXUAL FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Men",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Effects of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CAUSES OF SEXUAL DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Psychological and emotional factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hormonal abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Autonomic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Vascular insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SEXUAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Barriers to history taking",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ASSESSMENT AND INTERVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Organic causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Psychological causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Sexual therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Medical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Exercise and weight loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6839\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6839|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/46/33517\" title=\"figure 1\">",
"      Impotence in men by age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6839|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/9/23710\" title=\"table 1A\">",
"      Oral Rx sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/33/29212\" title=\"table 1B\">",
"      Nonoral Rx sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/45/9950\" title=\"table 2\">",
"      Inhibitors and inducers of cytochrome P450 3A4",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/45/20184?source=related_link\">",
"      Androgen production and therapy in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/1/43032?source=related_link\">",
"      Approach to the woman with sexual pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/28/38341?source=related_link\">",
"      Erectile dysfunction in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32533?source=related_link\">",
"      Evaluation of male sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/39/3704?source=related_link\">",
"      Major side effects of beta blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/44/42696?source=related_link\">",
"      Overview of male sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/24/386?source=related_link\">",
"      Patient information: Sex problems in men (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/17/11538?source=related_link\">",
"      Patient information: Sex problems in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/33/29205?source=related_link\">",
"      Patient information: Sexual problems in men (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/4/12357?source=related_link\">",
"      Patient information: Sexual problems in women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/15/8442?source=related_link\">",
"      Sexual activity in patients with heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/42/25258?source=related_link\">",
"      Sexual dysfunction in women: Epidemiology, risk factors, and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/10/34985?source=related_link\">",
"      Sexual dysfunction in women: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/36/30282?source=related_link\">",
"      Treatment of male sexual dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_57_42905="Surgical management of gastroesophageal reflux in adults";
var content_f41_57_42905=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Surgical management of gastroesophageal reflux in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/57/42905/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/57/42905/contributors\">",
"     Steven D Schwaitzberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/57/42905/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/57/42905/contributors\">",
"     Joseph S Friedberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/57/42905/contributors\">",
"     Nicholas J Talley, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/57/42905/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/57/42905/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/57/42905/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical management is generally reserved for patients with complications of reflux such as recurrent or refractory esophagitis, stricture, Barrett's metaplasia, persistent \"reflux symptoms\" despite acid suppression, or asthma. Patients who are unable to tolerate medication, noncompliant with medication, or who are medication dependent and unwilling to take lifelong medications are also surgical candidates.",
"   </p>",
"   <p>",
"    The surgical management of patients with GERD is reviewed in this topic. The pathophysiology, diagnosis, medical management, and complications of gastroesophageal reflux are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13928?source=see_link\">",
"     \"Pathophysiology of reflux esophagitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/11/16568?source=see_link&amp;anchor=H6#H6\">",
"     \"Motility testing: When does it help?\", section on 'Prior to antireflux surgery'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/53/42840?source=see_link\">",
"     \"Medical management of gastroesophageal reflux disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19253?source=see_link\">",
"     \"Complications of gastroesophageal reflux in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR OPERATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several indications for surgery in the patient with GERD:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Gastrointestinal indications",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Failed optimal medical management",
"     </li>",
"     <li>",
"      Noncompliance with medical therapy",
"     </li>",
"     <li>",
"      High volume reflux",
"     </li>",
"     <li>",
"      Severe esophagitis by endoscopy",
"     </li>",
"     <li>",
"      Benign stricture",
"     </li>",
"     <li>",
"      Barrett's columnar-lined epithelium (without severe dysplasia or carcinoma)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most frequent indication for antireflux surgery has traditionally been severe GERD unresponsive to optimal medical therapy, which consists of both drug therapy and lifestyle modifications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/1\">",
"     1",
"    </a>",
"    ]. Some patients continue to have substantial symptoms of \"reflux\" despite elimination of the heartburn component of their GERD and may wish to consider operation on this basis alone. However, continued symptoms despite adequate acid suppression with proton pump inhibitors (PPIs) should serve as a warning that symptoms may not be due to excess esophageal acid exposure but to functional heartburn, a malignancy, or extra-esophageal disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22168?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux in adults\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H8\">",
"     'Preoperative evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Non gastrointestinal indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;About one-half of patients with GERD report upper respiratory symptoms including hoarseness, laryngitis, wheezing, nocturnal asthma, cough, aspiration, or dental erosion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Relief of respiratory symptoms is usually achievable by fundoplication in patients who also have typical reflux symptoms; however, the outcome is less favorable in the substantial minority of patients in whom respiratory symptoms occur in association with abnormalities of esophageal motility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although cough may present as one of the most common extraesophageal symptoms of GERD, asthma, chronic bronchitis, laryngitis, idiopathic subglottic stenosis, and even laryngeal cancer have also been implicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See appropriate topic reviews.) Many of these patients do not have typical features of GERD, such as heartburn [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Laryngeal disease",
"      </strong>",
"      &mdash; There is no role for considering surgery as a first-line treatment for posterior laryngitis. However, it is reasonable to consider surgery for patients who have abnormal pharyngeal acid on a double probe pH study when medical therapy has been maximized, is not tolerated, or is impractical.",
"      <br/>",
"      <br/>",
"      Despite the large volume of literature, skepticism exists about the direct causal relationship between pharyngeal acid exposure and laryngeal diseases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. Paralleling this uncertainty is the debate whether entities such as posterior laryngitis should be treated empirically with anti-acid therapy or evaluated diagnostically to prove the existence of abnormal pharyngeal acid prior to initiating anti-acid therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/8-14\">",
"       8-14",
"      </a>",
"      ]. One of the most recent controlled trials demonstrated efficacy of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/14/3305?source=see_link\">",
"       lansoprazole",
"      </a>",
"      in the treatment of posterior laryngitis, supporting empiric therapy as first line treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/14\">",
"       14",
"      </a>",
"      ]. Numerous studies also support the effectiveness of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/62/26601?source=see_link\">",
"       omeprazole",
"      </a>",
"      and other anti-acid strategies in this setting [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/11,15\">",
"       11,15",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      On the other hand, some data suggest that symptoms recur after treatment is discontinued [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/15\">",
"       15",
"      </a>",
"      ], while other data have shown that laryngeal symptoms can be treated successfully by laparoscopic fundoplication [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/10/33960?source=see_link&amp;anchor=H11#H11\">",
"       \"Laryngopharyngeal reflux\", section on 'Dual sensor pH probe'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      A controlled trial suggested that surgery was not consistently effective in patients who were unresponsive to aggressive PPI therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/18\">",
"       18",
"      </a>",
"      ]; thus, failure to respond to a PPI should serve as a warning that symptoms may not be relieved with surgery. Documented response rates for airway diseases are less than that of fundoplication performed purely for typical gastroesophageal symptoms. Approximately 70 percent of patients will experience symptom improvement, while approximately 33 percent of patients may remain on medication but often at a far reduced dosage [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Asthma",
"      </strong>",
"      &mdash; Consensus has not been achieved on the role of surgery in patients with asthma that is thought to be related to GERD. A systematic review that included 24 reports (mostly case series and uncontrolled trials) suggested that surgery improved asthma symptoms, asthma medication use, and pulmonary function in 79, 88, and 27 percent of patients, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/20\">",
"       20",
"      </a>",
"      ]. A dramatic reduction in steroid dependency postoperatively was documented in another study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/21\">",
"       21",
"      </a>",
"      ]. Medical therapy is associated with an improvement in symptoms and reduction in asthma medication use in 60 to 70 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/22\">",
"       22",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39816?source=see_link\">",
"       \"Gastroesophageal reflux and asthma\"",
"      </a>",
"      .) Improvement in pulmonary function has not been documented after medical or surgical therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/20,22-24\">",
"       20,22-24",
"      </a>",
"      ]. Some consideration should be given to lowering the threshold to surgery in asthmatics, especially younger patients, in whom significant GER can be demonstrated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PREOPERATIVE EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus for the optimal preoperative investigation for appropriate surgical candidates (",
"    <a class=\"graphic graphic_table graphicRef82167 \" href=\"mobipreview.htm?25/46/26347\">",
"     table 1",
"    </a>",
"    ). Upper endoscopy, esophageal manometry, and an assessment of esophageal length and degree of hiatal herniation are the most useful tests in making surgical decisions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Upper endoscopy",
"      </strong>",
"      &mdash; Esophageal and gastric endoscopy should be performed to assess the esophageal and gastric mucosa for signs of malignancy prior to proceeding with a surgical antireflux procedure. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/9/12442?source=see_link\">",
"       \"Overview of upper gastrointestinal endoscopy (esophagogastroduodenoscopy)\"",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Esophageal manometry",
"      </strong>",
"      &mdash; Esophageal manometry studies are of value and should be used routinely in preoperative evaluation. Manometry occasionally provides alternative diagnoses, such as scleroderma or achalasia, for which antireflux surgery may be contraindicated. In addition, manometry may lead to a modification of the surgical approach or a change in management, although the need to modify the surgical procedure based upon the manometric findings has been questioned [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/25\">",
"       25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/11/16568?source=see_link&amp;anchor=H6#H6\">",
"       \"Motility testing: When does it help?\", section on 'Prior to antireflux surgery'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Esophageal length evaluation",
"      </strong>",
"      &mdash; Some assessment of esophageal length and the degree of hiatal herniation is also appropriate; a simple upper gastrointestinal series generally suffices for this purpose. The presence of a markedly shortened esophagus or a large hiatal hernia that does not reduce in the upright position may tip the scales in favor of a transthoracic approach [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CHOICE OF OPERATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current experience with antireflux surgery suggests that there is no one best operation for all patients. Factors such as the degree of esophageal shortening, disturbances of esophageal motility, prior operations, and local expertise with laparoscopic techniques influence the choice of operation. It remains unclear which patient characteristics influence postoperative success following fundoplication for GERD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/27\">",
"     27",
"    </a>",
"    ]. A comprehensive review of the literature shows that there is no consistent association between surgical outcomes and preoperative response to acid suppression medications, baseline symptoms, baseline acid exposure, degree of lower esophageal sphincter competence, or position of reflux.",
"   </p>",
"   <p>",
"    For the patient with normal esophageal length and motility, the operation of choice is probably a laparoscopic Nissen fundoplication. Studies comparing partial fundoplication to the 360 degree Nissen fundoplication have consistently reported less postoperative dysphagia with partial fundoplication but greater long-term durability with complete fundoplication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Early uncomplicated disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;One report, for example, proposed a \"tailored approach\" to antireflux surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/26\">",
"     26",
"    </a>",
"    ]. Trans-abdominal Nissen (laparoscopic if possible) fundoplication was recommended for most patients with early, uncomplicated disease (which accounted for approximately 65 percent of 104 patients seen over a seven-year period).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Laparoscopy versus laparotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of important questions exist about antireflux surgery, such as short-term and long-term outcomes of laparoscopic techniques in comparison with traditional approaches and whether earlier consideration of surgical therapy to prevent complications of GERD is warranted.",
"   </p>",
"   <p>",
"    A laparoscopic operation performed by an experienced surgeon can offer significant advantages over the open operation with similar efficacy and safety and may be an attractive alternative to lifelong medical therapy. A meta-analysis of 12 prospective trials found a 65 percent reduction of complication rates for patients treated with laparoscopic antireflux surgery compared with open antireflux surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/29\">",
"     29",
"    </a>",
"    ]. Patients undergoing a laparoscopic approach had a faster convalescent rate (three fewer days in hospital), a faster return to work (eight days sooner), and a similar treatment outcome. However, the patients undergoing laparoscopic surgery also had a 79 percent higher rate of reoperation (odds ratio 1.79, 95% CI 1.00-3.22).",
"   </p>",
"   <p>",
"    In addition to low morbidity rates, the 30-day mortality rates are also low. In a retrospective review of 7531 patients undergoing a laparoscopic fundoplication, the overall mortality rate was 0.19 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/30\">",
"     30",
"    </a>",
"    ]. The mortality rate was significantly lower for patients &lt;age 70 in comparison with patients &ge;age 70 years (0.05 versus 0.8 percent).",
"   </p>",
"   <p>",
"    Robotic surgery, a newer minimally-invasive technique, offers no specific advantages over other laparoscopic techniques and is more costly to perform [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/31\">",
"     31",
"    </a>",
"    ]. Randomized trials have not been performed to assess short-term or long-term benefits of the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Decreased motility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although surgery cannot directly influence esophageal motility in patients with GERD, Nissen fundoplication can lead to improvement in esophageal contraction amplitude. This benefit is limited to patients with preoperative amplitudes above the fifth percentile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/11/16568?source=see_link\">",
"     \"Motility testing: When does it help?\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For the patient with normal length but decreased motility, a complete fundoplication is discouraged; the laparoscopic or open Toupet or Hill or transthoracic Belsey procedure could be performed. Wrapping the distal esophagus circumferentially or partially with a portion of stomach increases the LES pressure. However, too high of an LES pressure may lead to obstructive symptoms; thus, an incomplete wrap is often recommended in patients with poor esophageal motility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/32,33\">",
"     32,33",
"    </a>",
"    ], although the results of at least one controlled trial raised questions about this recommendation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/11/16568?source=see_link\">",
"     \"Motility testing: When does it help?\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Shortened esophagus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a shortened esophagus from chronic inflammation or altered anatomy present a unique challenge to the surgeon. A Collis (esophageal lengthening) gastroplasty combined with an intra-abdominal or intra-thoracic fundoplication should be performed in these settings; however, opinions vary regarding what constitutes adequate esophageal mobilization. Trans-thoracic approaches should be considered for the patient with concurrent pulmonary disease requiring evaluation or extensive prior abdominal surgery.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increasing the intra-abdominal esophageal length can be accomplished by reduction of hiatal hernia, approximation of the diaphragmatic crura, or tethering of the distal esophagus below the diaphragm. The bulk of a fundoplication may also keep the gastroesophageal junction within the abdomen.",
"     </li>",
"     <li>",
"      A gastroplasty may sufficiently lengthen the esophagus so that a fundoplication can be placed below the diaphragm. However, a fundoplication need not be intra-abdominal to be effective [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/34\">",
"       34",
"      </a>",
"      ]. Extensive cephalad mobilization of the esophagus should be avoided and an intra-thoracic fundoplication performed in these settings.",
"     </li>",
"     <li>",
"      The need for adequate mobilization of the esophagus is one reason cited for transthoracic approaches [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/34\">",
"       34",
"      </a>",
"      ]. The length of the overall sphincter can be affected by altering the length of a fundoplication; however, too long a fundoplication may lead to obstructive symptoms.",
"     </li>",
"     <li>",
"      An incorrectly performed fundoplication may prevent appropriate relaxation of the LES with swallowing. The LES and fundus normally undergo vagally-mediated relaxation with swallowing. It is therefore important that the fundus is the",
"      <strong>",
"       only",
"      </strong>",
"      part of the stomach used for reinforcing the LES; the wrap is placed around the esophagus, not the upper stomach, and the vagal nerves must not be injured during dissection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Advocates of the importance of the gastroesophageal valve support restoration of the angle of His (between the esophagus and gastric fundus) in order to improve the competence of the valve [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/35\">",
"       35",
"      </a>",
"      ]. Reduction of hiatal hernia may also contribute to the efficacy of antireflux surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Reoperation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reoperation for failed antireflux surgery requires individual evaluation and consideration of alternative options for further management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SPECIFIC OPERATIVE TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of antireflux procedures have been described for the treatment of GERD (",
"    <a class=\"graphic graphic_figure graphicRef51213 graphicRef78957 \" href=\"mobipreview.htm?33/56/34693\">",
"     figure 1A-B",
"    </a>",
"    ). The most common procedures (Nissen fundoplication, Belsey Mark IV, and Hill repair) claim about an 85 percent success rates in relieving symptoms and healing esophagitis.",
"   </p>",
"   <p>",
"    Many surgical approaches focus on restoring a physiologic equivalent to the normal LES. Manometric studies of the LES have documented that reflux is correlated with a lower mean LES pressure, shorter mean intra-abdominal LES length, and shorter overall sphincter length [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/39\">",
"     39",
"    </a>",
"    ]. Each of these problems can be corrected by specific surgical procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Nissen fundoplication",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Nissen fundoplication has, in many series, been found superior to other procedures, with symptomatic improvement occurring in 85 to 90 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/34\">",
"     34",
"    </a>",
"    ]. This procedure originally involved passage of the gastric fundus behind the esophagus to encircle the distal 6 cm of the esophagus. However, many variations and modifications have been described, and a \"Nissen fundoplication\" may be performed differently by different surgeons. Variables include: approach (transthoracic or abdominal); portion of stomach wall used (anterior and posterior or anterior only); combination with other procedures (eg, vagotomy or gastroplasty); the looseness of the wrap; the completeness of the wrap; and the length of the wrap [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/34\">",
"     34",
"    </a>",
"    ]. Most surgeons choose to perform a loose (\"floppy\") Nissen fundic wrap that is about 1 to 2 cm in length including a posterior crural repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Laparoscopic Nissen fundoplication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nissen fundoplication can also be effectively performed laparoscopically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/40\">",
"     40",
"    </a>",
"    ]. Although there have been few long-term studies, a number of observational studies of laparoscopic fundoplication demonstrate comparable safety, short-term efficacy, and patient satisfaction, as well as shorter hospital stays and recuperative times than with open operation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/41-46\">",
"     41-46",
"    </a>",
"    ]. A prospective, randomized trial comparing open with laparoscopic fundoplication in 110 consecutive patients found, at up to 11 years follow-up, similar benefits on symptoms but a significantly higher incidence of incisional hernias and defective fundic wraps in the open group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 2005 systematic review concluded that laparoscopic fundoplication was as effective as open fundoplication for relieving heartburn and regurgitation, improving quality of life, and decreasing antisecretory medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/48\">",
"     48",
"    </a>",
"    ]. Almost 90 percent of patients who were followed for five or more years reported improvement in symptoms. However, when considering studies of both open and laparoscopic fundoplication, 10 to 65 percent of patients still required some form of antisecretory medications after surgery. No patient or procedure characteristic was consistently associated with surgical results with the exception of worse satisfaction and outcomes in patients with a significant psychiatric history.",
"   </p>",
"   <p>",
"    The most commonly reported complications for laparoscopic procedures were gastric or esophageal injury, splenic injury or splenectomy, pneumothorax, bleeding, pneumonia, fever, wound infections, bloating, and dysphagia. These major complications were uncommon.",
"   </p>",
"   <p>",
"    Some studies have suggested that the laparoscopic approach has been associated with a relatively high incidence of postoperative dysphagia (8 to 12 percent) compared with an open approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/46,49-51\">",
"     46,49-51",
"    </a>",
"    ]. Why this might occur is not well understood. It may be attributable at least in part to difficulty determining the looseness of the wrap at laparoscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/42\">",
"     42",
"    </a>",
"    ]. For this reason, many surgeons construct the wrap over a large esophageal Bougie (48 to 60 Fr) passed into the stomach by the anesthesiologist to ensure adequate \"floppiness.\"",
"   </p>",
"   <p>",
"    The type of procedure performed also may be a determinant of postoperative dysphagia. One report found that dysphagia was more frequent with the laparoscopic Rosetti-Nissen procedure (11 percent) than with either the laparoscopic Nissen (2 percent) or Toupet (2 percent) procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/52\">",
"     52",
"    </a>",
"    ]. Although preoperative testing cannot reliably predict postoperative dysphagia, preoperative swallowing difficulty appears to be the single greatest risk factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rate of development of laparoscopic expertise (learning curve) varies among studies. The number of procedures needed to be performed to develop technical expertise ranges from 20 to 60 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/54-56\">",
"     54-56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Nissen modifications",
"    </span>",
"    &nbsp;&mdash;&nbsp;A common modification is a 360 degree fundic wrap without ligation of the short gastric vessels (Rosetti-Nissen). A partial 270 degree posterior wrap (Toupet) is used for patients with severe associated motor abnormalities. A partial 180 degree anterior wrap (Dor) achieved laparoscopically has also been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Belsey Mark IV",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Belsey Mark IV operation involves a partial fundoplication performed by transthoracic approach, which allows full esophageal mobilization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/57\">",
"     57",
"    </a>",
"    ]. The incomplete fundoplication leads to fewer obstructive symptoms and is therefore recommended for patients with poor esophageal motility who might have other indications for a transthoracic approach (eg, obesity or a shortened esophagus) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Hill gastropexy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Hill procedure involves imbrication of the anterior and posterior lesser gastric curve around the esophagus with tethering of the complex to the median arcuate ligament and closure of the diaphragm. Intraoperative manometry is used to achieve a desired LES pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/35,57\">",
"     35,57",
"    </a>",
"    ]. This operation has also been performed laparoscopically and is advocated by those who support reconstruction of the angle of His and the importance of the \"gastroesophageal valve\" for preventing reflux [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/35\">",
"     35",
"    </a>",
"    ]. It can also be used in a patient with a small stomach because of prior gastric resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Gastric bypass",
"    </span>",
"    &nbsp;&mdash;&nbsp;For morbidly obese patients, Roux-en-Y gastric bypass (RYGB) shows promise as the procedure of choice for surgical treatment of gastroesophageal reflux disease. Several small series have reported a decrease in reflux symptoms as well as complete or partial regression of Barrett's esophagus in morbidly obese patients with RYGB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/31/33274?source=see_link\">",
"     \"Surgical management of severe obesity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/61/35802?source=see_link\">",
"     \"Management of Barrett's esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Angelchik prosthesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Angelchik prosthesis is a doughnut-shaped prosthesis placed around the distal esophagus. Use of the prosthesis was initially touted for ease of placement and reflux prevention, but fell into disfavor because of its high rate of complications and dysphagia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/57,58,62\">",
"     57,58,62",
"    </a>",
"    ]. This prosthesis is no longer used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Endoscopic methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of methods for treating GERD endoscopically have been developed. Their efficacy (particularly long-term) is still being defined. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/5/25688?source=see_link\">",
"     \"Endoscopic therapy for gastroesophageal reflux disease: Sewing and full-thickness plication techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE SYMPTOM MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of patients after fundoplication depends upon symptoms related to the size and tightness of the wrap.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Dysphagia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients have some degree of postoperative dysphagia and require a period of modified dietary intake primarily consisting of liquids from 2 to 12 weeks. The most common predictor of postoperative dysphagia is the presence of preoperative dysphagia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/53\">",
"     53",
"    </a>",
"    ]. Such patients should be counseled appropriately before surgery.",
"   </p>",
"   <p>",
"    Some patients describe a \"sticking\" sensation in their lower or mid chest that they mistakenly attribute to recurrent GERD. Such patients often resume antisecretory medications. However, it is unlikely that patients whose fundoplication is functionally intact have persistent gastroesophageal reflux. Thus, we suggest that they be studied radiographically prior to restarting antisecretory medications to identify those who require dilation or a revision.",
"   </p>",
"   <p>",
"    Dysphagia that persists for more than 12 weeks requires evaluation, which typically begins with a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow to assess the anatomic placement of the fundoplication. Patients should be asked to swallow a 13 mm barium tablet. Patients with dysphagia in whom the 13 mm barium tablet passes slowly through the esophagus and who had normal motility preoperatively should be considered candidates for dilation after 12 weeks. Approximately 6 to 12 percent of patients with fundoplication required dilation in various reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no consensus on the optimal dilation technique (ie, bougie versus guidewire dilation versus pneumatic dilations). The author performs direct bougie dilation, with or without endoscopic guidance. In the author&rsquo;s experience, the procedure is extremely well tolerated and produces good results. Tortuous pathways through the fundic wrap are best managed by guidewire dilation. Pneumatic dilation is rarely needed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39305?source=see_link\">",
"     \"Management of benign esophageal strictures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who have a 360 degree fundoplication may be candidates for revision to a partial fundoplication if dysphagia persists and effective",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    tablet passage cannot be established.",
"   </p>",
"   <p>",
"    A subset of patients has persistent symptoms without objective evidence of esophageal dysfunction radiographically or by esophageal pH studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. The cause of persistent symptoms in such patients is unclear but may involve anatomic, functional, and psychological factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/67\">",
"     67",
"    </a>",
"    ]. Care of such patients should be individualized. This is a setting in which we have upon",
"    <strong>",
"     rare",
"    </strong>",
"    occasion used a Bernstein test to assess the correlation of symptoms with acid exposure. Esophageal pH impedance studies may add diagnostic information in the setting of apparent surgical failure and help direct next steps (eg, adding a PPI). Medical therapy aimed at treating esophageal spasm can provide relief in some patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22168?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Small migration of the fundoplication in a cephalad direction may result from inadequate esophageal mobilization or an unrecognized shortened esophagus. However, it is not clear whether these findings are associated with symptoms and thus can account for the dysphagia. An asymptomatic patient can be followed expectantly. Patients with symptoms of dysphagia or perceived reflux should undergo manometry, pH testing, and endoscopy in order to understand the impact, if any, of cephalad migration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Gas bloat syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of gas bloat syndrome (a sensation of intestinal gas with the inability to belch) can be elicited in a significant number of patients after fundoplication. The pathogenesis is not well understood, although it was seen more frequently in the past when longer and tighter fundoplications were created [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/68\">",
"     68",
"    </a>",
"    ]. It may also be in part due to dysfunction in gastric emptying, which may have been unrecognized preoperatively (underscoring the need for careful preoperative evaluation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/69\">",
"     69",
"    </a>",
"    ]. Symptoms may be due to aerophagia or vagal dysfunction, although this has not been well studied. The author performs a solid phase gastric emptying study to confirm the diagnosis of long-term gastric emptying dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/12/43209?source=see_link&amp;anchor=H17#H17\">",
"     \"Etiology and diagnosis of delayed gastric emptying\", section on 'Scintigraphic gastric emptying'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with only mild symptoms, we suggest empiric trials of chewable",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/35/33332?source=see_link\">",
"     simethicone",
"    </a>",
"    tablets or charcoal caplets. We also instruct patients not to drink with a straw or ingest carbonated beverages until symptoms resolve, although there is no evidence that these strategies are effective. Although there are no randomized trials, an empiric trial with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    (10 to 15 mg four times daily) may be helpful. Short courses of two to three months are typical but some patients may require long-term treatment, placing them at risk for complications including irreversible tardive dyskinesia (especially in older patients).",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/43/1717?source=see_link\">",
"     Domperidone",
"    </a>",
"    is an alternative to consider and is available under an investigation new device (IND) program from compounding pharmacies in the US.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     Erythromycin",
"    </a>",
"    can be considered as an alternative; however, some patients experience significant gastric distress forcing discontinuation.",
"   </p>",
"   <p>",
"    Symptoms tend to lessen over time in most patients. In patients with severe persistent symptoms despite the above treatment approaches and who have documented gastroparesis, pyloroplasty, pyloric botox, and pneumatic pyloric dilatation are options in select patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. Some studies have described a reduced incidence of gas bloat with partial fundoplication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/68\">",
"     68",
"    </a>",
"    ]. As a result, conversion from a full to a partial fundoplication has been reported but is rarely required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Revisional surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 5 to 10 percent of patients will need revisional surgery after laparoscopic fundoplication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/72\">",
"     72",
"    </a>",
"    ]. The most frequent reasons for revision are recurrent heartburn and dysphagia, and the most common predictor of postoperative dysphagia was preoperative dysphagia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the author&rsquo;s experience, the most common reasons for failure are disruption of the fundoplication and excessive cephalad migration in the face of unrecognized shortened esophagus. In a series of 109 patients who underwent revisional surgery after a median time of 26 months, the indications for revisional surgery were dysphagia (48 percent), reflux (33 percent), paraesophageal herniation (15 percent), and atypical symptoms (4 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the success rate for revisional surgery is lower than primary surgery and about 10 percent of patients will continue to complain of reflux or dysphagia after revisional surgery. Medical therapy remains the only option at that point. Rare patient undergo distal esophageal resection but there are no outcomes data for this group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     LONG-TERM EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term observational studies of laparoscopic fundoplication by experienced operators generally report that 90 to 95 percent of adult patients are satisfied with the results of their surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. However, consensus has not been achieved on what constitutes treatment success or failure.",
"   </p>",
"   <p>",
"    As an example, while continued use of anti-acid medications has been considered to represent treatment failure, there are no studies that have described the proportion of patients who are placed on anti-acid medications following a surgical procedure who have objective evidence of reflux. Furthermore, some patients who require anti-acid medications after surgery still report high quality of life compared with preoperative status. Many patients on acid suppression medications do not have documental reflux [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H585085191\">",
"    <span class=\"h2\">",
"     Comparison of partial with complete fundoplication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both a total and partial fundoplication provide long-term relief of GERD symptoms. A randomized trial included 137 patients with chronic GERD and esophagitis undergoing either a partial wrap (Toupet posterior procedure) or a total wrap (Nissen procedure) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/75\">",
"     75",
"    </a>",
"    ]. Patients treated with a partial wrap had equivalent rates of control of symptoms of heartburn (80 versus 87 percent) and acid regurgitation (82 versus 90 percent) after a mean of 18 years of observation. Both groups had similar rates of long-term side effects such as bloating, flatulence, and dysphagia scores. The rate of flatulence, which typically occurs early in the postoperative period following a Nissen fundoplication, decreased over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31943978\">",
"    <span class=\"h2\">",
"     Comparison of an anterior with a posterior fundoplication",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laparoscopic anterior fundoplication (LAF) (90 to 180&deg; wrap) was proposed as an alternative to the laparoscopic posterior fundoplication (LPF) (180 to 360&deg; wrap) to reduce postfundoplication symptoms but was reported to have higher rates of recurrence of reflux [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/28,76-80\">",
"     28,76-80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of seven randomized trials found that the short-term results for 338 patients treated by a LPF included significantly less esophageal acid exposure time (0.8 versus 3.3 percent), heartburn (8 versus 21 percent), and a lower reoperation rate (4 versus 8 percent) compared with 345 patients undergoing LAF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/80\">",
"     80",
"    </a>",
"    ]. There were no significant short-term differences for the rate of esophagitis, regurgitation, belching, lower esophageal sphincter pressure, or satisfaction between the two approaches [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/80\">",
"     80",
"    </a>",
"    ]. The long-term outcomes for patients undergoing a LPF included a significantly lower rate of persistent heartburn (14 versus 31 percent) and a significantly lower reoperation rate (5 versus 10 percent) but no differences in dysphagia scores, inability to belch, gas bloating, or patient satisfaction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H585085142\">",
"    <span class=\"h2\">",
"     Comparison with medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relatively few controlled trials have described the long-term outcome following surgical treatment of GERD compared with medical treatment. Long-term mortality of surgical management is quite low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/81-84\">",
"     81-84",
"    </a>",
"    ]. Optimized, contemporary medical (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/39/15993?source=see_link\">",
"     esomeprazole",
"    </a>",
"    , 20 to 40",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and surgical (standardized laparoscopic reflux procedure [LARS]) management provide similar five-year remission rates for control of GERD symptoms. An exploratory randomized, open, parallel trial that included 372 patients found that patients undergoing LARS (n = 180) had a lower estimated five-year remission rate compared with patients treated with esomeprazole (85 versus 92 percent, log-rank P = 0.048) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/57/42905/abstract/85\">",
"     85",
"    </a>",
"    ]. The difference between the LARS and esomeprazole groups was no longer statistically significant following best-case scenario modeling of the effects of study dropout. The prevalence of dysphagia, bloating, and flatulence was significantly higher for patients treated with LARS (11 versus 5 percent, 40 versus 28 percent, 57 versus 40 percent, respectively). Acid regurgitation was significantly lower for patients treated with LARS (2 versus 13 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/33/37393?source=see_link\">",
"       \"Patient information: Hiatal hernia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/30/38373?source=see_link\">",
"       \"Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23494007\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastroesophageal reflux disease (GERD) is manifested by a spectrum of nonspecific symptoms, including heartburn, regurgitation, dysphagia, laryngitis, dental problems, adult onset asthma,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    aspiration pneumonia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most frequent indication for surgery for patients with GERD is severe GERD unresponsive to optimal medical therapy, which consists of both drug therapy and lifestyle modifications. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Indications for operation'",
"      </a>",
"      above.) Other reasons for operative management include noncompliance, severe esophagitis by endoscopy, benign stricture, Barrett's columnar-lined epithelium (without severe dysplasia or carcinoma), dental erosion by acid exposure, and recurrent pulmonary symptoms.",
"     </li>",
"     <li>",
"      The preoperative evaluation should include upper endoscopy, esophageal manometry, and an assessment of esophageal length and hiatal hernia (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Preoperative evaluation'",
"      </a>",
"      above). Esophageal pH monitoring should be reserved for patients who have a negative upper endoscopy or atypical symptoms.",
"     </li>",
"     <li>",
"      There is no consensus on which is the best antireflux operative procedure for all patients. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Choice of operation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with GERD, a laparoscopic Nissen fundoplication is preferred by the author. The laparoscopic approach has an equivalent control of symptoms and a faster recovery compared with the open approach. However, the reoperation rate is higher following the laparoscopic approach. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Laparoscopy versus laparotomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The laparoscopic approach offers several advantages with similar efficacy and safety as an open procedure.",
"     </li>",
"     <li>",
"      Postoperative symptoms of dysphagia occur in most patients. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Postoperative symptom management'",
"      </a>",
"      above.) There is no consensus on the optimal dilatation procedure for postoperative stenosis. Most patients with symptoms of gas-bloat syndrome improve over time.",
"     </li>",
"     <li>",
"      We recommend the laparoscopic posterior fundoplication (LPF) as the surgical approach for the treatment of GERD (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Patients undergoing a LPF had fewer short-term adverse outcomes (eg, esophageal acid exposure time, heart burn, and reoperation rate) and fewer long-term adverse outcomes (eg, heartburn, reoperation rate) compared with patients undergoing a laparoscopic anterior repair. (See",
"      <a class=\"local\" href=\"#H31943978\">",
"       'Comparison of an anterior with a posterior fundoplication'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/1\">",
"      Zaninotto G, Attwood SE. Surgical management of refractory gastro-oesophageal reflux. Br J Surg 2010; 97:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/2\">",
"      Downing TE, Sporn TA, Bollinger RR, et al. Pulmonary histopathology in an experimental model of chronic aspiration is independent of acidity. Exp Biol Med (Maywood) 2008; 233:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/3\">",
"      Lazarchik DA, Frazier KB. Dental erosion and acid reflux disease: an overview. Gen Dent 2009; 57:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/4\">",
"      Johnson WE, Hagen JA, DeMeester TR, et al. Outcome of respiratory symptoms after antireflux surgery on patients with gastroesophageal reflux disease. Arch Surg 1996; 131:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/5\">",
"      Johanson JF. Epidemiology of esophageal and supraesophageal reflux injuries. Am J Med 2000; 108 Suppl 4a:99S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/6\">",
"      Jindal JR, Milbrath MM, Shaker R, et al. Gastroesophageal reflux disease as a likely cause of \"idiopathic\" subglottic stenosis. Ann Otol Rhinol Laryngol 1994; 103:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/7\">",
"      Smullen JL, Lejeune FE Jr. Otolaryngologic manifestations of gastroesophageal reflux disease. J La State Med Soc 1999; 151:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/8\">",
"      Nostrant TT. Gastroesophageal reflux and laryngitis: a skeptic's view. Am J Med 2000; 108 Suppl 4a:149S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/9\">",
"      Ormseth EJ, Wong RK. Reflux laryngitis: pathophysiology, diagnosis, and management. Am J Gastroenterol 1999; 94:2812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/10\">",
"      Ulualp SO, Toohill RJ, Shaker R. Outcomes of acid suppressive therapy in patients with posterior laryngitis. Otolaryngol Head Neck Surg 2001; 124:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/11\">",
"      Hanson DG, Jiang JJ. Diagnosis and management of chronic laryngitis associated with reflux. Am J Med 2000; 108 Suppl 4a:112S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/12\">",
"      Hanson DG, Conley D, Jiang J, Kahrilas P. Role of esophageal pH recording in management of chronic laryngitis: an overview. Ann Otol Rhinol Laryngol Suppl 2000; 184:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/13\">",
"      Fraser AG, Morton RP, Gillibrand J. Presumed laryngo-pharyngeal reflux: investigate or treat? J Laryngol Otol 2000; 114:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/14\">",
"      El-Serag HB, Lee P, Buchner A, et al. Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial. Am J Gastroenterol 2001; 96:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/15\">",
"      Kamel PL, Hanson D, Kahrilas PJ. Omeprazole for the treatment of posterior laryngitis. Am J Med 1994; 96:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/16\">",
"      Hinder RA, Branton SA, Floch NR. Surgical therapy for supraesophageal reflux complications of gastroesophageal reflux disease. Am J Med 2000; 108 Suppl 4a:178S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/17\">",
"      Farrell TM, Richardson WS, Trus TL, et al. Response of atypical symptoms of gastro-oesophageal reflux to antireflux surgery. Br J Surg 2001; 88:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/18\">",
"      Swoger J, Ponsky J, Hicks DM, et al. Surgical fundoplication in laryngopharyngeal reflux unresponsive to aggressive acid suppression: a controlled study. Clin Gastroenterol Hepatol 2006; 4:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/19\">",
"      Kaufman JA, Houghland JE, Quiroga E, et al. Long-term outcomes of laparoscopic antireflux surgery for gastroesophageal reflux disease (GERD)-related airway disorder. Surg Endosc 2006; 20:1824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/20\">",
"      Field SK, Gelfand GA, McFadden SD. The effects of antireflux surgery on asthmatics with gastroesophageal reflux. Chest 1999; 116:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/21\">",
"      Spivak H, Smith CD, Phichith A, et al. Asthma and gastroesophageal reflux: fundoplication decreases need for systemic corticosteroids. J Gastrointest Surg 1999; 3:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/22\">",
"      Field SK, Sutherland LR. Does medical antireflux therapy improve asthma in asthmatics with gastroesophageal reflux?: a critical review of the literature. Chest 1998; 114:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/23\">",
"      Spechler SJ, Gordon DW, Cohen J, et al. The effects of antireflux therapy on pulmonary function in patients with severe gastroesophageal reflux disease. Department of Veterans Affairs Gastroesophageal Reflux Disease Study Group. Am J Gastroenterol 1995; 90:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/24\">",
"      Sontag SJ, O'Connell S, Khandelwal S, et al. Asthmatics with gastroesophageal reflux: long term results of a randomized trial of medical and surgical antireflux therapies. Am J Gastroenterol 2003; 98:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/25\">",
"      Fibbe C, Layer P, Keller J, et al. Esophageal motility in reflux disease before and after fundoplication: a prospective, randomized, clinical, and manometric study. Gastroenterology 2001; 121:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/26\">",
"      Kauer WK, Peters JH, DeMeester TR, et al. A tailored approach to antireflux surgery. J Thorac Cardiovasc Surg 1995; 110:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/27\">",
"      Ip S, Tatsioni A, Conant A, et al. Predictors of clinical outcomes following fundoplication for gastroesophageal reflux disease remain insufficiently defined: a systematic review. Am J Gastroenterol 2009; 104:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/28\">",
"      Ludemann R, Watson DI, Jamieson GG, et al. Five-year follow-up of a randomized clinical trial of laparoscopic total versus anterior 180 degrees fundoplication. Br J Surg 2005; 92:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/29\">",
"      Peters MJ, Mukhtar A, Yunus RM, et al. Meta-analysis of randomized clinical trials comparing open and laparoscopic anti-reflux surgery. Am J Gastroenterol 2009; 104:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/30\">",
"      Niebisch S, Fleming FJ, Galey KM, et al. Perioperative risk of laparoscopic fundoplication: safer than previously reported-analysis of the American College of Surgeons National Surgical Quality Improvement Program 2005 to 2009. J Am Coll Surg 2012; 215:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/31\">",
"      Morino M, Pellegrino L, Giaccone C, et al. Randomized clinical trial of robot-assisted versus laparoscopic Nissen fundoplication. Br J Surg 2006; 93:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/32\">",
"      Stein HJ, Bremner RM, Jamieson J, DeMeester TR. Effect of Nissen fundoplication on esophageal motor function. Arch Surg 1992; 127:788.",
"     </a>",
"    </li>",
"    <li>",
"     Peters JH, DeMeester TR. Esophagus and diaphragmatic hernia. In: Principles of Surgery, Schwartz, SI, Shires, GT, Spencer, FC (Eds), McGraw-Hill, New York 1994. p.1043.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/34\">",
"      Ellis FH Jr. The Nissen fundoplication. Ann Thorac Surg 1992; 54:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/35\">",
"      Kraemer SJ, Aye R, Kozarek RA, Hill LD. Laparoscopic Hill repair. Gastrointest Endosc 1994; 40:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/36\">",
"      Patti MG, Goldberg HI, Arcerito M, et al. Hiatal hernia size affects lower esophageal sphincter function, esophageal acid exposure, and the degree of mucosal injury. Am J Surg 1996; 171:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/37\">",
"      Stein HJ, Feussner H, Siewert JR. Failure of antireflux surgery: causes and management strategies. Am J Surg 1996; 171:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/38\">",
"      Gott JP, Polk HC Jr. Repeat operation for failure of antireflux procedures. Surg Clin North Am 1991; 71:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/39\">",
"      Stein HJ, DeMeester TR. Who benefits from antireflux surgery? World J Surg 1992; 16:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/40\">",
"      Hinder RA, Filipi CJ, Wetscher G, et al. Laparoscopic Nissen fundoplication is an effective treatment for gastroesophageal reflux disease. Ann Surg 1994; 220:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/41\">",
"      Trus TL, Laycock WS, Branum G, et al. Intermediate follow-up of laparoscopic antireflux surgery. Am J Surg 1996; 171:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/42\">",
"      Peters JH, Heimbucher J, Kauer WK, et al. Clinical and physiologic comparison of laparoscopic and open Nissen fundoplication. J Am Coll Surg 1995; 180:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/43\">",
"      Rattner DW, Brooks DC. Patient satisfaction following laparoscopic and open antireflux surgery. Arch Surg 1995; 130:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/44\">",
"      Nilsson G, Wenner J, Larsson S, Johnsson F. Randomized clinical trial of laparoscopic versus open fundoplication for gastro-oesophageal reflux. Br J Surg 2004; 91:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/45\">",
"      Rice S, Watson DI, Lally CJ, et al. Laparoscopic anterior 180 degrees partial fundoplication: five-year results and beyond. Arch Surg 2006; 141:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/46\">",
"      McKenzie D, Grayson T, Polk HC Jr. The impact of omeprazole and laparoscopy upon hiatal hernia and reflux esophagitis. J Am Coll Surg 1996; 183:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/47\">",
"      Salminen PT, Hiekkanen HI, Rantala AP, Ovaska JT. Comparison of long-term outcome of laparoscopic and conventional nissen fundoplication: a prospective randomized study with an 11-year follow-up. Ann Surg 2007; 246:201.",
"     </a>",
"    </li>",
"    <li>",
"     Ip S, Bonis P, Tatsioni A, et a. Comparative Effectiveness of Management Strategies for Gastroesophageal Reflux Disease. Evidence Report/Technology Assessment No. 1. (Prepared by Tufts-New England Medical Center. Evidence-based Practice Center under Contract No. 290-02-0022.) Rockville, MD: Agency for Healthcare Research and Quality. December 2005. www.effectivehealthcare.ahrq.gov/reports/final.cfm (Accessed on December 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/49\">",
"      Spechler SJ. Comparison of medical and surgical therapy for complicated gastroesophageal reflux disease in veterans. The Department of Veterans Affairs Gastroesophageal Reflux Disease Study Group. N Engl J Med 1992; 326:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/50\">",
"      Bais JE, Bartelsman JF, Bonjer HJ, et al. Laparoscopic or conventional Nissen fundoplication for gastro-oesophageal reflux disease: randomised clinical trial. The Netherlands Antireflux Surgery Study Group. Lancet 2000; 355:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/51\">",
"      Klaus A, Hinder RA, DeVault KR, Achem SR. Bowel dysfunction after laparoscopic antireflux surgery: incidence, severity, and clinical course. Am J Med 2003; 114:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/52\">",
"      Hunter JG, Swanstrom L, Waring JP. Dysphagia after laparoscopic antireflux surgery. The impact of operative technique. Ann Surg 1996; 224:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/53\">",
"      Herron DM, Swanstr&ouml;m LL, Ramzi N, Hansen PD. Factors predictive of dysphagia after laparoscopic Nissen fundoplication. Surg Endosc 1999; 13:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/54\">",
"      Watson DI, Baigrie RJ, Jamieson GG. A learning curve for laparoscopic fundoplication. Definable, avoidable, or a waste of time? Ann Surg 1996; 224:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/55\">",
"      Harris SC. Laparoscopic antireflux surgery. Am J Surg 1996; 171:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/56\">",
"      Cartlidge CW, Stewart GD, de Beaux AC, Paterson-Brown S. The evolution of laparoscopic antireflux surgery and its influence on postoperative stay. Scott Med J 2011; 56:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/57\">",
"      Little AG. Mechanisms of action of antireflux surgery: theory and fact. World J Surg 1992; 16:320.",
"     </a>",
"    </li>",
"    <li>",
"     Orlando RC. Reflux esophagitis. In: Textbook of Gastroenterology, Yamada, T (Eds), JB Lippincott Company, Philadelphia 1995. p.1214.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/59\">",
"      Csendes A, Burgos AM, Smok G, et al. Effect of gastric bypass on Barrett's esophagus and intestinal metaplasia of the cardia in patients with morbid obesity. J Gastrointest Surg 2006; 10:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/60\">",
"      Houghton SG, Romero Y, Sarr MG. Effect of Roux-en-Y gastric bypass in obese patients with Barrett's esophagus: attempts to eliminate duodenogastric reflux. Surg Obes Relat Dis 2008; 4:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/61\">",
"      Cobey F, Oelschlager B. Complete regression of Barrett's esophagus after Roux-en-Y gastric bypass. Obes Surg 2005; 15:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/62\">",
"      Kmiot WA, Kirby RM, Akinola D, Temple JG. Prospective randomized trial of Nissen fundoplication and Angelchik prosthesis in the surgical treatment of medically refractory gastro-oesophageal reflux disease. Br J Surg 1991; 78:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/63\">",
"      Dominitz JA, Dire CA, Billingsley KG, Todd-Stenberg JA. Complications and antireflux medication use after antireflux surgery. Clin Gastroenterol Hepatol 2006; 4:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/64\">",
"      Malhi-Chowla N, Gorecki P, Bammer T, et al. Dilation after fundoplication: timing, frequency, indications, and outcome. Gastrointest Endosc 2002; 55:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/65\">",
"      Boddy AP, Mehta S, Bennett J, et al. Postoperative esophageal physiology studies may help to predict long-term symptoms following laparoscopic Nissen fundoplication. Surg Endosc 2008; 22:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/66\">",
"      Lord RV, Kaminski A, Oberg S, et al. Absence of gastroesophageal reflux disease in a majority of patients taking acid suppression medications after Nissen fundoplication. J Gastrointest Surg 2002; 6:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/67\">",
"      Kalinowska E, Tarnowski W, Bielecki K, Banasiewicz J. Quality of life before and after laparoscopic fundoplication. Does quality of life depend on psychological factors? Preliminary report. Wiad Lek 2006; 59:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/68\">",
"      Granderath FA, Kamolz T, Granderath UM, Pointner R. Gas-related symptoms after laparoscopic 360 degrees Nissen or 270 degrees Toupet fundoplication in gastrooesophageal reflux disease patients with aerophagia as comorbidity. Dig Liver Dis 2007; 39:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/69\">",
"      De Vault K. Gas bloat syndrome: a pre- or postoperative dysmotility syndrome? Am J Gastroenterol 1995; 90:1536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/70\">",
"      Masqusi S, Velanovich V. Pyloroplasty with fundoplication in the treatment of combined gastroesophageal reflux disease and bloating. World J Surg 2007; 31:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/71\">",
"      Nguyen NT, Dholakia C, Nguyen XM, Reavis K. Outcomes of minimally invasive esophagectomy without pyloroplasty: analysis of 109 cases. Am Surg 2010; 76:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/72\">",
"      Lamb PJ, Myers JC, Jamieson GG, et al. Long-term outcomes of revisional surgery following laparoscopic fundoplication. Br J Surg 2009; 96:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/73\">",
"      Dassinger MS, Torquati A, Houston HL, et al. Laparoscopic fundoplication: 5-year follow-up. Am Surg 2004; 70:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/74\">",
"      Cowgill SM, Arnaoutakis D, Villadolid D, et al. Results after laparoscopic fundoplication: does age matter? Am Surg 2006; 72:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/75\">",
"      Mardani J, Lundell L, Engstr&ouml;m C. Total or posterior partial fundoplication in the treatment of GERD: results of a randomized trial after 2 decades of follow-up. Ann Surg 2011; 253:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/76\">",
"      Nijjar RS, Watson DI, Jamieson GG, et al. Five-year follow-up of a multicenter, double-blind randomized clinical trial of laparoscopic Nissen vs anterior 90 degrees partial fundoplication. Arch Surg 2010; 145:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/77\">",
"      Khan M, Smythe A, Globe J, et al. Randomized controlled trial of laparoscopic anterior versus posterior fundoplication for gastro-oesophageal reflux disease. ANZ J Surg 2010; 80:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/78\">",
"      Watson DI, Jamieson GG, Pike GK, et al. Prospective randomized double-blind trial between laparoscopic Nissen fundoplication and anterior partial fundoplication. Br J Surg 1999; 86:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/79\">",
"      Engstr&ouml;m C, L&ouml;nroth H, Mardani J, Lundell L. An anterior or posterior approach to partial fundoplication? Long-term results of a randomized trial. World J Surg 2007; 31:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/80\">",
"      Broeders JA, Roks DJ, Ahmed Ali U, et al. Laparoscopic anterior versus posterior fundoplication for gastroesophageal reflux disease: systematic review and meta-analysis of randomized clinical trials. Ann Surg 2011; 254:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/81\">",
"      Granderath FA, Kamolz T, Schweiger UM, et al. Long-term results of laparoscopic antireflux surgery. Surg Endosc 2002; 16:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/82\">",
"      Lundell L, Miettinen P, Myrvold HE, et al. Continued (5-year) followup of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease. J Am Coll Surg 2001; 192:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/83\">",
"      Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 2001; 285:2331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/84\">",
"      Mahon D, Rhodes M, Decadt B, et al. Randomized clinical trial of laparoscopic Nissen fundoplication compared with proton-pump inhibitors for treatment of chronic gastro-oesophageal reflux. Br J Surg 2005; 92:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/57/42905/abstract/85\">",
"      Galmiche JP, Hatlebakk J, Attwood S, et al. Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. JAMA 2011; 305:1969.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2278 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-78.134.254.52-C266496ECC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_57_42905=[""].join("\n");
var outline_f41_57_42905=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23494007\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INDICATIONS FOR OPERATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Gastrointestinal indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Non gastrointestinal indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PREOPERATIVE EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CHOICE OF OPERATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Early uncomplicated disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Laparoscopy versus laparotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Decreased motility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Shortened esophagus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Reoperation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SPECIFIC OPERATIVE TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Nissen fundoplication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Laparoscopic Nissen fundoplication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Nissen modifications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Belsey Mark IV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Hill gastropexy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Gastric bypass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Angelchik prosthesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Endoscopic methods",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      POSTOPERATIVE SYMPTOM MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Dysphagia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Gas bloat syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Revisional surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      LONG-TERM EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H585085191\">",
"      Comparison of partial with complete fundoplication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31943978\">",
"      Comparison of an anterior with a posterior fundoplication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H585085142\">",
"      Comparison with medical therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23494007\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/2278\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/2278|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/36/32320\" title=\"figure 1A\">",
"      Nissen fundoplication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/32/27136\" title=\"figure 1B\">",
"      Toupet fundoplication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/2278|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/46/26347\" title=\"table 1\">",
"      Preoperative eval GERD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22168?source=related_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19253?source=related_link\">",
"      Complications of gastroesophageal reflux in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/5/25688?source=related_link\">",
"      Endoscopic therapy for gastroesophageal reflux disease: Sewing and full-thickness plication techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/12/43209?source=related_link\">",
"      Etiology and diagnosis of delayed gastric emptying",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39816?source=related_link\">",
"      Gastroesophageal reflux and asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/10/33960?source=related_link\">",
"      Laryngopharyngeal reflux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/61/35802?source=related_link\">",
"      Management of Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39305?source=related_link\">",
"      Management of benign esophageal strictures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/53/42840?source=related_link\">",
"      Medical management of gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/11/16568?source=related_link\">",
"      Motility testing: When does it help?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/9/12442?source=related_link\">",
"      Overview of upper gastrointestinal endoscopy (esophagogastroduodenoscopy)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13928?source=related_link\">",
"      Pathophysiology of reflux esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/30/38373?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/33/37393?source=related_link\">",
"      Patient information: Hiatal hernia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/31/33274?source=related_link\">",
"      Surgical management of severe obesity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_57_42906="ECG ST-T changes with LVH tutorial";
var content_f41_57_42906=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F76497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F76497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1264px;\">",
"  <div class=\"figure\" style=\"width: 550px\">",
"   <div class=\"ttl\">",
"    Left ventricular hypertrophy (LVH) with strain pattern",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 530px; height: 232px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The ST-T wave abnormalities secondary to left ventricular hypertrophy (often termed \"strain\") are most often seen in the anterolateral leads (eg, I, aVL, V4-V6). Typical abnormalitites include a horizontal or downsloping ST segment and T wave inversions. In some cases there is concavity to the ST segment which has a final downward turn that blends into an inverted T wave.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 594px\">",
"   <div class=\"ttl\">",
"    Normal ECG",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 594px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75&deg;.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_57_42906=[""].join("\n");
var outline_f41_57_42906=null;
var title_f41_57_42907="Key indicators diagnosis COPD";
var content_f41_57_42907=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Key indicators for considering a diagnosis of COPD",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Chronic cough:",
"       </td>",
"       <td>",
"        Present intermittently or every day. Often present throughout the day; seldom only nocturnal.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic sputum production:",
"       </td>",
"       <td>",
"        Any pattern of chronic sputum production may indicate COPD.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Dyspnea that is:",
"       </td>",
"       <td>",
"        Progressive (worsens over time).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Persistent (present every day).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Described by the patient as an \"increased effort to breathe,\" \"heaviness,\" \"air hunger,\" or \"gasping.\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Worse on exercise.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Worse during respiratory infections.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Limitation of activity that is:",
"       </td>",
"       <td>",
"        Progressive.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Not clearly attributable to other causes.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        History of exposure to risk factors, especially:",
"       </td>",
"       <td>",
"        Tobacco smoke.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Occupational dusts and chemicals.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Smoke from home cooking and heating fuels.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Consider the diagnosis of COPD and perform spirometry if any of these indicators are present. These indicators are not diagnostic by themselves, but the presence of multiple key indicators increases the probability of a diagnosis of COPD. Spirometry is needed to establish a diagnosis of COPD.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced and updated with permission from the Global Initiative for Chronic Obstructive Pulmonary Disease, based on an April 1998 meeting of the National Heart, Lung, and Blood Institute and the World Health Organization.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_57_42907=[""].join("\n");
var outline_f41_57_42907=null;
var title_f41_57_42908="Anticoagulant trials acute CVT";
var content_f41_57_42908=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F69484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F69484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Placebo-controlled randomized trials of anticoagulants in acute CVT",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Einhaupl et al trial, 1991, intravenous heparin versus placebo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Heparin versus placebo",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Outcome at three months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"4\">",
"        Heparin group",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" colspan=\"2\">",
"        Total recovery",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"2\">",
"        8 (80 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" colspan=\"2\">",
"        Residual motor deficit",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"2\">",
"        2 (20 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"4\">",
"        Placebo group",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" colspan=\"2\">",
"        Total recovery",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"2\">",
"        1 (10 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" colspan=\"2\">",
"        Minor residual deficit",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"2\">",
"        6 (60 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" colspan=\"2\">",
"        Deaths",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"2\">",
"        3 (30 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        De Bruijn et al trial, 1999, subcutaneous nadroparin versus placebo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Outcome difference",
"       </td>",
"       <td class=\"subtitle2\">",
"        Nadroparin",
"       </td>",
"       <td class=\"subtitle2\">",
"        Placebo",
"       </td>",
"       <td class=\"subtitle2\">",
"        Risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"4\">",
"        At three weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Deaths",
"       </td>",
"       <td class=\"sublist_other\">",
"        2",
"       </td>",
"       <td class=\"sublist_other\">",
"        4",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        BI score &lt;15",
"       </td>",
"       <td class=\"sublist_other\">",
"        4",
"       </td>",
"       <td class=\"sublist_other\">",
"        3",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Death or BI &lt;15",
"       </td>",
"       <td class=\"sublist_other\">",
"        6 (20 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        7 (24 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        4 percent (-25 a 17)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"4\">",
"        At 12 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Deaths",
"       </td>",
"       <td class=\"sublist_other\">",
"        2",
"       </td>",
"       <td class=\"sublist_other\">",
"        4",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Dependent (R 3-5)",
"       </td>",
"       <td class=\"sublist_other\">",
"        2",
"       </td>",
"       <td class=\"sublist_other\">",
"        2",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Death or dependent (R 3-5)",
"       </td>",
"       <td class=\"sublist_other\">",
"        4 (13 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        +6 (21 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        7 percent (-26 a 12)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     BI: Barthel Index; R: modified Rankin scale score.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_57_42908=[""].join("\n");
var outline_f41_57_42908=null;
var title_f41_57_42909="Sex-related MIP variation";
var content_f41_57_42909=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70873&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70873&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    The mean maximal inspiratory pressure (MIP, shown on the vertical axis in cmH",
"    <sub>",
"     2",
"    </sub>",
"    O) declines with age during adulthood and is lower in women than men",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 266px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Harik-Khan, RI, Wise, RA, Fozard, JL. Determinants of maximal inspiratory pressure: the Baltimore Longitudinal Study of Aging. Am J Respir Crit Care Med 1998; 158:1459.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_57_42909=[""].join("\n");
var outline_f41_57_42909=null;
var title_f41_57_42910="Vitreous toxoplasmosis";
var content_f41_57_42910=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F74181&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F74181&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Peripheral vitreous toxoplasmosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 346px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Funduscopic photograph from a patient with toxoplasmosis shows a peripheral lesion, characterized by a vitreous inflammatory reaction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael Tolentino, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_57_42910=[""].join("\n");
var outline_f41_57_42910=null;
var title_f41_57_42911="Schematic for incisions";
var content_f41_57_42911=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F63976&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F63976&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Escharotomy incisions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 426px; height: 462px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This drawing shows the approximate location for escharotomy incisions, should such incisions become necessary due to compromised respiratory function or inadequate distal perfusion. Escharotomy is rarely required in the emergency department and ideally is performed by experienced clinicians to avoid injury to underlying tissue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_57_42911=[""].join("\n");
var outline_f41_57_42911=null;
